⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77336 | 1.00 | — | — | |
| SCHEMBL145545 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL113877 | 0.98 | ACE (0.46) | — | |
| Water SCHEMBL2694310 | 0.98 | ACE (0.46) | — | |
| Bromide SCHEMBL6632312 | 0.98 | ACE (0.46) | — | |
| Water SCHEMBL1598128 | 0.98 | ACE (0.46) | — | |
| Hydrochloric Acid SCHEMBL113878 | 0.98 | ACE (0.46) | — | |
| Water SCHEMBL1598131 | 0.98 | ACE (0.46) | — | |
| Hydrochloric Acid SCHEMBL1721046 | 0.98 | ACE (0.46) | — | |
| SCHEMBL26612359 | 0.98 | ACE (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2612 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119492837-A | Method for detecting N-methyl-D-prolinol isomer | 江苏恒瑞医药股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| WO-2025032025-A1 | STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS | VITROPEP (FR) | 2025-02-13 | — | — | WO | claimed |
| CN-118184561-A | Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine | 济宁晟泰药业有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | claimed |
| US-20200146989-A1 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE | UNIVERSITY OF COPENHAGEN (DK) | 2020-05-14 | — | — | US | claimed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | claimed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | claimed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | claimed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | claimed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | claimed |
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-17 | — | — | US | disclosed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| EP-3980085-B1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | UNIV RAMOT (IL) | 2026-03-11 | — | — | EP | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049121-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | UNIV JOHNS HOPKINS (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4676600-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | Deliver Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3606615-B1 | METHOD OF STRAIGHTENING HAIR, METHOD FOR MAINTENANCE OF STRAIGHTENED HAIR AND KIT FOR STRAIGHTENING HAIR | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250369136-A1 | PEPTIDE SELF-ASSEMBLY AS A STRATEGY FOR FACILE IMMOBILIZATION OF ENZYMES AND MICROORGANISMS ON ELECTRODES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-12-04 | — | — | US | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250345412-A1 | Coronavirus Vaccine | The Univesity of Melbourne Grattan Street (AU) | 2025-11-13 | — | — | US | disclosed |
| US-12466875-B2 | Supramolecular high affinity protein-binding system for purification of biomacromolecules | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | OMEICOS THERAPEUTICS GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250263696-A1 | PROTEIN TRANSLATION SYSTEM | TSINGHUA UNIVERSITY (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| US-12370245-B2 | ALK polypeptides and methods of use thereof | Elicio Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12357965-B2 | Supramolecular filamentous assemblies for protein purification | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| US-12357673-B2 | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof | THE JOHNS HOPKINS UNIVERSITY | 2025-07-15 | — | — | US | disclosed |
| US-12358897-B2 | Compounds and method of treating COVID-19 | PFIZER INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12351605-B2 | Optically controllable FGFR stimulation using wireless controlled cellular lighting system | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250186554-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250188150-A1 | PEPTIDES FOR THE TREATMENT OF FIBROSIS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186555-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186559-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| EP-3559049-B1 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2025-06-11 | — | — | EP | disclosed |
| EP-4566617-A2 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME | Immunity Pharma Ltd. (IL) | 2025-06-11 | — | — | EP | disclosed |
| US-20250177497-A1 | NOVEL BACTERIA-BASED DELIVERY SYSTEM FOR TACE (ADAM17) SELECTIVE BIOLOGICAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-06-05 | — | — | US | disclosed |
| US-20250177503-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-06-05 | — | — | US | disclosed |
| US-20250171821-A1 | HIF-1 ACTIVATORS AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-05-29 | — | — | US | disclosed |
| US-20250163133-A1 | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2025-05-22 | — | — | US | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025091087-A1 | BISPECIFIC PROTEINS | MONASH UNIVERSITY (AU) | 2025-05-08 | — | — | WO | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| US-12286466-B2 | PD1-4-1BBL variant fusion protein and methods of use thereof | KAHR MEDICAL LTD. (IL) | 2025-04-29 | — | — | US | disclosed |
| US-20250127937-A1 | FAP INHIBITOR | UNIV HEIDELBERG (DE) | 2025-04-24 | — | — | US | disclosed |
| CN-119855820-A | Camptothecins compound and its preparation method and use | 上海齐鲁制药研究中心有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-3647319-B1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER SHANGHAI CO LTD (CN) | 2025-04-09 | — | — | EP | disclosed |
| EP-3256113-B1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD (IL) | 2025-04-02 | — | — | EP | disclosed |
| EP-3820882-B1 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME | IMMUNITY PHARMA LTD (IL) | 2025-04-02 | — | — | EP | disclosed |
| WO-2025064869-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064873-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025055942-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025055943-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4514803-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12239691-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2025-03-04 | — | — | US | disclosed |
| EP-4511367-A1 | FAP INHIBITORS | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119492837-A | Method for detecting N-methyl-D-prolinol isomer | 江苏恒瑞医药股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-114375333-B | Compositions comprising a propeptide of lysyl oxidase and uses thereof | 耶达研究及发展有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| WO-2025032025-A1 | STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS | VITROPEP (FR) | 2025-02-13 | — | — | WO | disclosed |
| US-20250051410-A1 | LILRB POLYPEPTIDES AND USES THEREOF | KAHR MEDICAL LTD. (IL) | 2025-02-13 | — | — | US | disclosed |
| US-12214066-B2 | Hair care compositions | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| WO-2025019889-A1 | NOVEL HYDROGENASES | MONASH UNIVERSITY (AU) | 2025-01-30 | — | — | WO | disclosed |
| US-20250032581-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-01-30 | — | — | US | disclosed |
| US-20250034222-A1 | IL-38 VARIANTS | MONASH UNIVERSITY (AU) | 2025-01-30 | — | — | US | disclosed |
| US-20250032580-A1 | USE OF ADNF POLYPEPTIDES IN THERAPY | UNIV RAMOT (IL) | 2025-01-30 | — | — | US | disclosed |
| CN-119367342-A | CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250026809-A1 | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2025-01-23 | — | — | US | disclosed |
| US-20250011388-A1 | VARIANT CTLA4 PROTEINS | UNIV MONASH (AU) | 2025-01-09 | — | — | US | disclosed |
| CN-114980933-B | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119255981-A | Nitrogen-containing heterocyclic compound and use thereof | BNH研究有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4482511-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240415936-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2024-12-19 | — | — | US | disclosed |
| US-20240415955-A1 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | ARAVAX PTY LTD. (AU) | 2024-12-19 | — | — | US | disclosed |
| US-20240398904-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2024-12-05 | — | — | US | disclosed |
| US-20240398906-A1 | PROPEPTIDE OF LYSYL OXIDASE FOR TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-12-05 | — | — | US | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-12156922-B2 | Copper-containing complex and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2024-12-03 | — | — | US | disclosed |
| CN-119053336-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2024-11-29 | — | — | CN | disclosed |
| US-12134638-B2 | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof | KAHR MEDICAL LTD. (IL) | 2024-11-05 | — | — | US | disclosed |
| CN-118894908-A | Multi-targeting compounds and uses thereof | 成都社泰医疗科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-12129312-B2 | Peptide compound, application thereof and composition containing same | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| CN-118834213-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240350599-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD (AU) | 2024-10-24 | — | — | US | disclosed |
| US-20240350600-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD (AU) | 2024-10-24 | — | — | US | disclosed |
| CN-114685531-B | Tetrafused ring compound, and pharmaceutical composition and application thereof | 武汉誉祥医药科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4444745-A1 | IL-38 VARIANTS | Monash University (AU) | 2024-10-16 | — | — | EP | disclosed |
| US-12115207-B2 | Treatment of inflammation | Ariel Scientific Innovations Ltd. (IL) | 2024-10-15 | — | — | US | disclosed |
| WO-2024197333-A1 | REAGENTS AND METHODS FOR ENERGY GENERATION | MONASH UNIVERSITY (AU) | 2024-10-03 | — | — | WO | disclosed |
| EP-4436562-A1 | SYNTHETIC EICOSANOID ANALOGUES FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH INCREASED GDF15 PLASMA CONCENTRATION | OMEICOS Therapeutics GmbH (DE) | 2024-10-02 | — | — | EP | disclosed |
| EP-4433495-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024186579-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | DELIVER THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20240293316-A1 | ENZYME-RESPONSIVE POLYMER PEPTIDE AMPHIPHILES FOR TARGETED DRUG DELIVERY TO TREAT LOCAL AND SYSTEMIC INFLAMMATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-09-05 | — | — | US | disclosed |
| US-12076373-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2024-09-03 | — | — | US | disclosed |
| CN-118541378-A | Novel auristatin analogues and immunoconjugates thereof | 艾德森特克斯治疗股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240270741-A1 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240252607-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD (AU) | 2024-08-01 | — | — | US | disclosed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4405352-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4400174-A2 | IMMUNOREGULATORY MOLECULES AND USES THEREFOR | The Francis Crick Institute Limited (GB) | 2024-07-17 | — | — | EP | disclosed |
| EP-4400164-A2 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | Yeda Research and Development Co. Ltd (IL) | 2024-07-17 | — | — | EP | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-118271212-A | Caryophyllane derivative, preparation method, application and pharmaceutical composition | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| US-20240209023-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024125627-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118184561-A | Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine | 济宁晟泰药业有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184561-A | Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine | 济宁晟泰药业有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190919-A1 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME | IMMUNITY PHARMA LTD. (IL) | 2024-06-13 | — | — | US | disclosed |
| CN-118146274-A | PNN tridentate ligand with face chirality and phosphine chirality and application thereof in free radical asymmetric functionalization and related reaction | 武汉大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146196-A | FAP inhibitors | 海德堡大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| US-20240182532-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-06-06 | — | — | US | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11986522-B2 | Immunotherapeutic composition and uses thereof | ARA VAX PTY LTD (AU) | 2024-05-21 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11980658-B2 | Immunotherapeutic molecules and uses thereof | ARAVAX PTY LTD (AU) | 2024-05-14 | — | — | US | disclosed |
| CN-117980303-A | Novel compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| US-20240117005-A1 | NOVEL BICYCLIC PEPTIDES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-04-11 | — | — | US | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| US-20240100134-A1 | FUSION PROTEINS | MONASH UNIVERSITY (AU) | 2024-03-28 | — | — | US | disclosed |
| US-20240094224-A1 | ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-21 | — | — | US | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240082816-A1 | SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION | BRISTOL-MYERS SQUIBB COMPANY | 2024-03-14 | — | — | US | disclosed |
| US-20240076346-A1 | TYPE I MEMBRANE PROTEINS HETERODIMERS AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2024-03-07 | — | — | US | disclosed |
| US-11912790-B2 | Peptide compounds and therapeutic uses of same | IMMUNITY PHARMA LTD. (IL) | 2024-02-27 | — | — | US | disclosed |
| US-20240059740-A1 | CYCLIC PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-02-22 | — | — | US | disclosed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
| US-11897941-B2 | Compositions and methods for reducing bacterial aggregation | LA TROBE UNIVERSITY (AU) | 2024-02-13 | — | — | US | disclosed |
| US-20240042104-A1 | METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-02-08 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024022332-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
| US-20240029819-A1 | AGENTS BINDING MODIFIED ANTIGEN PRESENTED PEPTIDES AND USE OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-11879893-B2 | Rapid detection test for SARS-CoV-2 | NLC PHARMA LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-11873323-B2 | Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20240009315-A1 | METHODS OF TARGETING AGENTS TO ACE2 RECEPTORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-11 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240002814-A1 | MODIFIED URICASE AND USES THEREOF | PROTALIX LTD. (IL) | 2024-01-04 | — | — | US | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11858972-B2 | Micropeptides and uses thereof | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-01-02 | — | — | US | disclosed |
| US-20230416707-A1 | LONG-ACTING DNASE | PROTALIX LTD. (IL) | 2023-12-28 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-117157299-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4281471-A1 | FUSION PROTEINS | Monash University (AU) | 2023-11-29 | — | — | EP | disclosed |
| US-11820833-B2 | Peptides that inhibit binding of EPCR to its ligand to treat inflammation | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2023-11-21 | — | — | US | disclosed |
| US-11819481-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-117043175-A | Oligopeptide with collagen gel contraction promoting effect and application thereof | 前田宪寿 | 2023-11-10 | — | — | CN | disclosed |
| US-20230355727-A1 | TREATMENT OF RETINAL DISORDERS | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| WO-2023208092-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
| EP-4267251-A1 | CYCLIC PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267180-A1 | CORONAVIRUS VACCINE | The University of Melbourne (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-116947879-A | BBI608 derivative, preparation method thereof and application thereof in preparing medicines for treating STAT3 mediated diseases | 沈阳药科大学 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023202655-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2023-10-26 | — | — | WO | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11786640-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| EP-3655009-B1 | NANOPARTICLE COMPOSITIONS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2023-10-11 | — | — | EP | disclosed |
| US-20230313156-A1 | CHEMICAL SYNTHESIS OF LARGE AND MIRROR-IMAGE PROTEINS AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230302108-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | 2023-09-28 | — | — | US | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11744877-B2 | Method for permeabilizing tumor vasculature using a tumor vasculature permeabilizing molecule to improve access of a therapeutic or diagnostic agent to a tumor | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11745165-B2 | Supramolecular filamentous assemblies for protein purification | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023164476-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230263884-A1 | METHODS AND COMPOSITIONS FOR TREATING CORONAVIRAL INFECTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-24 | — | — | US | disclosed |
| US-11732013-B2 | Astexin peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230212261-A1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-07-06 | — | — | US | disclosed |
| US-20230202973-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. (HKI) (DE) | 2023-06-29 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3615502-B1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV TASMANIA (AU) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023102605-A1 | IL-38 VARIANTS | MONASH UNIVERSITY (AU) | 2023-06-15 | — | — | WO | disclosed |
| EP-4192512-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230173023-A1 | TREATMENT OF AN ISCHEMIC HEART DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| WO-2023094615-A1 | SYNTHETIC EICOSANOID ANALOGUES FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH INCREASED GDF15 PLASMA CONCENTRATION | OMEICOS THERAPEUTICS GMBH (DE) | 2023-06-01 | — | — | WO | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-2506825-B2 | HATCHING FLUID ENZYMES AND USES THEREOF | AQUA BIO TECH ASA (NO) | 2023-05-31 | — | — | EP | disclosed |
| US-11660270-B2 | Nanoparticle compositions | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661587-B2 | Light-emitting molecules | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023089052-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023089074-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3313816-B1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| EP-4175970-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023070160-A1 | VARIANT CTLA4 PROTEINS | MONASH UNIVERSITY (AU) | 2023-05-04 | — | — | WO | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3368058-B1 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RES & DEV (IL) | 2023-05-03 | — | — | EP | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | NATIONAL SCIENCE FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-20230127559-A1 | PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEIN | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-27 | — | — | US | disclosed |
| US-20230120707-A1 | Compounds and Method of Treating COVID-19 | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230112012-A1 | FAP INHIBITOR | UNIVERSITAT HEIDELBERG (DE) | 2023-04-13 | — | — | US | disclosed |
| US-11623002-B2 | ALK polypeptides and methods of use thereof | Elicio Therapeutics, Inc. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230105479-A1 | OPTICALLY CONTROLLABLE FGFR STIMULATION USING WIRELESS CONTROLLED CELLULAR LIGHTING SYSTEM | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3464322-B1 | NOVEL MOLECULES FOR THE TREATMENT OF INFLAMMATION | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2023-04-05 | — | — | EP | disclosed |
| US-20230090502-A1 | RAPID DETECTION TEST FOR SARS-COV-2 | NLC PHARMA LTD (IL) | 2023-03-23 | — | — | US | disclosed |
| WO-2023041756-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-23 | — | — | WO | disclosed |
| US-20230082611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11583571-B2 | Stromal derived factor 1 and its use in the prevention and treatment of erectile dysfunction | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230049549-A1 | PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME | IMMUNITY PHARMA LTD. (IL) | 2023-02-16 | — | — | US | disclosed |
| US-20230050031-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | THE JOHNS HOPKINS UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| EP-3717032-B1 | METHODS OF PREVENTING OR TREATING NEUROGENIC SHOCK | UNIV RAMOT (IL) | 2023-02-15 | — | — | EP | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11560417-B2 | Isolated polypeptides of CD44 and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-01-24 | — | — | US | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230000904-A1 | ANTI-HEMORRHAGING COMPOSITIONS | Ariel Scientific Innovations Ltd. (IL) | 2023-01-05 | — | — | US | disclosed |
| US-20230001010-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-05 | — | — | US | disclosed |
| EP-3548106-B1 | COMBINED TREATMENT FOR NERVE INJURIES | UNIV RAMOT (IL) | 2023-01-04 | — | — | EP | disclosed |
| US-11542508-B2 | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-01-03 | — | — | US | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220387557-A1 | TNF MUTEINS AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| US-11518783-B2 | Peptides having tetrahedral mimicking groups as inhibitors of rhomboid proteases | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-12-06 | — | — | US | disclosed |
| EP-2751132-B1 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2022-11-30 | — | — | EP | disclosed |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220332774-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11471504-B2 | Combination therapy for the treatment of cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-10-18 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220324909-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324925-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324911-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220306710-A1 | TREATING ALZHEIMER'S DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| US-20220305079-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220306691-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4058465-A1 | CXCR4 ANTAGONIST PEPTIDES | Cohbar Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022183246-A1 | NEONATAL SEPSIS PREVENTION AND THERAPY | TELETHON KIDS INSTITUTE (AU) | 2022-09-09 | — | — | WO | disclosed |
| US-20220280637-A1 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | ARAVAX PTY LTD. (AU) | 2022-09-08 | — | — | US | disclosed |
| WO-2022183053-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-114980933-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220267409-A1 | HETERODIMERS AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2022-08-25 | — | — | US | disclosed |
| US-20220267751-A1 | METHODS FOR MAKING RECOMBINANT PROTEIN | MONASH UNIVERSITY (AU) | 2022-08-25 | — | — | US | disclosed |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220251153-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | UGH PHARMA, INC. (PA) | 2022-08-11 | — | — | US | disclosed |
| US-20220251182-A1 | AGENTS WHICH INHIBIT GADS DIMERIZATION AND METHODS OF USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-08-11 | — | — | US | disclosed |
| US-20220251159-A1 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2022-08-11 | — | — | US | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | disclosed |
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | disclosed |
| US-11406682-B2 | Roundabout (Robo) receptor inhibitors and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2022-08-09 | — | — | US | disclosed |
| US-20220241219-A1 | SUPRAMOLECULAR HYDROGEL APPLICATIONS TO THE CAROTID BODIES TO TREAT HYPERTENSION AND SLEEP APNEA IN OBESITY | THE JOHNS HOPKINS UNIVERSITY | 2022-08-04 | — | — | US | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220233578-A1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155706-A1 | FUSION PROTEINS | MONASH UNIVERSITY (AU) | 2022-07-28 | — | — | WO | disclosed |
| US-20220226432-A1 | DEFERRED TREATMENT OF NERVE INJURIES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-07-21 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4028392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4025256-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728937-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220211811-A1 | COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-07 | — | — | US | disclosed |
| CN-114685531-A | Tetraheterocyclic compounds, pharmaceutical compositions and uses thereof | 武汉誉祥医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022133547-A1 | CORONAVIRUS VACCINE | THE UNIVERSITY OF MELBOURNE (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022133540-A1 | CYCLIC PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135610-A1 | TETRACYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉誉祥医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| EP-4019506-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017529-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11370757-B2 | Photocleavable nitroindoline-based crosslinkers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013440-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-11359005-B2 | Supramolecular high affinity protein-binding system for purification of biomacromolecules | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220175943-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-114599389-A | Variant FC domains and uses thereof | 奇达拉治疗公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220169693-A1 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-06-02 | — | — | US | disclosed |
| US-11344611-B2 | Polypeptide, compositions and uses thereof | AUSTRALIAN MEAT & LIVE STOCK (AU) | 2022-05-31 | — | — | US | disclosed |
| CN-114539235-A | Biphenyl compound, preparation method and application thereof | 药康众拓(江苏)医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3999110-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11337427-B2 | Antimicrobial agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-05-24 | — | — | US | disclosed |
| EP-3997231-A1 | METHODS FOR MAKING RECOMBINANT PROTEIN | Monash University (AU) | 2022-05-18 | — | — | EP | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
| US-20220133701-A1 | METHODS OF TREATING PAIN | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-05-05 | — | — | US | disclosed |
| EP-3990478-A1 | TNF MUTEINS AND USES THEREOF | Oxford University Innovation Limited (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11311610-B2 | Immune-modulating agents and uses therefor | UNIVERSITY OF TECHNOLOGY SYDNEY (AU) | 2022-04-26 | — | — | US | disclosed |
| US-11311625-B2 | Peptide-based multiple-drug delivery vehicle | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2022-04-26 | — | — | US | disclosed |
| CN-114390929-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220119459-A1 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| US-20220120732-A1 | TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| EP-3982994-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3982993-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114375333-A | Compositions comprising a propeptide of lysyl oxidase and uses thereof | 耶达研究及发展有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220088159-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD. (AU) | 2022-03-24 | — | — | US | disclosed |
| US-11273201-B2 | Compositions and methods for inducing thrombopoiesis | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2022-03-15 | — | — | US | disclosed |
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3964232-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | Aravax Pty Ltd (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-08 | — | — | US | disclosed |
| US-11266737-B2 | Immunotherapeutic composition and uses thereof | ARAVAX PTY LTD (AU) | 2022-03-08 | — | — | US | disclosed |
| CN-114075168-A | Pyrazole derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220049236-A1 | COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| EP-3387007-B1 | PROTEINACEOUS MOLECULES AND METHODS OF USE | UNIV QUEENSLAND (AU) | 2022-02-16 | — | — | EP | disclosed |
| US-11246907-B2 | Immunosuppressive agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-02-15 | — | — | US | disclosed |
| US-11246908-B2 | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022032175-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3083579-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-11229614-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230578-B2 | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| EP-3307767-B1 | IL-37 VARIANTS | UNIV MONASH (AU) | 2022-01-12 | — | — | EP | disclosed |
| WO-2022000043-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2022-01-06 | — | — | WO | disclosed |
| US-20210403506-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3917944-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| WO-2021234181-A1 | USE OF FAP INHIBITOR IN A METHOD OF DIAGNOSIS | Universität Heidelberg (DE) | 2021-11-25 | — | — | WO | disclosed |
| US-20210363187-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2021-11-25 | — | — | US | disclosed |
| US-11179437-B2 | COP9 signalosome (CSN) complex modulators and uses thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-23 | — | — | US | disclosed |
| US-20210353569-A1 | Analogs of CYP-Eicosanoids for Use in Treating or Preventing a Disorder Associated with Neovascularization and/or Inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-11160875-B2 | Therapeutic nanofiber hydrogels for local treatment of brain-related diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021211784-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-11136351-B2 | Alpha conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-10-05 | — | — | US | disclosed |
| EP-3610005-B1 | PEPTIDE LIGASE AND USE THEREOF | UNIV OXFORD INNOVATION LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-11130772-B2 | CYP-eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN | 2021-09-28 | — | — | US | disclosed |
| US-20210292397-A1 | COMPOSITIONS AND METHODS FOR REDUCING BACTERIAL AGGREGATION | LA TROBE UNIVERSITY (AU) | 2021-09-23 | — | — | US | disclosed |
| US-11124550-B2 | Proteinaceous molecules and methods of use | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-09-21 | — | — | US | disclosed |
| US-20210284711-A1 | PD1-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2021-09-16 | — | — | US | disclosed |
| US-11117930-B2 | Peptide inhibitors of transcription factor aggregation | ADRX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11111271-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-111747954-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-2914286-B1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD (AU) | 2021-08-18 | — | — | EP | disclosed |
| EP-3046870-B1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | UNIV QUEENSLAND (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11084855-B2 | IL-37 variants | MONASH UNIVERSITY (AU) | 2021-08-10 | — | — | US | disclosed |
| WO-2021155194-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-113194983-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210221858-A1 | OPTICALLY CONTROLLABLE FGFR STIMULATION USING WIRELESS CONTROLLED CELLULAR LIGHTING SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| US-20210214417-A1 | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2021-07-15 | — | — | US | disclosed |
| EP-3846846-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | Cidara Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3846854-A2 | IMPROVED POLYPEPTIDE COUPLED ANTIBIOTICS | Mier, Walter (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-11059855-B2 | Antimicrobial peptides and methods of making and using same | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059867-B2 | Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| US-20210205638-A1 | PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS DISEASE | THE JOHNS HOPKINS UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| US-20210205424-A1 | POLYPEPTIDE, COMPOSITIONS AND USES THEREOF | MEAT & LIVESTOCK AUSTRALIA LIMITED (AU) | 2021-07-08 | — | — | US | disclosed |
| US-20210196792-A1 | IMMUNOREGULATORY MOLECULES AND USES THEREFOR | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3837250-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3615556-B1 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF | UNIV OXFORD INNOVATION LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-11028127-B2 | Peptides capable of reactivating p53 mutants | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-06-08 | — | — | US | disclosed |
| US-20210162025-A1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-06-03 | — | — | US | disclosed |
| US-20210154261-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-05-27 | — | — | US | disclosed |
| US-11013696-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2021-05-25 | — | — | US | disclosed |
| WO-2021097256-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210130294-A1 | PHOTOCLEAVABLE NITROINDOLINE-BASED CROSSLINKERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-06 | — | — | US | disclosed |
| EP-1836216-B1 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS | DENDROCYTE BIOTECH PTY LTD (AU) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021078978-A1 | ANTIBACTERIAL BONE CEMENT AND USES THEREOF | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081515-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3261443-B1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIV RICE WILLIAM M (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10987302-B2 | Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin | AQUA BIO TECHNOLOGY ASA (NO) | 2021-04-27 | — | — | US | disclosed |
| US-20210115096-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10981986-B2 | Fusions of antibodies to CD38 and attenuated interferon alpha | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2021-04-20 | — | — | US | disclosed |
| US-10980866-B2 | Alpha-1 anti-trypsin for treating liver diseases | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2021-04-20 | — | — | US | disclosed |
| US-20210107950-A1 | ASTEXIN PEPTIDES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3065759-B1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIV SCI & TECH NTNU (NO) | 2021-03-31 | — | — | EP | disclosed |
| EP-3303374-B1 | METHODS AND PRODUCTS FOR FUSION PROTEIN SYNTHESIS | UNIV OXFORD INNOVATION LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| CN-108349880-B | CYP eicosanoid metabolism robust analogs for treatment of cardiac disorders | 奥迈科斯治疗公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10933122-B2 | Variants of TACE pro-domain as TNF-A inhibitor and their medical use | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-03-02 | — | — | US | disclosed |
| US-10934253-B2 | Therapeutic compounds and methods | UNIVERSITY OF TASMANIA (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20210052520-A1 | SUPRAMOLECULAR HYDROGEL APPLICATIONS TO THE CAROTID BODIES TO TREAT HYPERTENSION AND SLEEP APNEA IN OBESITY | THE JOHNS HOPKINS UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| WO-2021035177-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10927152-B2 | Astexin peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2021030469-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030794-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030752-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030792-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030799-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030749-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210038749-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-10906937-B2 | Peptides and compositions comprising same and uses thereof in the treatment of diseases | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2021-02-02 | — | — | US | disclosed |
| CN-112279837-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210023164-A1 | TREATMENT OF INFLAMMATION | Ariel Scientific Innovations Ltd. (IL) | 2021-01-28 | — | — | US | disclosed |
| WO-2021016082-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-28 | — | — | WO | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| WO-2021007612-A1 | METHODS FOR MAKING RECOMBINANT PROTEIN | MONASH UNIVERSITY (AU) | 2021-01-21 | — | — | WO | disclosed |
| US-20210017242-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2021-01-21 | — | — | US | disclosed |
| EP-3762360-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10889622-B2 | Peptide ligase and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| US-20200405834-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | 2020-12-31 | — | — | US | disclosed |
| WO-2020260900-A1 | TNF MUTEINS AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| US-10874728-B2 | Tumor vascular marker-targeted vaccines | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020252396-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392203-A1 | IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-12-17 | — | — | US | disclosed |
| US-20200390800-A1 | METHODS OF PREVENTING OR TREATING NEUROGENIC SHOCK | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-12-17 | — | — | US | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3749663-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2020-12-16 | — | — | EP | disclosed |
| CN-112055709-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200362018-A1 | INHIBITORS OF THE 20S PROTEASOME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-11-19 | — | — | US | disclosed |
| US-20200353030-A1 | ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2020-11-12 | — | — | US | disclosed |
| US-20200339691-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-10-29 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-10808007-B2 | Desacetoxytubulysin H and analogs thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10808007-B2 | Desacetoxytubulysin H and analogs thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200323777-A1 | NANOPARTICLE COMPOSITIONS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323953-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2020-10-15 | — | — | US | disclosed |
| US-10799616-B2 | Cross-linked resilin-containing materials | COLLPLANT LTD. (IL) | 2020-10-13 | — | — | US | disclosed |
| CN-111747954-A | Pyrazine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20200306343-A1 | TREATMENT OF AN ISCHEMIC HEART DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-10-01 | — | — | US | disclosed |
| US-10786543-B2 | P75NTR antagonists and treatment of acute and chronic cardiac disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200297796-A1 | COP9 SIGNALOSOME (CSN) COMPLEX MODULATORS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-09-24 | — | — | US | disclosed |
| US-20200299339-A1 | PROTEINACEOUS MOLECULES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-24 | — | — | US | disclosed |
| US-20200297878-A1 | COPPER-CONTAINING COMPLEX AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2020-09-24 | — | — | US | disclosed |
| CN-111699181-A | FAP inhibitors | 海德堡大学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3707144-A1 | COPPER-CONTAINING COMPLEX AND USES THEREOF | Bar Ilan University (IL) | 2020-09-16 | — | — | EP | disclosed |
| US-10774114-B2 | Respiratory syncytial virus (RSV) replication inhibitors | FONDATION THE ARK (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20200247848-A1 | NOVEL ALPHA CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-08-06 | — | — | US | disclosed |
| WO-2020160003-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10729815-B2 | Combined treatment for nerve injuries | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-08-04 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200222494-A1 | ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF | MONASH UNIVERSITY (AU) | 2020-07-16 | — | — | US | disclosed |
| US-20200216495-A1 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3065760-B1 | ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIV SCI & TECH NTNU (NO) | 2020-07-08 | — | — | EP | disclosed |
| US-20200207836-A1 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | MONASH UNIVERSITY (AU) | 2020-07-02 | — | — | US | disclosed |
| EP-3672992-A1 | ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF | Bar-Ilan University (IL) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197902-A1 | SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION | THE JOHNS HOPKINS UNIVERSITY | 2020-06-25 | — | — | US | disclosed |
| EP-3668640-A1 | SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION | The Johns Hopkins University (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668888-A1 | IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSES | Yeda Research and Development Co. Ltd. (IL) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668886-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | Adrx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10688330-B2 | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-06-23 | — | — | US | disclosed |
| US-20200188483-A1 | STROMAL DERIVED FACTOR 1 AND IT'S USE IN THE PREVENTION AND TREATMENT OF ERECTILE DYSFUNCTION | JPMORGAN CHASE BANK, N.A. | 2020-06-18 | — | — | US | disclosed |
| US-20200181234-A1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-06-11 | — | — | US | disclosed |
| US-20200181197-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200172604-A1 | AGENTS WHICH INHIBIT GADS DIMERIZATION AND METHODS OF USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2020-06-04 | — | — | US | disclosed |
| EP-3658169-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Yeda Research and Development Co. Ltd (IL) | 2020-06-03 | — | — | EP | disclosed |
| EP-3655009-A1 | NANOPARTICLE COMPOSITIONS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2020-05-27 | — | — | EP | disclosed |
| US-10662229-B2 | Spider venom peptides and methods of use for modulating sodium channels | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-05-26 | — | — | US | disclosed |
| US-20200146989-A1 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE | UNIVERSITY OF COPENHAGEN (DK) | 2020-05-14 | — | — | US | disclosed |
| US-20200138913-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-20200139162-A1 | METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| EP-3647319-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131233-A1 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2020-04-30 | — | — | US | disclosed |
| US-20200121581-A1 | HAIR CARE COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-04-23 | — | — | US | disclosed |
| US-20200115422-A1 | PEPTIDE LIGASE AND USE THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3634978-A1 | TAU AGGREGATION INHIBITORS | Adrx, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10611819-B2 | Isolated polypeptides of CD44 and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-04-07 | — | — | US | disclosed |
| US-20200095282-A1 | PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-03-26 | — | — | US | disclosed |
| US-20200095286-A1 | ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2020-03-26 | — | — | US | disclosed |
| EP-3169343-B1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD (IL) | 2020-03-25 | — | — | EP | disclosed |
| US-10589132-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-03-17 | — | — | US | disclosed |
| US-10583177-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2020-03-10 | — | — | US | disclosed |
| US-20200069811-A1 | PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2020-03-05 | — | — | US | disclosed |
| EP-3615502-A1 | THERAPEUTIC COMPOUNDS AND METHODS | University Of Tasmania (AU) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615556-A1 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF | Oxford University Innovation Limited (GB) | 2020-03-04 | — | — | EP | disclosed |
| US-20200062804-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062827-A1 | A SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2020-02-27 | — | — | US | disclosed |
| US-10570180-B2 | Anti-bacterial agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2020-02-25 | — | — | US | disclosed |
| US-20200056161-A1 | LIGHT-EMITTING MOLECULES | PROMEGA CORPORATION | 2020-02-20 | — | — | US | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
| EP-3610005-A1 | PEPTIDE LIGASE AND USE THEREOF | Oxford University Innovation Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-20200048303-A1 | ANTIMICROBIAL PEPTIDES AND METHODS OF MAKING AND USING SAME | THE JOHNS HOPKINS UNIVERSITY | 2020-02-13 | — | — | US | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3606615-A1 | HAIR CARE COMPOSITIONS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2020-02-12 | — | — | EP | disclosed |
| US-10556937-B2 | Methods for the production of a cosmetic composition comprising leukolectin and uses thereof | AQUA BIO TECHNOLOGY ASA (NO) | 2020-02-11 | — | — | US | disclosed |
| EP-3601362-A1 | A SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | The Johns Hopkins University (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10550152-B2 | Peptides capable of reactivating p53 mutants | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-02-04 | — | — | US | disclosed |
| US-10526379-B2 | Methods and products for fusion protein synthesis | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-01-07 | — | — | US | disclosed |
| US-10487115-B2 | Proteinaceous compounds and uses therefor | UNIVERSITY OF CANBERRA (AU) | 2019-11-26 | — | — | US | disclosed |
| US-20190350837-A1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION FROM HATCHING FLUID AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECHNOLOGY ASA (NO) | 2019-11-21 | — | — | US | disclosed |
| US-10478507-B2 | Peptide-based multiple-drug delivery vehicle | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2019-11-19 | — | — | US | disclosed |
| US-20190343934-A1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-11-14 | — | — | US | disclosed |
| EP-3559049-A2 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | Teva Pharmaceuticals Australia Pty Ltd (AU) | 2019-10-30 | — | — | EP | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2487182-B1 | SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | FULCRUM SP LTD (IL) | 2019-10-23 | — | — | EP | disclosed |
| US-10450348-B2 | Antimicrobial agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2019-10-22 | — | — | US | disclosed |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315804-A1 | PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-10-17 | — | — | US | disclosed |
| EP-3548106-A1 | COMBINED TREATMENT FOR NERVE INJURIES | Ramot at Tel-Aviv University Ltd. (IL) | 2019-10-09 | — | — | EP | disclosed |
| EP-3545095-A1 | ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USING SAME FOR EXPRESSING AN EXPRESSION PRODUCT OF INTEREST | Yeda Research and Development Co., Ltd. (IL) | 2019-10-02 | — | — | EP | disclosed |
| US-10426821-B2 | Variants of TACE pro-domain as TNF-A inhibitor and their medical use | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-10-01 | — | — | US | disclosed |
| US-10428317-B2 | Light-emitting molecules | GENE STREAM PTY LTD (AU) | 2019-10-01 | — | — | US | disclosed |
| US-10426737-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2019-10-01 | — | — | US | disclosed |
| EP-3538651-A1 | PHOSPHOTRIESTERASES FOR TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | Yeda Research and Development Co., Ltd. (IL) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539975-A1 | MICROPEPTIDES AND USES THEREOF | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (ES) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019170705-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. - HANS-KNÖLL-INSTITUT - (DE) | 2019-09-12 | — | — | WO | disclosed |
| EP-3536684-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (DE) | 2019-09-11 | — | — | EP | disclosed |
| EP-2635596-B1 | IMMUNE-MODULATING AGENTS AND USES THEREFOR | UNIV SYDNEY TECHNOLOGY (AU) | 2019-09-04 | — | — | EP | disclosed |
| US-20190264213-A1 | ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USING SAME FOR EXPRESSING AN EXPRESSION PRODUCT OF INTEREST | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
| EP-3197913-B1 | ALPHA-1 ANTI-TRYPSIN FOR TREATING LIVER DISEASES | HADASIT MED RES SERVICE (IL) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3526205-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2950808-B1 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF | UNIV RAMOT (IL) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019154859-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154886-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | disclosed |
| US-20190247464-A1 | COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-08-15 | — | — | US | disclosed |
| EP-3519431-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | Cohbar Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-110072855-A | Therapeutic compound and its application method | 基因泰克公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20190209657-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2019-07-11 | — | — | US | disclosed |
| US-20190209649-A1 | COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-11 | — | — | US | disclosed |
| US-10336789-B2 | Peptides capable of reactivating p53 mutants | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-07-02 | — | — | US | disclosed |
| US-20190194253-A1 | PEPTIDES AND COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF DISEASES | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2019-06-27 | — | — | US | disclosed |
| EP-3500291-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2019-06-26 | — | — | EP | disclosed |
| US-10328021-B2 | Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin | AQUA BIO TECHNOLOGY ASA (NO) | 2019-06-25 | — | — | US | disclosed |
| EP-3498711-A1 | MORPHINAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-10307462-B2 | Compositions and methods for inducing thrombopoiesis | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-06-04 | — | — | US | disclosed |
| US-20190153031-A1 | NOVEL MOLECULES FOR THE TREATMENT OF INFLAMMATION | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2019-05-23 | — | — | US | disclosed |
| US-20190144498-A1 | PEPTIDES HAVING TETRAHEDRAL MIMICKING GROUPS AS INHIBITORS OF RHOMBOID PROTEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-16 | — | — | US | disclosed |
| US-20190142919-A1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-05-16 | — | — | US | disclosed |
| US-10287262-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-14 | — | — | US | disclosed |
| US-20190133976-A1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2019-05-09 | — | — | US | disclosed |
| EP-3097076-B1 | NOVEL CYP-EICOSANOID DERIVATIVES | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-08 | — | — | EP | disclosed |
| EP-2506825-B1 | HATCHING FLUID ENZYMES AND USES THEREOF | AQUA BIO TECH ASA (NO) | 2019-05-08 | — | — | EP | disclosed |
| US-20190117597-A1 | ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | MAX DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20190117846-A1 | COMBINED TREATMENT FOR NERVE INJURIES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| US-10266567-B2 | Peptides and compositions comprising same and uses thereof in the treatment of diseases | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2019-04-23 | — | — | US | disclosed |
| US-20190111132-A1 | PHOTOREACTIVE COLLAGEN-LIKE PEPTIDES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3464322-A1 | NOVEL MOLECULES FOR THE TREATMENT OF INFLAMMATION | Tel HaShomer Medical Research Infrastructure and Services Ltd. (IL) | 2019-04-10 | — | — | EP | disclosed |
| US-10251943-B2 | PLIF multimeric peptides and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-04-09 | — | — | US | disclosed |
| US-10246488-B2 | Use of inhibitory peptides for the treatment of inflammatory diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-04-02 | — | — | US | disclosed |
| EP-2934556-B1 | COSMETIC AND PHARMACEUTICAL COMPOSITIONS FROM FISH HATCHING FLUID | AQUA BIO TECH ASA (NO) | 2019-03-27 | — | — | EP | disclosed |
| US-10240133-B2 | ERK-derived peptides and uses thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-03-26 | — | — | US | disclosed |
| US-20190083836-A1 | ISOLATED PHOSPHOTRIESTERASE POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-03-21 | — | — | US | disclosed |
| WO-2019038772-A1 | ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019036725-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036631-A1 | SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035128-A1 | IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-02-21 | — | — | WO | disclosed |
| US-20190048053-A1 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-02-14 | — | — | US | disclosed |
| US-20190048047-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190040107-A1 | ASTEXIN PEPTIDES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040103-A1 | PROTEINACEOUS COMPOUNDS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2019-02-07 | — | — | US | disclosed |
| EP-3435993-A1 | ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS Therapeutics GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| WO-2019021284-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-01-31 | — | — | WO | disclosed |
| US-10189885-B2 | Non-hemolytic LLO fusion proteins and methods of utilizing same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2019016819-A1 | NANOPARTICLE COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019010533-A1 | TREATMENT OF OCULAR CONDITIONS | Factor Therapeutics Limited (AU) | 2019-01-17 | — | — | WO | disclosed |
| EP-3046929-B1 | ERK-DERIVED PEPTIDES AND USES THEREOF | YEDA RES & DEV (IL) | 2019-01-16 | — | — | EP | disclosed |
| EP-2922862-B1 | COMPLEX-FORMATION-MODULATING AGENTS AND USES THEREFOR | FACTOR THERAPEUTICS LTD (AU) | 2019-01-02 | — | — | EP | disclosed |
| EP-3416975-A1 | NOVEL ALPHA CONOTOXIN PEPTIDES | The University of Queensland (AU) | 2018-12-26 | — | — | EP | disclosed |
| US-20180360987-A1 | THERAPEUTIC NANOFIBER HYDROGELS FOR LOCAL TREATMENT OF BRAIN-RELATED DISEASES | THE JOHNS HOPKINS UNIVERSITY | 2018-12-20 | — | — | US | disclosed |
| WO-2018226992-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-3411390-A1 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 | Yeda Research and Development Co. Ltd (IL) | 2018-12-12 | — | — | EP | disclosed |
| EP-3407871-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Vedantra Pharmaceuticals Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2018213125-A1 | STROMAL DERIVED FACTOR 1 AND IT'S USE IN THE PREVENTION AND TREATMENT OF ERECTILE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180334477-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-22 | — | — | US | disclosed |
| US-10123967-B2 | Cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin | AQUA BIO TECHNOLOGY ASA (NO) | 2018-11-13 | — | — | US | disclosed |
| US-10124034-B2 | Leukolectins and uses thereof | LEUKOLECT AS (NO) | 2018-11-13 | — | — | US | disclosed |
| US-20180318612-A1 | METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-11-08 | — | — | US | disclosed |
| WO-2018197854-A1 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018191789-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2018-10-25 | — | — | WO | disclosed |
| US-10106582-B2 | Complex-formation-modulating agents and uses therefor | Factor Therapeutics Limited (AU) | 2018-10-23 | — | — | US | disclosed |
| US-20180298067-A1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION COMPRISING LEUKOLECTIN AND USES THEREOF | AQUA BIO TECHNOLOGY ASA (NO) | 2018-10-18 | — | — | US | disclosed |
| WO-2018189517-A1 | PEPTIDE LIGASE AND USE THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018187574-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018185768-A1 | HAIR CARE COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-10-11 | — | — | WO | disclosed |
| EP-2955193-B1 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | SP NANO LTD (IL) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018183417-A1 | A SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180282696-A1 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2018-10-04 | — | — | US | disclosed |
| EP-2082235-B1 | A METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME | MEDVET SCIENCE PTY LTD (AU) | 2018-10-03 | — | — | EP | disclosed |
| US-20180271931-A1 | P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE | VANDERBILT UNIVERSITY | 2018-09-27 | — | — | US | disclosed |
| US-10072048-B2 | Astexin peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180250414-A1 | PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2018-09-06 | — | — | US | disclosed |
| EP-3368058-A1 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | Yeda Research and Development Co., Ltd. (IL) | 2018-09-05 | — | — | EP | disclosed |
| US-10066024-B2 | Methods of generating antibodies to metalloenzymes | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-09-04 | — | — | US | disclosed |
| US-20180244730-A1 | Methods and Products for Fusion Protein Synthesis | OXFORD UNIVERSITY INNOVATION LIMITED | 2018-08-30 | — | — | US | disclosed |
| WO-2018156892-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-3362465-A1 | PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE | Ariel-University Research and Development Company Ltd. (IL) | 2018-08-22 | — | — | EP | disclosed |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2018-08-09 | — | — | US | disclosed |
| US-10040836-B2 | Peptides for the treatment of neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2018-08-07 | — | — | US | disclosed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180193409-A1 | PEPTIDYL TPOR ANTAGONISTS AND USES THEREOF | POLYMERS CRC LIMITED (AU) | 2018-07-12 | — | — | US | disclosed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018127544-A1 | USE OF RADICAL S-ADENOSYL METHIONINE (SAM) ENZYMES FOR INTRODUCING α-KETO-β3-AMINO ACIDS INTO (POLY)PEPTIDES | ETH ZURICH (CH) | 2018-07-12 | — | — | WO | disclosed |
| US-10017552-B2 | Methods of using a composition comprising leukolectin for cosmetic skin treatment | AQUA BIO TECHNOLOGY ASA (NO) | 2018-07-10 | — | — | US | disclosed |
| US-10004828-B2 | Self-assembled Fmoc-ff hydrogels | Romat at Tel-Aviv University Ltd. (IL) | 2018-06-26 | — | — | US | disclosed |
| EP-3065745-B1 | CROSS-LINKED RESILIN-CONTAINING MATERIALS | COLLPLANT LTD (IL) | 2018-06-20 | — | — | EP | disclosed |
| EP-2632956-B1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | YEDA RES & DEV (IL) | 2018-06-20 | — | — | EP | disclosed |
| US-10000737-B2 | Generation of cytotoxic tumor specific cell lines and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2018-06-19 | — | — | US | disclosed |
| US-10000771-B2 | Nuclear targeting sequences | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-06-19 | — | — | US | disclosed |
| US-20180162918-A1 | IL-37 VARIANTS | Hudson Institute of Medical Research (AU) | 2018-06-14 | — | — | US | disclosed |
| EP-3331546-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | Biokine Therapeutics Ltd. (IL) | 2018-06-13 | — | — | EP | disclosed |
| US-20180153995-A1 | USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-06-07 | — | — | US | disclosed |
| WO-2018100511-A1 | COMBINED TREATMENT FOR NERVE INJURIES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148483-A2 | Mu-Conotoxin Peptides And Use Thereof As A Local Anesthetic | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096547-A1 | ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USING SAME FOR EXPRESSING AN EXPRESSION PRODUCT OF INTEREST | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-31 | — | — | WO | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9982181-B2 | Multi-site modified SP1 polypeptides and uses thereof | SP NANO LTD. (IL) | 2018-05-29 | — | — | US | disclosed |
| US-20180141977-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2018-05-24 | — | — | US | disclosed |
| WO-2018087759-A1 | PHOSPHOTRIESTERASES FOR TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-17 | — | — | WO | disclosed |
| US-20180134808-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-17 | — | — | US | disclosed |
| US-20180127463-A1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-05-10 | — | — | US | disclosed |
| EP-3313816-A1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS Therapeutics GmbH (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2828280-B1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | UNIV RAMOT (IL) | 2018-05-02 | — | — | EP | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-3310396-A2 | THERAPEUTIC NANOFIBER HYDROGELS FOR LOCAL TREATMENT OF BRAIN-RELATED DISEASES | The Johns Hopkins University (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9950031-B2 | Hatching fluid enzymes and uses thereof | AQUA BIO TECHNOLOGY ASA (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| EP-1948685-B1 | MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC | ACTIVEN SA (CH) | 2018-04-18 | — | — | EP | disclosed |
| EP-3307767-A1 | IL-37 VARIANTS | Monash University (AU) | 2018-04-18 | — | — | EP | disclosed |
| EP-3303374-A1 | METHODS AND PRODUCTS FOR FUSION PROTEIN SYNTHESIS | Oxford University Innovation Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018064098-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | COHBAR, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2989119-B1 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES | YEDA RES & DEV (IL) | 2018-03-21 | — | — | EP | disclosed |
| US-20180072771-A1 | PEPTIDES AND COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF DISEASES | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2018-03-15 | — | — | US | disclosed |
| EP-3291826-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | Norwegian University of Science and Technology (NTNU) (NO) | 2018-03-14 | — | — | EP | disclosed |
| US-20180066286-A1 | NUCLEAR TARGETING SEQUENCES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-03-08 | — | — | US | disclosed |
| WO-2018037416-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055907-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2018-03-01 | — | — | US | disclosed |
| US-20180057533-A1 | PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-03-01 | — | — | US | disclosed |
| US-9902783-B2 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-02-27 | — | — | US | disclosed |
| WO-2018033927-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2018-02-22 | — | — | WO | disclosed |
| US-20180050096-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2018-02-22 | — | — | US | disclosed |
| EP-2934700-B1 | A COSMETIC COMPOSITION FROM FISH HATCHING FLUID, METHODS FOR ITS PRODUCTION AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECH ASA (NO) | 2018-02-14 | — | — | EP | disclosed |
| US-20180036234-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | ENTERA BIO LTD. (IL) | 2018-02-08 | — | — | US | disclosed |
| US-20180036382-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | ENTERA BIO LTD. (IL) | 2018-02-08 | — | — | US | disclosed |
| US-20180028622-A1 | TREATMENT OF OSTEOPOROSIS | ENTERA BIO LTD. (IL) | 2018-02-01 | — | — | US | disclosed |
| US-20180021272-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2018-01-25 | — | — | US | disclosed |
| EP-3269379-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | Immusant, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2839839-B1 | Nuclear targeting sequences | YEDA RES AND DEVELOPMENT COMPANY LIMITED (IL) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009859-A1 | PHARMACOLOGICAL MODULATORS OF GABAA RECEPTORS AND THEIR USE | UNIV JOHNS HOPKINS (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180002376-A1 | ANTI-MICROBIAL PEPTIDES AND USES OF SAME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-01-04 | — | — | US | disclosed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3261443-A1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | William Marsh Rice University (US) | 2018-01-03 | — | — | EP | disclosed |
| EP-2855507-B1 | FUNCTIONALIZED TITANIUM BINDING PEPTIDES AND IMPLANTS COATED WITH SAME | BEN-GURION UNIV OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2018-01-03 | — | — | EP | disclosed |
| US-9856289-B2 | Peptides capable of reactivating p53 mutants | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-01-02 | — | — | US | disclosed |
| CN-107529754-A | Remove acetoxyl group tubulysin H and the like | 威廉马歇莱思大学 | 2018-01-02 | — | — | CN | disclosed |
| EP-3256114-A1 | TREATMENT OF OSTEOPOROSIS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256149-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256153-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256152-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256113-A1 | TREATMENT OF HYPOPARATHYROIDISM | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017214076-A1 | PEPTIDES HAVING TETRAHEDRAL MIMICKING GROUPS AS INHIBITORS OF RHOMBOID PROTEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355736-A1 | MORTALIN PEPTIDES AND ANTIBODIES AND USES THEREOF FOR INHIBITING MORTALIN ACTIVITY AND TREATING A DISEASE ASSOCIATED WITH A PATHOLOGICAL CELL | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2017212476-A1 | NOVEL MOLECULES FOR THE TREATMENT OF INFLAMMATION | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-12-14 | — | — | WO | disclosed |
| EP-2764009-B1 | PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS | PARADIGM BIOPHARMACEUTICALS LTD (AU) | 2017-12-06 | — | — | EP | disclosed |
| EP-2358745-B1 | LEUKOLECTINS AND USES THEREOF | LEUKOLECT AS (NO) | 2017-11-29 | — | — | EP | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170328895-A1 | FUNCTIONALIZED TITANIUM BINDING PEPTIDES AND IMPLANTS COATED WITH SAME | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2017-11-16 | — | — | US | disclosed |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9815874-B2 | Compositions comprising fibrous polypeptides and polysaccharides | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-11-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2723311-B1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION COMPRISING LEUKOLECTIN AND USES THEREOF | AQUA BIO TECH ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| US-9808506-B2 | Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2017-11-07 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170304412-A1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-10-26 | — | — | US | disclosed |
| US-9796764-B2 | Cyclotide genes in the fabaceae plant family | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-10-24 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9783490-B2 | Antimicrobial compounds, their synthesis and applications thereof | THE SECRETARY OF STATE FOR HEALTH (GB) | 2017-10-10 | — | — | US | disclosed |
| WO-2017168007-A1 | ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS THERAPEUTICS GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283457-A1 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-10-05 | — | — | US | disclosed |
| US-20170281739-A1 | ALPHA-1 ANTI-TRYPSIN FOR TREATING LIVER DISEASES | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2017-10-05 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2785692-B1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3222612-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-3221350-A1 | MORTALIN PEPTIDES AND ANTIBODIES AND USES THEREOF FOR INHIBITING MORTALIN ACTIVITY AND TREATING A DISEASE ASSOCIATED WITH A PATHOLOGICAL CELL | Ramot at Tel-Aviv University Ltd. (IL) | 2017-09-27 | — | — | EP | disclosed |
| US-9770503-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2017-09-26 | — | — | US | disclosed |
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9764008-B2 | Variants of TACE pro-domain as TNF-A inhibitor and their medical use | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-09-19 | — | — | US | disclosed |
| US-9765129-B2 | Treatment of obesity | BAKER MEDICAL RESEARCH INSTITUTE (AU) | 2017-09-19 | — | — | US | disclosed |
| EP-3216805-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | Yeda Research and Development Co. Ltd (IL) | 2017-09-13 | — | — | EP | disclosed |
| EP-2840083-B1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-9758548-B2 | Anti-microbial peptides and uses of same | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-09-12 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2861217-B1 | NANOEMULSIONS | UNIV QUEENSLAND (AU) | 2017-09-06 | — | — | EP | disclosed |
| EP-2509618-B1 | Systemic administration of an agent that permeabilises tumour vasculature | UNIV OXFORD INNOVATION LTD (GB) | 2017-08-30 | — | — | EP | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| WO-2017139845-A1 | NOVEL ALPHA CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-08-24 | — | — | WO | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170233449-A1 | FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2017-08-17 | — | — | US | disclosed |
| US-20170233702-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-17 | — | — | US | disclosed |
| US-9731048-B2 | Functionalized titanium binding peptides and implants coated with same | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2017-08-15 | — | — | US | disclosed |
| WO-2017134671-A1 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226166-A1 | Mu-Conotoxin Peptides And Use Thereof As A Local Anesthetic | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20170218045-A1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-08-03 | — | — | US | disclosed |
| WO-2017132555-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | VEDANTRA PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-3197913-A1 | ALPHA-1 ANTI-TRYPSIN FOR TREATING LIVER DISEASES | Hadasit Medical Research Services And Development (IL) | 2017-08-02 | — | — | EP | disclosed |
| US-9714268-B2 | Use of inhibitory peptides for the treatment of inflammatory diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-07-25 | — | — | US | disclosed |
| US-9708380-B2 | Human leukolectins and uses thereof | LEUKOLECT AS (NO) | 2017-07-18 | — | — | US | disclosed |
| US-20170189478-A1 | HATCHING FLUID ENZYMES AND USES THEREOF | AQUA BIO TECHNOLOGY ASA (NO) | 2017-07-06 | — | — | US | disclosed |
| EP-2977053-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9695402-B2 | ERK-derived peptides and uses thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-07-04 | — | — | US | disclosed |
| US-9687583-B2 | Adhesive biopolymers and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-27 | — | — | US | disclosed |
| US-20170174764-A1 | T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-06-22 | — | — | US | disclosed |
| EP-2771351-B1 | PAT-LM1 EPITOPES AND METHODS FOR USING SAME | PATRYS LTD (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-20170158743-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170152292-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS | INSTITUT NATIONAL DE RECHERCHE AGRONOMIQUE (INRA) (FR) | 2017-06-01 | — | — | US | disclosed |
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3169343-A1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-05-24 | — | — | EP | disclosed |
| US-9644011-B2 | Mu-conotoxin peptides and use thereof as a local anesthetic | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2017-05-09 | — | — | US | disclosed |
| US-20170121381-A1 | PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-05-04 | — | — | US | disclosed |
| WO-2017072772-A1 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-05-04 | — | — | WO | disclosed |
| EP-2846819-B1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RES & DEV (IL) | 2017-05-03 | — | — | EP | disclosed |
| WO-2017068577-A1 | PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2017-04-27 | — | — | WO | disclosed |
| US-9624483-B2 | Hatching fluid enzymes and uses thereof | AQUA BIO TECHNOLOGY ASA (NO) | 2017-04-18 | — | — | US | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2591786-B1 | Immunomodulating compositions and uses therefor | CANCURE LTD (AU) | 2017-04-12 | — | — | EP | disclosed |
| US-20170095547-A1 | MALARIAL ANTIGENS DERIVED FROM SUBTILISIN-LIKE PROTEASE 2 AND VACCINES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY | 2017-04-06 | — | — | US | disclosed |
| US-9611322-B2 | Fusions of antibodies to CD38 and attenuated interferon alpha | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2017-04-04 | — | — | US | disclosed |
| WO-2017053506-A1 | P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-2646548-B1 | IMPROVED LIGHT-EMITTING MOLECULES | GENE STREAM PTY LTD (AU) | 2017-03-22 | — | — | EP | disclosed |
| US-9598478-B2 | Peptides for the treatment of neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-03-21 | — | — | US | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-03-02 | — | — | US | disclosed |
| EP-2781223-B1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR USE IN THE TREATMENT OF CANCER | RAPPAPORT FAMILY INST FOR RES IN THE MEDICAL SCIENCES (IL) | 2017-02-22 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2688582-B1 | NEUROPROTECTIVE PEPTIDES | NEURIM PHARMACEUTICALS (1991) LTD (IL) | 2017-02-15 | — | — | EP | disclosed |
| WO-2017021963-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | BIOKINE THERAPEUTICS LTD. (IL) | 2017-02-09 | — | — | WO | disclosed |
| EP-3122768-A2 | T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES | Yeda Research and Development Co. Ltd. (IL) | 2017-02-01 | — | — | EP | disclosed |
| US-9554995-B2 | Nanoemulsions | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-01-31 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| WO-2017013265-A1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2017-01-26 | — | — | WO | disclosed |
| US-20170022258-A1 | PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS | C4M PHARMACEUTICALS PTY LTD. (AU) | 2017-01-26 | — | — | US | disclosed |
| US-20170015708-A1 | CHEMOKINE BINDING POLYPEPTIDES FOR TREATING AUTOIMMUNITY, AND INFLAMMATION | BIOKINE THERAPEUTICS LTD. (IL) | 2017-01-19 | — | — | US | disclosed |
| EP-3116538-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS | Fondation The Ark (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2723453-B1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION FROM HATCHING FLUID OF SALMONIDAE EGGS AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECH ASA (NO) | 2017-01-18 | — | — | EP | disclosed |
| WO-2017004672-A1 | PEPTIDYL TPOR ANTAGONISTS AND USES THEREOF | POLYMERS CRC LIMITED (AU) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008918-A1 | NOVEL CYP-EICOSANOID DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-12 | — | — | US | disclosed |
| WO-2016177898-A9 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016177899-A9 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-12-29 | — | — | WO | disclosed |
| US-20160375130-A1 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | ARAVAX PTY LTD (AU) | 2016-12-29 | — | — | US | disclosed |
| US-20160367695-A1 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2016-12-22 | — | — | US | disclosed |
| WO-2016201503-A1 | IL-37 VARIANTS | MONASH UNIVERSITY (AU) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205459-A2 | THERAPEUTIC NANOFIBER HYDROGELS FOR LOCAL TREATMENT OF BRAIN-RELATED DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016193746-A1 | METHODS AND PRODUCTS FOR FUSION PROTEIN SYNTHESIS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2016-12-08 | — | — | WO | disclosed |
| US-9511120-B2 | Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation | PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2016-12-06 | — | — | US | disclosed |
| EP-3097076-A1 | NOVEL CYP-EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-20160340659-A1 | ACTIN BINDING PEPTIDES AND COMPOSITIONS COMPRISING SAME FOR INHIBITING ANGIOGENESIS AND TREATING MEDICAL CONDITIONS ASSOCIATED WITH SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-11-24 | — | — | US | disclosed |
| US-20160340655-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-11-24 | — | — | US | disclosed |
| US-9499602-B2 | Non-hemolytic LLO fusion proteins and methods of utilizing same | ADVAXIS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160331819-A1 | TUMOR VASCULAR MARKER-TARGETED VACCINES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2016-11-17 | — | — | US | disclosed |
| US-9493557-B2 | Chemokine binding polypeptides for treating autoimmunity and inflammation | BIOKINE THERAPEUTICS LTD. (IL) | 2016-11-15 | — | — | US | disclosed |
| WO-2016177899-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177900-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177898-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160317458-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3083579-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| CN-106061942-A | Novel cyp-eicosanoid derivatives | 分子医学马克斯德尔布吕克中心 | 2016-10-26 | — | — | CN | disclosed |
| US-9474789-B2 | Methods and compositions for promoting organ growth and development | KINTAN PTY LTD. (AU) | 2016-10-25 | — | — | US | disclosed |
| US-20160303246-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2016-10-20 | — | — | US | disclosed |
| EP-1737884-B1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | UNIV QUEENSLAND (AU) | 2016-10-19 | — | — | EP | disclosed |
| US-9464120-B2 | Compositions for treatment of celiac disease | IMMUSANT, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160289272-A1 | ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2016-10-06 | — | — | US | disclosed |
| US-20160287677-A1 | BACTERIAL ANTI-PHAGE DEFENSE SYSTEMS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-10-06 | — | — | US | disclosed |
| US-9458198-B1 | Cyclic peptide-based NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20160279193-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2016-09-29 | — | — | US | disclosed |
| US-20160279295-A1 | CROSS-LINKED RESILIN-CONTAINING MATERIALS | COLLPLANT LTD. (IL) | 2016-09-29 | — | — | US | disclosed |
| US-20160263182-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2016-09-15 | — | — | US | disclosed |
| EP-3065760-A1 | ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY | Norwegian University of Science and Technology (NTNU) (NO) | 2016-09-14 | — | — | EP | disclosed |
| EP-3065745-A1 | CROSS-LINKED RESILIN-CONTAINING MATERIALS | CollPlant Ltd. (IL) | 2016-09-14 | — | — | EP | disclosed |
| EP-3065759-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | Norwegian University of Science and Technology (NTNU) (NO) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257765-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-09-08 | — | — | US | disclosed |
| WO-2016138288-A1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016138288-A1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-09-01 | — | — | WO | disclosed |
| CN-103339141-B | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | 百时美施贵宝公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2016128970-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128972-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128974-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128973-A1 | TREATMENT OF OSTEOPOROSIS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128971-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| EP-1910535-B1 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME | INST MEDICAL W & E HALL (AU) | 2016-08-17 | — | — | EP | disclosed |
| US-9416195-B2 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-08-16 | — | — | US | disclosed |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160222415-A1 | NUCLEAR TARGETING SEQUENCES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-08-04 | — | — | US | disclosed |
| US-9403887-B2 | Endothelial cell-specific polynucleotides and use thereof | VASCULAR BIOGENICS LTD. (IL) | 2016-08-02 | — | — | US | disclosed |
| US-20160213765-A1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-07-28 | — | — | US | disclosed |
| US-20160215019-A1 | PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-07-28 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| EP-3046929-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | Yeda Research and Development Co., Ltd. (IL) | 2016-07-27 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| WO-2016115290-A1 | PHARMACOLOGICAL MODULATORS OF GABAΑ RECEPTORS AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-21 | — | — | WO | disclosed |
| US-9393287-B2 | Methods and compositions for promoting organ development | KINTAN PTY LTD. (AU) | 2016-07-19 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160193581-A1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| EP-1620558-B1 | VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN AND PROTEIN OF INTEREST | ARTES BIOTECHNOLOGY GMBH (DE) | 2016-07-06 | — | — | EP | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2407484-B1 | Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same | INST MEDICAL W & E HALL (AU) | 2016-06-22 | — | — | EP | disclosed |
| US-20160168212-A1 | COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-06-16 | — | — | US | disclosed |
| WO-2016092555-A2 | ISOLATED PHOSPHOTRIESTERASE POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-06-16 | — | — | WO | disclosed |
| US-20160151454-A1 | LEUKOLECTINS AND USES THEREOF | LEUKOLECT AS (NO) | 2016-06-02 | — | — | US | disclosed |
| EP-3026057-A2 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Ramot at Tel Aviv University Ltd. (IL) | 2016-06-01 | — | — | EP | disclosed |
| EP-2478009-B1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | UNIV RAMOT (IL) | 2016-06-01 | — | — | EP | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9354174-B2 | Biosensor using whispering gallery modes in microspheres | GENERA BIOSYSTEMS LIMITED (AU) | 2016-05-31 | — | — | US | disclosed |
| US-9353359-B2 | Bacterial anti-phage defense systems | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-05-31 | — | — | US | disclosed |
| WO-2016079745-A1 | MORTALIN PEPTIDES AND ANTIBODIES AND USES THEREOF FOR INHIBITING MORTALIN ACTIVITY AND TREATING A DISEASE ASSOCIATED WITH A PATHOLOGICAL CELL | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-26 | — | — | WO | disclosed |
| US-20160145311-A1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-05-26 | — | — | US | disclosed |
| US-9334308-B2 | PLIF multimeric peptides and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-10 | — | — | US | disclosed |
| US-20160122715-A1 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-05 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20160115196-A1 | SELF-ASSEMBLED MICRO-AND NANOSTRUCTURES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| US-9321810-B2 | Uses of kappa opioid synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321810-B2 | Uses of kappa opioid synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160108434-A1 | PHOTOCATALYTIC HYDROGEN PRODUCTION AND POLYPEPTIDES CAPABLE OF SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-04-21 | — | — | US | disclosed |
| EP-1438427-B1 | NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM AND/OR ADENOMA | CLINICAL GENOMICS PTY LTD (AU) | 2016-04-20 | — | — | EP | disclosed |
| US-9315547-B2 | Nuclear targeting sequences | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-04-19 | — | — | US | disclosed |
| EP-3003968-A1 | SELF-ASSEMBLED MICRO- AND NANO-STRUCTURES | Ramot at Tel-Aviv University Ltd. (IL) | 2016-04-13 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2016046822-A1 | ALPHA-1 ANTI-TRYPSIN FOR TREATING LIVER DISEASES | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2016-03-31 | — | — | WO | disclosed |
| US-9290556-B2 | Tumor vascular marker-targeted vaccines | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2339029-B1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | CLINICAL GENOMICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| EP-2073899-B1 | THE USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER | MEDVET SCIENCE PTY LTD (AU) | 2016-03-02 | — | — | EP | disclosed |
| EP-2989119-A1 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Yeda Research and Development Co., Ltd. (IL) | 2016-03-02 | — | — | EP | disclosed |
| US-9273152-B2 | Compositions comprising fibrous polypeptides and polysaccharides | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-03-01 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20160052967-A1 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-02-25 | — | — | US | disclosed |
| US-20160053249-A1 | HATCHING FLUID ENZYMES AND USES THEREOF | AQUA BIO TECHNOLOGY ASA (NO) | 2016-02-25 | — | — | US | disclosed |
| US-9265817-B2 | PAT-LM1 epitopes and methods for using same | PATRYS LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9260498-B2 | Leukolectins and uses thereof | LEUKOLECT AS (NO) | 2016-02-16 | — | — | US | disclosed |
| US-9260454-B2 | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9255132-B2 | Angiopoietin derived peptides | COMPUGEN LTD. (IL) | 2016-02-09 | — | — | US | disclosed |
| US-20160024173-A1 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2016-01-28 | — | — | US | disclosed |
| EP-2977053-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | Immusant, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2406279-B1 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV RAMOT (IL) | 2016-01-27 | — | — | EP | disclosed |
| US-9243032-B2 | Compositions for treatment of neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-01-26 | — | — | US | disclosed |
| WO-2016009436-A1 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-01-21 | — | — | WO | disclosed |
| EP-2155691-B1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RES & DEV (IL) | 2016-01-13 | — | — | EP | disclosed |
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150377890-A1 | METHOD OF DIAGNOSING NEOPLASTIC CONDITIONS | MEDVET SCIENCE PTY LTD (AU) | 2015-12-31 | — | — | US | disclosed |
| US-9217041-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-12-22 | — | — | US | disclosed |
| US-20150359846-A1 | THERAPEUTIC METHOD | PARANTA BIOSCIENCES LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| EP-2955193-A1 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | Fulcrum S.P. Materials Ltd (IL) | 2015-12-16 | — | — | EP | disclosed |
| WO-2015187652-A1 | MALARIAL ANTIGENS DERIVED FROM SUBTILISIN-LIKE PROTEASE 2 AND VACCINES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-2950808-A1 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2015-12-09 | — | — | EP | disclosed |
| CN-101415724-B | Peptide, anti-peptide antibody and carry out the method for Diagnosis and Treat diseases associated with amyloid protein with them | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2015-12-02 | — | — | CN | disclosed |
| US-20150328140-A1 | A COSMETIC COMPOSITION FROM FISH HATCHING FLUID, METHODS FOR ITS PRODUCTION AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECHNOLOGY ASA (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328283-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329478-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | THE SECRETARY OF STATE FOR HEALTH (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150328294-A1 | Novel Immunotherapeutic Molecules and Uses Thereof | ARAVAX PTY LTD (AU) | 2015-11-19 | — | — | US | disclosed |
| US-20150328290-A1 | COSMETIC COMPOSITIONS FROM FISH HATCHING FLUID | AQUA BIO TECHNOLOGY ASA (NO) | 2015-11-19 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-9181555-B2 | Photocatalytic hydrogen production and polypeptides capable of same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-10 | — | — | US | disclosed |
| US-9173882-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307572-A1 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME | COMPUGEN LTD. (IL) | 2015-10-29 | — | — | US | disclosed |
| EP-2934700-A2 | A COSMETIC COMPOSITION FROM FISH HATCHING FLUID, METHODS FOR ITS PRODUCTION AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | Aqua Bio Technology ASA (NO) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934556-A1 | COSMETIC COMPOSITIONS FROM FISH HATCHING FLUID | Aqua Bio Technology ASA (NO) | 2015-10-28 | — | — | EP | disclosed |
| CN-105007990-A | A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin | AQUA BIO TECHNOLOGY ASA | 2015-10-28 | — | — | CN | disclosed |
| US-9169293-B2 | NPR-B agonists | Shire Orphan Thereapies GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20150299263-A1 | COMPLEX-FORMATION-MODULATING AGENTS AND USES THEREFOR | Factor Therapeutics Limited (AU) | 2015-10-22 | — | — | US | disclosed |
| EP-2142256-B1 | TREATMENT OF OBESITY | BAKER MED RES INST (AU) | 2015-10-14 | — | — | EP | disclosed |
| US-9155781-B2 | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2015-10-13 | — | — | US | disclosed |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-10-01 | — | — | US | disclosed |
| US-20150273076-A1 | SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | FULCRUM SP LTD. (IL) | 2015-10-01 | — | — | US | disclosed |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-10-01 | — | — | US | disclosed |
| WO-2015145449-A2 | T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-10-01 | — | — | WO | disclosed |
| EP-2473520-B1 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | SP NANO LTD (IL) | 2015-09-30 | — | — | EP | disclosed |
| US-9145463-B2 | Compositions comprising fibrous polypeptides and polysaccharides | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-09-29 | — | — | US | disclosed |
| US-20150265701-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-09-24 | — | — | US | disclosed |
| US-20150259392-A1 | PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-09-17 | — | — | US | disclosed |
| WO-2015135925-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS | FONDATION THE ARK (CH) | 2015-09-17 | — | — | WO | disclosed |
| US-9133256-B2 | Hatching fluid enzymes and uses thereof | AQUA BIO TECHNOLOGY ASA (NO) | 2015-09-15 | — | — | US | disclosed |
| US-9132164-B2 | Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2015-09-15 | — | — | US | disclosed |
| US-20150252362-A1 | PROGRAMMABLE ITERATED ELONGATION: A METHOD FOR MANUFACTURING SYNTHETIC GENES AND COMBINATORIAL DNA AND PROTEIN LIBRARIES | YEDA RES & DEV (IL) | 2015-09-10 | — | — | US | disclosed |
| EP-2914286-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | Monash University (AU) | 2015-09-09 | — | — | EP | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9120865-B2 | T cell epitopes of the Cyn d 1 allergen from bermuda grass pollen | CIRCASSIA LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| EP-2220112-B1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | YISSUM RES DEV CO (IL) | 2015-08-26 | — | — | EP | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
| EP-2907514-A1 | Purine derivative compounds for medical use | Manros Therapeutics (FR) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906583-A1 | PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Ramot at Tel-Aviv University Ltd. (IL) | 2015-08-19 | — | — | EP | disclosed |
| US-20150225463-A1 | ASTEXIN PEPTIDES | NATIONAL SCIENCE FOUNDATION | 2015-08-13 | — | — | US | disclosed |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-08-06 | — | — | US | disclosed |
| WO-2015114633-A1 | ACTIN BINDING PEPTIDES AND COMPOSITIONS COMPRISING SAME FOR INHIBITING ANGIOGENES IS AND TREATING MEDICAL CONDITIONS ASSOCIATED WITH SAME | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015110262-A1 | NOVEL CYP-EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2015-07-30 | — | — | WO | disclosed |
| EP-2487616-B1 | Programmable iterated elongation: a method for manufacturing synthetic genes and combinatorial DNA and protein libraries | YEDA RES & DEV (IL) | 2015-07-29 | — | — | EP | disclosed |
| EP-2719394-B1 | Peptides for treating amyloid-associated diseases | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2015-07-29 | — | — | EP | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2015104713-A1 | COLORING COMPOSITIONS AND METHODS | Ramot at Tel- Aviv University Ltd. (IL) | 2015-07-16 | — | — | WO | disclosed |
| EP-2242751-B1 | HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-15 | — | — | EP | disclosed |
| US-9079898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150190472-A1 | USE OF THE ANGIOTENSIN-(1-9) PEPTIDE OR DERIVATIVES THEREOF, USE OF VECTORS OVEREXPRESSING THE ACE2 ENZYME THAT PRODUCES ANGIOTENSIN-(1-9) FOR PREPARING MEDICAMENTS USEFUL FOR PREVENTING, REVERTING, INHIBITING AND/OR REDUCING HYPERTENSION AND/OR INDUCING VASODILATION | PONTIFICA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2015-07-09 | — | — | US | disclosed |
| EP-1931370-B1 | USE OF DES-ASPARTATE-ANGIOTENSIN I | UNIV SINGAPORE (SG) | 2015-07-08 | — | — | EP | disclosed |
| US-9073990-B2 | Protease-activatable pore-forming polypeptides | BAR-LLAN UNIVERSITY (IL) | 2015-07-07 | — | — | US | disclosed |
| WO-2015095346-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-1756548-B1 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES | GENERA BIOSYSTEMS LTD (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-9063155-B2 | Immunotherapeutic method of treating neoplastic conditions | MEDVET SCIENCE PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150164992-A1 | METHODS AND COMPOSITIONS FOR PROMOTING ORGAN GROWTH AND DEVELOPMENT | KINTAN PTY LTD. (AU) | 2015-06-18 | — | — | US | disclosed |
| US-9050352-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-06-09 | — | — | US | disclosed |
| US-9051379-B2 | Sp1 polypeptides, modified Sp1 polypeptides and uses thereof | FULCRUM SP LTD. (IL) | 2015-06-09 | — | — | US | disclosed |
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152311-A1 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | FULCRUM S.P. MATERIALS LTD. (IL) | 2015-06-04 | — | — | US | disclosed |
| EP-2563806-B1 | HUMAN LEUKOLECTINS AND USES THEREOF | LEUKOLECT AS (NO) | 2015-06-03 | — | — | EP | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| EP-1609865-B1 | Hepatitis B virus (HBV) variants | ABL SA (LU) | 2015-05-27 | — | — | EP | disclosed |
| EP-2443137-B1 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2015-05-20 | — | — | EP | disclosed |
| EP-2367561-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT INC (US) | 2015-05-20 | — | — | EP | disclosed |
| CN-102348678-B | Novel eicosanoid derivatives | MAX DELBRUECK CENTRUM | 2015-05-20 | — | — | CN | disclosed |
| WO-2015067713-A1 | ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067712-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015068160-A1 | CROSS-LINKED RESILIN-CONTAINING MATERIALS | COLLPLANT LTD. (IL) | 2015-05-14 | — | — | WO | disclosed |
| US-20150132395-A1 | NANOEMULSIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-05-14 | — | — | US | disclosed |
| US-20150132281-A1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-05-14 | — | — | US | disclosed |
| US-9029526-B2 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-05-12 | — | — | US | disclosed |
| US-20150125430-A1 | COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-9023800-B2 | Peptides for the treatment of oxidative stress related disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-05-05 | — | — | US | disclosed |
| US-20150119334-A1 | FUNCTIONALIZED TITANIUM BINDING PEPTIDES AND IMPLANTS COATED WITH SAME | Ben-Gurion niversity of the Negev Research and Development Authority (IL) | 2015-04-30 | — | — | US | disclosed |
| US-9018390-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018390-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20150111957-A1 | Endothelial Cell-Specific Polynucleotides and Use Thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-04-23 | — | — | US | disclosed |
| EP-2861217-A1 | NANOEMULSIONS | The University Of Queensland (AU) | 2015-04-22 | — | — | EP | disclosed |
| US-9012152-B2 | Anti-bacterial peptides and methods of treating diseases using same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-04-21 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-1597350-B1 | NUCLEIC ACID MOLECULES, AND COMPOSITIONS CONTAINING SAME USEFUL FOR TREATING AND DETECTING INFLUENZA VIRUS INFECTION | YEDA RES & DEV (IL) | 2015-04-08 | — | — | EP | disclosed |
| EP-2568044-B1 | Tumor vascular marker-targeted vaccines | UNIV PENNSYLVANIA (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855507-A1 | FUNCTIONALIZED TITANIUM BINDING PEPTIDES AND IMPLANTS COATED WITH SAME | Ben-Gurion University of The Negev Research and Development Authority (IL) | 2015-04-08 | — | — | EP | disclosed |
| US-20150094452-A1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | COLLPLANT LTD. (IL) | 2015-04-02 | — | — | US | disclosed |
| US-8993510-B2 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2015-03-31 | — | — | US | disclosed |
| WO-2015040609-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-03-26 | — | — | WO | disclosed |
| US-8987191-B2 | Bioactive peptides and methods of using same | COMPUGEN LTD. (IL) | 2015-03-24 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2419433-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2840083-A1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2839839-A1 | Nuclear targeting sequences | Yeda Research And Development Company Limited (IL) | 2015-02-25 | — | — | EP | disclosed |
| US-8962532-B2 | Programmable iterated elongation: a method for manufacturing synthetic genes and combinatorial DNA and protein libraries | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-02-24 | — | — | US | disclosed |
| US-20150050303-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-8957189-B2 | Multi-site modified SP1 polypeptides and uses thereof | FULCRUM S.P. MATERIALS LTD. (IL) | 2015-02-17 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031600-A1 | DESIGNED BIOSURFACTANTS, THEIR MANUFACTURE, PURIFICATION AND USE | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-29 | — | — | US | disclosed |
| EP-2828280-A1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2015-01-28 | — | — | EP | disclosed |
| WO-2015006833-A1 | A METHOD FOR TREATING TYPE 1 DIABETES | ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-01-22 | — | — | WO | disclosed |
| EP-2825642-A1 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | Yeda Research and Development Co. Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2063906-B1 | CSF-1 FOR PROMOTING KIDNEY AND LUNG DEVELOPMENT | KINTAN PTY LTD (AU) | 2015-01-07 | — | — | EP | disclosed |
| US-8927689-B2 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-01-06 | — | — | US | disclosed |
| US-20150005227-A1 | METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURY-RELATED DISORDER BY ADMINISTERING GPCR LIGANDS | COMPUGEN LTD. (IL) | 2015-01-01 | — | — | US | disclosed |
| US-8921306-B2 | Nociceptin mimetics | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8920806-B2 | Method of modulating inflammatory response by downregulation of activin | PARANTA BIOSCIENCES LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-20140371131-A1 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-12-18 | — | — | US | disclosed |
| US-8906651-B2 | Compositions comprising fibrous polypeptides and polysaccharides | COLLPLANT LTD. (IL) | 2014-12-09 | — | — | US | disclosed |
| US-8906859-B2 | Uses of kappa opioid synthetic peptide amides | Cera Therapeutics, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906859-B2 | Uses of kappa opioid synthetic peptide amides | Cera Therapeutics, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014191997-A1 | SELF-ASSEMBLED MICRO- AND NANO-STRUCTURES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-12-04 | — | — | WO | disclosed |
| US-8901074-B2 | Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY (IL) | 2014-12-02 | — | — | US | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2014-11-27 | — | — | US | disclosed |
| US-8895698-B2 | Binding partners of antibodies specific for dendritic cell antigens | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2014-11-25 | — | — | US | disclosed |
| EP-2092071-B1 | COMPOSITIONS AND METHODS FOR CONCENTRATING AND DEPLETING MICROORGANISMS | TECHNION RES & DEV FOUNDATION (IL) | 2014-11-12 | — | — | EP | disclosed |
| US-20140329761-A1 | PREVENTION AND TREATMENT OF ACUTE INFLAMMATORY CONDITIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-11-06 | — | — | US | disclosed |
| CN-101965357-B | Polypeptides, matrices, hydrogels and methods of using them for tissue regeneration and repair | UNIV RAMOT | 2014-11-05 | — | — | CN | disclosed |
| WO-2014174520-A1 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-10-30 | — | — | WO | disclosed |
| US-20140315740-A1 | ANTIGEN ARRAY AND DIAGNOSTIC USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-10-23 | — | — | US | disclosed |
| EP-2377544-B1 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2014-10-22 | — | — | EP | disclosed |
| EP-2435425-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140302074-A1 | Pat-LM1 Epitopes and Methods for Using Same | PATRYS LIMITED (AU) | 2014-10-09 | — | — | US | disclosed |
| US-20140296169-A1 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| EP-2049114-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2414352-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8846023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140286895-A1 | Methods and Compositions for Promoting Organ Development | KINTAN PTY LTD. (AU) | 2014-09-25 | — | — | US | disclosed |
| EP-2781223-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2014-09-24 | — | — | EP | disclosed |
| US-8835603-B2 | Agents for the treatment of celiac disease | IMMUSANT, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140255455-A1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION COMPRISING LEUKOLECTIN AND USES THEREOF | AQUA BIO TECHNOLOGY ASA (NO) | 2014-09-11 | — | — | US | disclosed |
| US-20140256641-A1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | COLLPLANT LTD. (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8828940-B2 | Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands | COMPUGEN LTD. (IL) | 2014-09-09 | — | — | US | disclosed |
| US-20140248304-A1 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME | ADVAXIS (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248238-A1 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2014-09-04 | — | — | US | disclosed |
| EP-2771351-A1 | PAT-LM1 EPITOPES AND METHODS FOR USING SAME | Patrys Limited (AU) | 2014-09-03 | — | — | EP | disclosed |
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2764009-A1 | PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS | C4m Pharmaceuticals Pty Ltd. (AU) | 2014-08-13 | — | — | EP | disclosed |
| US-8802625-B2 | Methods for promoting organ development | KINTAN PTY LTD. (AU) | 2014-08-12 | — | — | US | disclosed |
| WO-2014118785-A1 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-08-07 | — | — | WO | disclosed |
| US-20140220088-A1 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION FROM HATCHING FLUID AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECHNOLOGY ASA (NO) | 2014-08-07 | — | — | US | disclosed |
| US-8796023-B2 | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-08-05 | — | — | US | disclosed |
| US-20140212438-A1 | NUCLEAR TARGETING SEQUENCES | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-07-31 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785373-B2 | Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) | 2014-07-22 | — | — | US | disclosed |
| WO-2014066936-A9 | SUPRAMOLECULAR STRUCTURE | MONASH UNIVERSITY (AU) | 2014-07-10 | — | — | WO | disclosed |
| EP-2751132-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2014-07-09 | — | — | EP | disclosed |
| EP-2752423-A2 | GPCR ligands and method of using same | Compugen Ltd. (IL) | 2014-07-09 | — | — | EP | disclosed |
| US-8771702-B2 | Non-hemolytic LLO fusion proteins and methods of utilizing same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014102782-A1 | COMPOSITIONS AND METHODS OF KILLING BACTERIA | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2014-07-03 | — | — | WO | disclosed |
| EP-2417126-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2435429-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140178483-A1 | SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2014-06-26 | — | — | US | disclosed |
| US-20140178353-A1 | BACTERIAL ANTI-PHAGE DEFENSE SYSTEMS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-06-26 | — | — | US | disclosed |
| WO-2014096187-A2 | A COSMETIC COMPOSITION FROM FISH HATCHING FLUID, METHODS FOR ITS PRODUCTION AND USES THEREOF FOR IMPROVING THE COSMETIC APPEARANCE OF SKIN | AQUA BIO TECHNOLOGY ASA (NO) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014094918-A1 | COSMETIC COMPOSITIONS FROM FISH HATCHING FLUID | AQUA BIO TECHNOLOGY ASA (NO) | 2014-06-26 | — | — | WO | disclosed |
| EP-2210092-B1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF | RAPPAPORT FAMILY INST FOR RES (IL) | 2014-06-11 | — | — | EP | disclosed |
| US-8748415-B2 | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748371-B2 | Nuclear targeting sequences | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-06-10 | — | — | US | disclosed |
| US-20140154249-A1 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2014-06-05 | — | — | US | disclosed |
| WO-2014082379-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| US-8741843-B2 | Compositions and methods for inducing angiogenesis | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-06-03 | — | — | US | disclosed |
| WO-2014078889-A1 | IMPROVED INHIBITORS OF GRB7 | MONASH UNIVERSITY (AU) | 2014-05-30 | — | — | WO | disclosed |
| CN-101784522-B | Proton acceptor iminium/carbocationic coupling agents | LUXEMBOURG BIOTECHNOLOGIES LTD | 2014-05-28 | — | — | CN | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735124-B2 | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735348-B2 | Casein derived peptides and uses thereof | Peptera Ltd. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-20140141014-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-05-22 | — | — | US | disclosed |
| US-20140140949-A1 | TREATMENT OF OBESITY | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140127762-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE | API CORPORATION (JP) | 2014-05-08 | — | — | US | disclosed |
| WO-2014066939-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | MONASH UNIVERSITY (AU) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014066936-A1 | SUPRAMOLECULAR STRUCTURE | MONASH UNIVERSITY (AU) | 2014-05-08 | — | — | WO | disclosed |
| US-8716222-B2 | Methods and compositions for promoting organ development | KINTAN PTY LTD. (AU) | 2014-05-06 | — | — | US | disclosed |
| US-8710179-B2 | Compositions and methods for concentrating and depleting microorganisms | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-04-29 | — | — | US | disclosed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20140105898-A1 | APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR | Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo (IT) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057484-A1 | PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-04-17 | — | — | WO | disclosed |
| EP-1765378-B1 | AGENT CAPABLE OF DOWNREGULATING AN MSF-A-DEPENDENT HIF-1A AND USE THEREOF IN CANCER TREATMENT | MEDICAL RES FUND OF TEL AVIV SOURASKY MEDICAL CT (IL) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719394-A1 | Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases | Tel Aviv University Future Technology Development L.P. (IL) | 2014-04-16 | — | — | EP | disclosed |
| US-8697078-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-04-15 | — | — | US | disclosed |
| US-8697634-B2 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2014-04-15 | — | — | US | disclosed |
| US-20140087997-A1 | ANTI-MICROBIAL PEPTIDES AND USES OF SAME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-03-27 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| EP-1677816-B1 | FOLLISTATIN FOR USE IN DOWN-REGULATION AN INFLAMMATORY RESPONSE | PARANTA BIOSCIENCES LTD (AU) | 2014-03-12 | — | — | EP | disclosed |
| US-8669050-B2 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | CLINICAL GENOMICS PTY. LTD. (AU) | 2014-03-11 | — | — | US | disclosed |
| WO-2014036213-A1 | ASTEXIN PEPTIDES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140056811-A1 | NEW CELL-PENETRATING PEPTIDES AND USES THEREOF | COMPUGEN LTD. (IL) | 2014-02-27 | — | — | US | disclosed |
| EP-1569956-B1 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2014-02-26 | — | — | EP | disclosed |
| US-20140050695-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050695-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140045764-A1 | NEUROPROTECTIVE PEPTIDES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2014-02-13 | — | — | US | disclosed |
| CN-101702906-B | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | YEDA RES & DEV | 2014-02-12 | — | — | CN | disclosed |
| US-8642025-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642025-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140027655-A1 | PEPTIDE NANOSTRUCTURES AND METHODS OF GENERATING AND USING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-01-30 | — | — | US | disclosed |
| EP-2688582-A1 | NEUROPROTECTIVE PEPTIDES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017195-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-8629241-B2 | Alpha helical mimics, their uses and methods for their production | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-01-14 | — | — | US | disclosed |
| US-20140004175-A1 | ANGIOPOIETIN DERIVED PEPTIDES | COMPUGEN LTD. (IL) | 2014-01-02 | — | — | US | disclosed |
| US-20140005097-A1 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME | COMPUGEN LTD. (IL) | 2014-01-02 | — | — | US | disclosed |
| US-20130345136-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130345394-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-1328647-B1 | ISOMALTULOSE SYNTHASE | UNIV QUEENSLAND (AU) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013185178-A1 | NANOEMULSIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-12-19 | — | — | WO | disclosed |
| US-20130338076-A1 | PEPTIDES AND METHODS USING SAME FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASE | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2013-12-19 | — | — | US | disclosed |
| EP-2015766-B1 | CYCLISED ALPHA-CONOTOXIN VC1.1 FOR USE IN THE ORAL TREATMENT OF PAIN | UNIV QUEENSLAND (AU) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013183048-A1 | FUNCTIONALIZED TITANIUM BINDING PEPTIDES AND IMPLANTS COATED WITH SAME | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2013-12-12 | — | — | WO | disclosed |
| US-20130330349-A1 | HIGH AFFINITY MOLECULES CAPABLE OF BINDING A TYPE A PLEXIN RECEPTOR AND USES OF SAME | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2013-12-12 | — | — | US | disclosed |
| EP-1858914-B1 | PEPTIDE NETWORKS | UNIV QUEENSLAND (AU) | 2013-12-04 | — | — | EP | disclosed |
| US-8575307-B2 | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2013-11-05 | — | — | US | disclosed |
| US-8574563-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8574563-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575107-B2 | Clusterin derived peptide | COMPUGEN LTD. (IL) | 2013-11-05 | — | — | US | disclosed |
| US-20130287726-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2013-10-31 | — | — | US | disclosed |
| US-20130287806-A1 | IMMUNE-MODULATING AGENTS AND USES THEREFOR | UNIVERSITY OF TECHNOLOGY, SYDNEY (AU) | 2013-10-31 | — | — | US | disclosed |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-24 | — | — | US | disclosed |
| US-8563273-B2 | Method of screening for compounds that disaggregate amyloid aggregates | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-17 | — | — | US | disclosed |
| US-20130273582-A1 | LIGHT-EMITTING MOLECULES | PROMEGA CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8551938-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-08 | — | — | US | disclosed |
| CN-103339141-A | C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-10-02 | — | — | CN | disclosed |
| US-8546330-B2 | Compositions and methods for treatment of neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-10-01 | — | — | US | disclosed |
| US-8546523-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2013140389-A1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-09-26 | — | — | WO | disclosed |
| US-20130252905-A1 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-09-26 | — | — | US | disclosed |
| CN-101027546-B | Biosensor using whispering gallery modes in microspheres | GENERA BIOSYSTEM PTY LTD | 2013-09-25 | — | — | CN | disclosed |
| WO-2013136335-A1 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244946-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-09-19 | — | — | US | disclosed |
| CN-101595577-B | Photovoltaic device and method for manufacturing same | UNIV RAMOT | 2013-09-11 | — | — | CN | disclosed |
| US-8529943-B2 | Angiopoietin derived peptides | COMPUGEN LTD. (IL) | 2013-09-10 | — | — | US | disclosed |
| US-8530407-B2 | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2013-09-10 | — | — | US | disclosed |
| US-8524898-B2 | Proton acceptor iminium/carbocation-type coupling agents | LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) | 2013-09-03 | — | — | US | disclosed |
| US-20130225793-A1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | COLLPLANT LTD. (IL) | 2013-08-29 | — | — | US | disclosed |
| US-20130224225-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2013-08-29 | — | — | US | disclosed |
| US-8513194-B2 | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2013-08-20 | — | — | US | disclosed |
| US-8512708-B2 | GP96 derived peptides | COMPUGEN LTD. (IL) | 2013-08-20 | — | — | US | disclosed |
| US-20130209491-A1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2013-08-15 | — | — | US | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2013114363-A2 | ANTIMICROBIAL AGENTS | YEDA RESEARCH AND DEVELOPMENT CO.LTD. (IL) | 2013-08-08 | — | — | WO | disclosed |
| US-20130203667-A1 | Methods and Compositions for Promoting Organ Development | KINTAN PTY LTD. (AU) | 2013-08-08 | — | — | US | disclosed |
| US-20130203676-A1 | MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC | ACTIVEN SA (CH) | 2013-08-08 | — | — | US | disclosed |
| US-8501697-B2 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-08-06 | — | — | US | disclosed |
| US-20130189706-A1 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES | PAUL MULVANEY (AU) | 2013-07-25 | — | — | US | disclosed |
| US-20130189223-A1 | Methods and Compositions for Promoting Renal Repair and Regeneration | KINTAN PTY LTD. (AU) | 2013-07-25 | — | — | US | disclosed |
| US-8492329-B2 | Bioactive peptides and methods of using same | COMPUGEN LTD. (IL) | 2013-07-23 | — | — | US | disclosed |
| US-8492553-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492553-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486653-B2 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| US-8489339-B2 | Crystalline composition of GM-CSF/GM-CSFR | ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-16 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8470770-B2 | Antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2013-06-25 | — | — | US | disclosed |
| US-20130157928-A1 | NOCICEPTIN MIMETICS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-06-20 | — | — | US | disclosed |
| EP-2600885-A2 | METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES | Ramot at Tel Aviv University, Ltd. (IL) | 2013-06-12 | — | — | EP | disclosed |
| US-8461297-B2 | Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseases | RAMOT AT TEL-AVIV UNIVERSITY, LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| EP-2599790-A1 | Compositions comprising fibrous polypeptides and polysachharides | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2013-06-05 | — | — | EP | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-8450323-B2 | Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20130129742-A1 | Human leukolectins and uses thereof | LEUKOLECT AS (NO) | 2013-05-23 | — | — | US | disclosed |
| US-20130130976-A1 | METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-05-23 | — | — | US | disclosed |
| US-20130121915-A1 | PROTEASE-ACTIVATABLE PORE-FORMING POLYPEPTIDES | BAR-LLAN UNIVERSITY (IL) | 2013-05-16 | — | — | US | disclosed |
| US-20130123187-A1 | PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-05-16 | — | — | US | disclosed |
| EP-2591786-A1 | Immunomodulating compositions and uses therefor | Ralph, Stephen John (AU) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116342-A1 | SALT-RESISTANT EMULSIONS | PEPFACTANTS PTY LTD (AU) | 2013-05-09 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013059885-A2 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | CEPHALON AUSTRALIA PTY LTD (AU) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2013059886-A1 | PAT-LM1 EPITOPES AND METHODS FOR USING SAME | PATRYS LIMITED (AU) | 2013-05-02 | — | — | WO | disclosed |
| US-8431158-B2 | Compositions comprising fibrous polypeptides and polysaccharides | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-04-30 | — | — | US | disclosed |
| US-20130101550-A1 | PRODUCT AND METHOD FOR PERMEABILISATION OF TUMOR VASCULATURE | ISIS INNOVATION LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130096073-A1 | Casein Derived Peptides And Uses Thereof | SIDELMAN ZVI (IL) | 2013-04-18 | — | — | US | disclosed |
| EP-1121128-B1 | Amiloride analogues for use in a method of modulating ion channel functional activity and treating HIV infection | BIOTRON LTD (AU) | 2013-04-17 | — | — | EP | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085262-A1 | NOVEL SURFACE ANTIGEN | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085188-A1 | PEPTIDE NETWORKS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130085261-A1 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130075703-A1 | PEPTIDE NANOSTRUCTURES ENCAPSULATING A FOREIGN MATERIAL AND METHOD OF MANUFACTURING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079390-A1 | NUCLEIC ACID MOLECULES, POLYPEPTIDES, ANTIBODIES AND COMPOSITIONS FOR TREATING AND DETECTING INFLUENZA VIRUS INFECTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-8399202-B2 | Peptides for development of diagnostic and therapeutic agents and methods of using same | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-03-19 | — | — | US | disclosed |
| US-20130065961-A1 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2185575-B1 | POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR | UNIV RAMOT (IL) | 2013-03-13 | — | — | EP | disclosed |
| EP-2568044-A1 | Tumor vascular marker-targeted vaccines | The Trustees of The University of Pennsylvania (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013030840-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-03-07 | — | — | WO | disclosed |
| US-8388962-B2 | Molecules and methods of using same for treating MCP-1/CCR2 associated diseases | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2013-03-05 | — | — | US | disclosed |
| WO-2013026089-A1 | PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS | C4M PHARMACEUTICALS PTY LTD (AU) | 2013-02-28 | — | — | WO | disclosed |
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8377980-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377980-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378070-B2 | Peptides for the regulation of neurotransmitter sequestration and release | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-02-19 | — | — | US | disclosed |
| US-20130039922-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-02-14 | — | — | US | disclosed |
| EP-2556085-A2 | PROTEASE-ACTIVATABLE PORE-FORMING POLYPEPTIDES | Bar-Ilan University (IL) | 2013-02-13 | — | — | EP | disclosed |
| US-8372818-B2 | Targeted double stranded RNA mediated cell killing | Yissum Research Development Company of the Hebrew Univiersity of Jerusalem (IL) | 2013-02-12 | — | — | US | disclosed |
| US-20130034520-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130034520-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130030158-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-01-31 | — | — | US | disclosed |
| EP-2550291-A1 | SALT-RESISTANT EMULSIONS | Pepfactants PTY Ltd (AU) | 2013-01-30 | — | — | EP | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-8357789-B2 | comprising an RNA sequence capable of specifically binding a polypeptide participating in influenza virus infection of cells | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-01-22 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8354372-B2 | Cyclised alpha-conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-01-15 | — | — | US | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| US-8349801-B2 | Peptide ligands for G-protein coupled receptors | COMPUGEN LTD. (IL) | 2013-01-08 | — | — | US | disclosed |
| US-8350004-B2 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-01-08 | — | — | US | disclosed |
| US-20130004457-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-03 | — | — | US | disclosed |
| US-20130004457-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-03 | — | — | US | disclosed |
| US-20120328570-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-27 | — | — | US | disclosed |
| US-20120328570-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-27 | — | — | US | disclosed |
| US-8338370-B2 | Methods and compositions for promoting organ development | KINTAN PTY LTD. (AU) | 2012-12-25 | — | — | US | disclosed |
| US-8329159-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329159-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120309689-A1 | HATCHING FLUID ENZYMES AND USES THEREOF | AQUA BIO TECHNOLOGY ASA (NO) | 2012-12-06 | — | — | US | disclosed |
| EP-2528949-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-12-05 | — | — | EP | disclosed |
| US-8324355-B2 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | Yeda Reearch and Development Co. Ltd (IL) | 2012-12-04 | — | — | US | disclosed |
| US-20120295837-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-11-22 | — | — | US | disclosed |
| US-8314069-B2 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-11-20 | — | — | US | disclosed |
| WO-2012153337-A2 | ANTI-MICROBIAL PEPTIDES AND USES OF SAME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-11-15 | — | — | WO | disclosed |
| EP-1578787-B1 | NOVEL CHI-CONOTOXIN PEPTIDES (-II) | XENOME LTD (AU) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283192-A1 | METHOD OF TREATING CONDITIONS ASSOCIATED WITH AIRWAY TISSUE REMODELING | CRC FOR ASTHMA AND AIRWAYS LTD. (AU) | 2012-11-08 | — | — | US | disclosed |
| US-8303944-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8303944-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-01 | — | — | US | disclosed |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-01 | — | — | US | disclosed |
| US-20120277166-A1 | CONOTOXIN PEPTIDES USEFUL AS INHIBITORS OF NEURONAL AMINE TRANSPORTERS | XENOME LIMITED (AU) | 2012-11-01 | — | — | US | disclosed |
| EP-1468076-B1 | AroQ-deficient Bordetella strain and uses thereof | MUKKUR TRILOCHAN KANWALJIT SINGH (AU) | 2012-10-31 | — | — | EP | disclosed |
| US-8299219-B2 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-10-30 | — | — | US | disclosed |
| US-8299027-B2 | Method of modulating cell survival and reagents useful for same | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-10-30 | — | — | US | disclosed |
| WO-2012142666-A1 | METHOD OF MODULATING AMINE OXIDASE ACTIVITY AND AGENTS USEFUL FOR SAME | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012142659-A1 | SITE-SELECTIVE MODIFICATION OF PROTEINS | BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2012-10-26 | — | — | WO | disclosed |
| CN-101065131-B | Antimicrobial agents | TECHNION RES & DEV FOUNDATION | 2012-10-24 | — | — | CN | disclosed |
| US-20120264676-A1 | MULTI-COMPONENT ANTIOXIDANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR REDUCING OR PREVENTING OXIDATIVE STRESS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-10-18 | — | — | US | disclosed |
| EP-2509618-A2 | SYSTEMIC ADMINISTRATION OF AN AGENT THAT PERMEABILISES TUMOUR VASCULATURE | Isis Innovation Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-8288562-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288562-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120258070-A1 | Methods and Compositions for Promoting Organ Development | KINTAN PTY LTD. (AU) | 2012-10-11 | — | — | US | disclosed |
| WO-2012127475-A1 | NEUROPROTECTIVE PEPTIDES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2012-09-27 | — | — | WO | disclosed |
| US-20120244575-A1 | CYCLOTIDE GENES IN THE FABACEAE PLANT FAMILY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-09-27 | — | — | US | disclosed |
| US-8273527-B2 | Identifying nucleoside resistant hepatitis b virus based on presence of mutation in polymerase gene | MELBOURNE HEALTH (AU) | 2012-09-25 | — | — | US | disclosed |
| US-20120238507-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-09-20 | — | — | US | disclosed |
| EP-1599226-B1 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY LTD (AU) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225822-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-09-06 | — | — | US | disclosed |
| US-20120219498-A1 | COMPOSITIONS AND METHODS FOR INDUCING ANGIOGENESIS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-08-30 | — | — | US | disclosed |
| WO-2012114339-A1 | HIGH AFFINITY MOLECULES CAPABLE OF BINDING A TYPE A PLEXIN RECEPTOR AND USES OF SAME | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2012-08-30 | — | — | WO | disclosed |
| EP-2492278-A1 | Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy | Compugen Ltd. (IL) | 2012-08-29 | — | — | EP | disclosed |
| US-20120213834-A1 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-08-23 | — | — | US | disclosed |
| EP-2487616-A1 | Programmable iterated elongation: a method for manufacturing synthetic genes and combinatorial DNA and protein libraries | Yeda Research And Development Company Limited (IL) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487182-A2 | SP1 polypeptides, modified SP1 polypeptides and uses thereof | FULCRUM SP Ltd. (IL) | 2012-08-15 | — | — | EP | disclosed |
| US-8242076-B2 | Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-08-14 | — | — | US | disclosed |
| US-20120202397-A1 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | FULCRUM S.P. MATERIALS LTD. (IL) | 2012-08-09 | — | — | US | disclosed |
| EP-2242752-B1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-08 | — | — | EP | disclosed |
| CN-101516902-B | Polypeptides and polynucleotides encoding same and their use in treating medical conditions associated with ischemia | VASCULAR BIOGENICS LTD | 2012-08-08 | — | — | CN | disclosed |
| US-8236766-B2 | Uses of synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236766-B2 | Uses of synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2478009-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | Ramot at Tel-Aviv University Ltd. (IL) | 2012-07-25 | — | — | EP | disclosed |
| US-8227419-B2 | Method of treating conditions associated with airway tissue remodeling | CRC FOR ASTHMA AND AIRWAYS LTD. (AU) | 2012-07-24 | — | — | US | disclosed |
| US-8227413-B2 | Compositions and methods for inducing angiogenesis | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-07-24 | — | — | US | disclosed |
| WO-2012095523-A1 | ANALGESIC COMPOSITION FOR TRANSBUCCAL ADMINISTRATION | THERALPHA (FR) | 2012-07-19 | — | — | WO | disclosed |
| US-20120183580-A1 | Analgesic Composition for Transbuccal Administration | THERALPHA (FR) | 2012-07-19 | — | — | US | disclosed |
| EP-2476410-A1 | An analgesic peptide-containing composition for transbuccal administration | Theralpha (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178668-A1 | PROTEINACEOUS COMPOUNDS AND USES THEREFOR | BAKER HEART RESEARCH INSTITUTE (AU) | 2012-07-12 | — | — | US | disclosed |
| EP-2473520-A2 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | Fulcrum S.P. Materials Ltd (IL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012090150-A2 | NEW CELL-PENETRATING PEPTIDES AND USES THEREOF | COMPUGEN LTD (IL) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANGIOTENSIN-(1-9), DERIVATIVES THEREOF, OR A VECTOR EXPRESSING ACE2, USEFUL FOR TREATING CARDIOVASCULAR, PULMONARY, CEREBRAL, AND/OR RENAL REMODELING | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2012-07-05 | — | — | US | disclosed |
| EP-2167534-B1 | BIOACTIVE PEPTIDES AND METHOD OF USING SAME | COMPUGEN LTD (IL) | 2012-07-04 | — | — | EP | disclosed |
| US-8211928-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211852-B2 | Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2012-07-03 | — | — | US | disclosed |
| US-8212001-B2 | Peptides for the treatment of oxidative stress related disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-07-03 | — | — | US | disclosed |
| US-8211928-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212005-B2 | Optoelectronic device and method of fabricating the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-07-03 | — | — | US | disclosed |
| EP-2468294-A1 | A method of modulating cellular activity and agents for use therein | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2012-06-27 | — | — | EP | disclosed |
| EP-1723235-B1 | MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME | INST MEDICAL W & E HALL (AU) | 2012-06-27 | — | — | EP | disclosed |
| US-8207309-B2 | Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| WO-2012079125-A1 | DESIGNED BIOSURFACTANTS, THEIR MANUFACTURE, PURIFICATION AND USE | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-06-21 | — | — | WO | disclosed |
| US-8193310-B2 | Short chain peptide; conformation scaffolds; diecting amino acids into positions; controlling apoptosis; tumor suppression; alcoholism; drug abuse; antiepileptic agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-06-05 | — | — | US | disclosed |
| EP-2146984-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8188048-B2 | Combination therapy | XENOME LIMITED (AU) | 2012-05-29 | — | — | US | disclosed |
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129776-A1 | Bioactive peptides and method of using same | COMPUGEN LTD. (IL) | 2012-05-24 | — | — | US | disclosed |
| US-20120128659-A1 | AGENTS CAPABLE OF DOWNREGULATING AN MSF-A - DEPENDENT HIF-1ALPHA AND USE THEREOF IN CANCER TREATMENT | MEDICAL RESEARCH FUND OF TEL AVIV SOURASKY MEDICAL CENTER (IL) | 2012-05-24 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120123093-A1 | NOVEL SURFACE ANTIGEN | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8173659-B2 | Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20120101029-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2012-04-26 | — | — | US | disclosed |
| EP-2245027-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20120087969-A1 | Mu-Conotoxin Peptides and Use Thereof as a Local Anesthetic | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-04-12 | — | — | US | disclosed |
| US-20120087921-A1 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2012-04-12 | — | — | US | disclosed |
| US-8153584-B2 | Methods for promoting organ development | KINTAN PTY LTD. (AU) | 2012-04-10 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-1988915-B1 | Tumstatin for the treatment of conditions associated with airway tissue remodeling | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2012-03-28 | — | — | EP | disclosed |
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143228-B2 | Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment | MEDICAL RESEARCH FUND OF TEL AVIV SOURASKY MEDICAL CENTER (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-1436624-B1 | A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME | INST MEDICAL W & E HALL (AU) | 2012-03-21 | — | — | EP | disclosed |
| US-8138215-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138215-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120063276-A1 | PEPTIDE NANOSTRUCTURES AND METHODS OF GENERATING AND USING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| WO-2012027794-A2 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2012-03-08 | — | — | WO | disclosed |
| EP-1572725-B1 | CHI-CONOTOXIN PEPTIDES HAVING A N-TERMINAL PYROGLUTAMIC ACID | XENOME LTD (AU) | 2012-02-29 | — | — | EP | disclosed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2049116-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8124373-B2 | Isomaltulose synthases, polynucleotides encoding them and uses therefor | THE UNIVERSITY OF QUEENSLAND (GB) | 2012-02-28 | — | — | US | disclosed |
| US-20120046444-A1 | PEPTIDE NETWORKS | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-02-23 | — | — | US | disclosed |
| US-20120035529-A1 | TUMOR VASCULAR MARKER-TARGETED VACCINES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2012-02-09 | — | — | US | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017439-A2 | METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-02-09 | — | — | WO | disclosed |
| CN-102348678-A | Novel eicosanoid derivatives | MAX DELBRUECK CT | 2012-02-08 | — | — | CN | disclosed |
| US-20120028894-A1 | PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-02-02 | — | — | US | disclosed |
| EP-2412719-A1 | Chi-conotoxin peptides | Xenome Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| EP-2407484-A2 | Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-18 | — | — | EP | disclosed |
| US-20120009139-A1 | Methods and Compositions for Promoting Organ Development | KINTAN PTY. LTD. (AU) | 2012-01-12 | — | — | US | disclosed |
| EP-1896496-B1 | PROTEIN KINASE C INHIBITORS FOR PREVENTION OF INSULIN RESISTANCE AND TYPE 2 DIABETES | HADASIT MED RES SERVICE (IL) | 2012-01-11 | — | — | EP | disclosed |
| US-8093243-B2 | Inhibit the function of the non-structural proteins (NS5A) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093243-B2 | Inhibit the function of the non-structural proteins (NS5A) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088735-B2 | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20110319334-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-12-29 | — | — | US | disclosed |
| US-20110319479-A1 | POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA | VASCULAR BIOGENICS LTD. (IL) | 2011-12-29 | — | — | US | disclosed |
| US-8076087-B2 | Galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases | Medical Research Fund of Tel Aviv Souraskv Medical Center (IL) | 2011-12-13 | — | — | US | disclosed |
| US-8075899-B1 | Peptides of the A-chain of proinsulin or insulin | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-12-13 | — | — | US | disclosed |
| US-20110293644-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-8067004-B2 | Antigens with nucleotide sequences for protein codes for treatment of nisseria with a predicted molecular weight | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-11-29 | — | — | US | disclosed |
| US-8067398-B2 | Biodegradable polymers having a pre-determined chirality | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-11-29 | — | — | US | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110280882-A1 | LEUKOLECTINS AND USES THEREOF | LEUKOLECT AS (NO) | 2011-11-17 | — | — | US | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
| WO-2011141658-A1 | PEPTIDES WITH ANTIPROTEASE ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2011-11-17 | — | — | WO | disclosed |
| EP-2386566-A2 | Chi-conotoxin peptides (II) | Xenome Ltd (AU) | 2011-11-16 | — | — | EP | disclosed |
| US-8057800-B2 | antiallergens; antibody for patient hypersensitive to peanuts or tree nuts; isolated peptide comprising an Ara h 2 T cell epitope; diagnosing or monitoring the allergenic condition in a mammal | CIRCASSIA LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-8058242-B2 | taipan natriuretic peptide is used for treating congestive heart failure, stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth; antigen-binding molecule | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-11-15 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| WO-2011137486-A1 | DIAGNOSTIC AND PROGNOSTIC AND THERAPEUTIC METHODS | MONASH UNIVERSITY (AU) | 2011-11-10 | — | — | WO | disclosed |
| CN-101163793-B | Molecular optoelectronic device and method of fabricating the same | UNIV RAMOT | 2011-11-09 | — | — | CN | disclosed |
| US-8053554-B2 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-11-08 | — | — | US | disclosed |
| US-20110266517-A1 | PEPTIDE NANOSTRUCTURES ENCAPSULATING A FOREIGN MATERIAL AND METHOD OF MANUFACTURING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| EP-2064234-B1 | BIOACTIVE PEPTIDES AND METHOD OF USING SAME | COMPUGEN LTD (IL) | 2011-11-02 | — | — | EP | disclosed |
| US-20110262447-A1 | HUMAN SYNTHETIC SINGLE-CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND THEIR USES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-10-27 | — | — | US | disclosed |
| EP-2377544-A2 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | Pontificia Universidad Católica De Chile (CL) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376432-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-8039594-B2 | Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-10-18 | — | — | US | disclosed |
| US-8039582-B2 | Peptide networks | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-10-18 | — | — | US | disclosed |
| WO-2011125015-A2 | PROTEASE-ACTIVATABLE PORE-FORMING POLYPEPTIDES | BAR-ILAN UNIVERSITY (IL) | 2011-10-13 | — | — | WO | disclosed |
| US-8034358-B2 | Surface antigen | The University of Queesland (AT) | 2011-10-11 | — | — | US | disclosed |
| US-20110244564-A1 | CYSTINE KNOT MOLECULES | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-10-06 | — | — | US | disclosed |
| EP-1853708-B1 | MOLECULAR OPTOELECTRONIC DEVICE AND METHOD OF FABRICATING THE SAME | UNIV RAMOT (IL) | 2011-10-05 | — | — | EP | disclosed |
| EP-1133309-B1 | Composition and methods for neural tissue repair | INST MEDICAL W & E HALL (AU) | 2011-10-05 | — | — | EP | disclosed |
| US-20110236975-A1 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| WO-2011116411-A1 | SALT-RESISTANT EMULSIONS | PEPFACTANTS PTY LTD (AU) | 2011-09-29 | — | — | WO | disclosed |
| EP-2367561-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | Immusant, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110229892-A1 | METHOD FOR PREDICTING A PATIENT'S RESPONSIVENESS TO ANTI-FOLATE THERAPY | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2011-09-22 | — | — | US | disclosed |
| US-8017586-B2 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-20110217325-A1 | T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN | CIRCASSIA LIMITED (GB) | 2011-09-08 | — | — | US | disclosed |
| US-8012929-B2 | Peptides directed for diagnosis and treatment of amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2011-09-06 | — | — | US | disclosed |
| US-20110212896-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-09-01 | — | — | US | disclosed |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212051-A1 | VARIANTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR AND USE THEREOF | COMPUGEN LTD. | 2011-09-01 | — | — | US | disclosed |
| US-20110207181-A1 | ISOMALTULOSE SYNTHASES, POLYNUCLEOTIDES ENCODING THEM AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND, ST. LUCIA (AU) | 2011-08-25 | — | — | US | disclosed |
| US-20110206760-A1 | ANGIOPOIETIN DERIVED PEPTIDES | COMPUGEN LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| EP-2360257-A2 | Hepatitis B virus (HBV) variants | Melbourne Health (AU) | 2011-08-24 | — | — | EP | disclosed |
| US-7998934-B2 | PAI-2 conjugates for the treatment and imaging of cancer | PAI-2 PTY LIMITED (AU) | 2011-08-16 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195083-A1 | CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-08-11 | — | — | US | disclosed |
| US-20110195909-A1 | NOVEL X-CONOTOXIN PEPTIDES (-II) | XENOME LTD. (AU) | 2011-08-11 | — | — | US | disclosed |
| EP-2354230-A1 | Neisseria meningitidis surface protein | The University of Queensland (AU) | 2011-08-10 | — | — | EP | disclosed |
| US-7994128-B2 | Conotoxin peptides useful as inhibitors of neuronal amine transporters | XENOME LIMITED (AU) | 2011-08-09 | — | — | US | disclosed |
| US-20110189188-A1 | NOVEL GP96 DERIVED PEPTIDES | COMPUGEN LTD. (IL) | 2011-08-04 | — | — | US | disclosed |
| US-20110190195-A1 | MULTI-COMPONENT ANTIOXIDANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR REDUCING OR PREVENTING OXIDATIVE STRESS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-08-04 | — | — | US | disclosed |
| WO-2011092700-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-08-04 | — | — | WO | disclosed |
| US-20110177998-A1 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME | COMPUGEN LTD. (IL) | 2011-07-21 | — | — | US | disclosed |
| US-20110177102-A1 | TARGETED DOUBLE STRANDED RNA MEDIATED CELL KILLING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-07-21 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981867-B2 | Prophylaxis of influenza A infections; hypoglycemic agents; obesity; bulimia nervosa | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2011-07-19 | — | — | US | disclosed |
| US-7981997-B2 | Growth factor which acts through ErbB-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. (IL) | 2011-07-19 | — | — | US | disclosed |
| US-20110172126-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2011-07-14 | — | — | US | disclosed |
| US-20110172143-A1 | METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME | UNIVERSITY OF QUEENSLAND, THE (AU) | 2011-07-14 | — | — | US | disclosed |
| EP-2342334-A1 | TUMOR VASCULAR MARKER-TARGETED VACCINES | The Trustees Of The University Of Pennsylvania (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7977082-B2 | Sucrose isomerases for use in production of isomaltulose from sucrose; sugar substitute | THE UNIVERSITY OF QUEENSLAND OF ST. LUCIA (AU) | 2011-07-12 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2341152-A1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | Clinical Genomics Pty. Ltd (AU) | 2011-07-06 | — | — | EP | disclosed |
| US-20110156109-A1 | METHOD AND SYSTEM FOR MANIPULATING ORGANIC NANOSTRUCTURES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-06-30 | — | — | US | disclosed |
| EP-2339029-A1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | Clinical Genomics Pty. Ltd (AU) | 2011-06-29 | — | — | EP | disclosed |
| EP-2339028-A1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | Clinical Genomics Pty. Ltd (AU) | 2011-06-29 | — | — | EP | disclosed |
| US-20110150820-A1 | METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075439-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110150884-A1 | CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR | ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-23 | — | — | US | disclosed |
| US-20110150761-A1 | POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES THEREAGAINST AND METHODS OF USING SAME FOR DIAGNOSING AND TREATING CANCER AND SKELETAL DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| WO-2011070358-A2 | PRODUCT AND METHOD | ISIS INNOVATION LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| EP-2331561-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | Xenome Ltd (AU) | 2011-06-15 | — | — | EP | disclosed |
| US-7960340-B2 | Cystine knot molecules | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-06-14 | — | — | US | disclosed |
| US-20110136726-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2011-06-09 | — | — | US | disclosed |
| EP-2330221-A1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | Clinical Genomics Pty. Ltd (AU) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-7951775-B2 | Gonadotropin-releasing hormone (gnrh); gene expression inhibition; for treatment of T-cell related neoplastic diseases | KOCH, YITZHAK, PROF (IL) | 2011-05-31 | — | — | US | disclosed |
| EP-2325335-A2 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | Clinical Genomics Pty. Ltd (AU) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323980-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-1575867-B1 | PEPTIDE NANOSTRUCTURES, METHODS FOR THEIR PREPARATION AND USE | UNIV RAMOT (IL) | 2011-05-18 | — | — | EP | disclosed |
| US-20110112167-A1 | THERAPEUTIC AGENTS AND TARGETS | AUTOGEN RESEARCH PTY LTD (AU) | 2011-05-12 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7939634-B2 | Polynucleotides encoding polypeptides and methods using same | COMPUGEN LTD. (IL) | 2011-05-10 | — | — | US | disclosed |
| US-7939513-B2 | Tetracycline derivatives as antibacterial agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-05-10 | — | — | US | disclosed |
| US-7939513-B2 | Tetracycline derivatives as antibacterial agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-05-10 | — | — | US | disclosed |
| US-20110104225-A1 | POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| US-20110104167-A1 | Compositions and Methods for Diagnosing and Treating Insulin Resistance | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| WO-2011033506-A9 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051673-A1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051672-A1 | AZAINDOLE DERIVATIVES | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105417-A1 | Drug Conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-05-05 | — | — | US | disclosed |
| US-20110105386-A1 | USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| US-20110104217-A1 | Bioactive Peptides and Method of Using Same | COMPUGEN LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| US-20110097333-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | Th Corporation of the Trustees of the Order of the Sisters of Mercy in Queensland (AU) | 2011-04-28 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110092448-A1 | Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics | METABOLIC PHARMACEUTICALS LIMITED (AU) | 2011-04-21 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7927792-B2 | Targeted double stranded RNA mediated cell killing | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-19 | — | — | US | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| US-7919602-B2 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-05 | — | — | US | disclosed |
| US-7919471-B2 | administering peptides, polypeptides, proteins or mimetics which correspond to non-membrane associated form of the p75 neurotrophin receptor (p75NTR) death signal region; antiapoptosis | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-04-05 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-7915223-B2 | Antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2011-03-29 | — | — | US | disclosed |
| WO-2011033511-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-03-24 | — | — | WO | disclosed |
| EP-1285004-B1 | method of producing synthetic peptides | SAVINE THERAPEUTICS PTY LTD (AU) | 2011-03-23 | — | — | EP | disclosed |
| US-20110064669-A1 | USE OF GALANIN IN A METHOD OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2011-03-17 | — | — | US | disclosed |
| EP-1436320-B1 | T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN | CIRCASSIA LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| EP-1412388-B1 | HUMANIZED ANTIBODIES DERIVED FROM DD-3B6/22, SPECIFIC FOR THE D-DIMER FRAGMENT OF FIBRIN | AGEN BIOMEDICAL LTD (AU) | 2011-03-16 | — | — | EP | disclosed |
| US-7906635-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer | COMPUGEN LTD. (IL) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| WO-2011027342-A2 | MULTI-SITE MODIFIED SP1 POLYPEPTIDES AND USES THEREOF | FULCRUM S.P. MATERIALS LTD. (IL) | 2011-03-10 | — | — | WO | disclosed |
| EP-2292642-A1 | Immunomodulating compositions, uses therefor and processes for their production | Opal Therapeutics Pty Ltd (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110052603-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-03-03 | — | — | US | disclosed |
| EP-1351992-B1 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | UNIV RAMOT (IL) | 2011-03-02 | — | — | EP | disclosed |
| US-7897570-B2 | EPH gene expression inhibition to facilitate tissue repair arising from disease or injuries of the nervous system; treatment of spinal cord injury as well as other central nervous system diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-03-01 | — | — | US | disclosed |
| US-20110033521-A1 | Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2011-02-10 | — | — | US | disclosed |
| US-7884180-B2 | Peptides which bind to G protein-coupled receptors | COMPUGEN LTD (IL) | 2011-02-08 | — | — | US | disclosed |
| CN-101965357-A | Polypeptides, matrices, hydrogels and methods of using them for tissue regeneration and repair | UNIV RAMOT | 2011-02-02 | — | — | CN | disclosed |
| US-7879212-B2 | electrodes coated with self-assembled peptides containing nanostructures exhibit enhanced electrochemical sensitivity and thus are highly suitable for use in electrochemical detection of various molecules and particularly as sensitive biosensors in biomolecular diagnostics | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-01 | — | — | US | disclosed |
| EP-1773867-B1 | PROTEINACEOUS COMPOUNDS AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2011-01-19 | — | — | EP | disclosed |
| WO-2011005980-A1 | NOVEL HETEROBIFUNCTIONAL POLYETHYLENE GLYCOL REAGENTS, THEIR PREPARATION AND USES THEREOF | INTRADIGM CORPORATION (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20110008417-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | OPAL THERAPEUTICS PTY LTD (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20100331537-A1 | NOVEL SURFACE ANTIGEN | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-12-30 | — | — | US | disclosed |
| US-20100322938-A1 | NOVEL CLUSTERIN DERIVED PEPTIDE | COMPUGEN LTD. (IL) | 2010-12-23 | — | — | US | disclosed |
| US-20100322856-A1 | Compositions and Methods for Inducing Angiogenesis | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-12-23 | — | — | US | disclosed |
| EP-1290182-B1 | SPHINGOSINE KINASE AND USES THEREOF | MEDVET SCIENCE PTY LTD (AU) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010141974-A1 | THERAPEUTIC APPLICATIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317601-A1 | Casein Derived Peptides And Uses Thereof | SIDELMAN ZVI | 2010-12-16 | — | — | US | disclosed |
| US-20100317588-A1 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| EP-2260864-A1 | Therapeutic applications | University of Melbourne (AU) | 2010-12-15 | — | — | EP | disclosed |
| US-7851444-B2 | amino acid sequence containing Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; prophylaxis; neuropathic pain, inflammation, incontinence, cardiovascular conditions | XENOME LTD. (AU) | 2010-12-14 | — | — | US | disclosed |
| US-20100310450-A1 | METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME | MEDVET SCIENCE PTY. LTD. (AU) | 2010-12-09 | — | — | US | disclosed |
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-02 | — | — | US | disclosed |
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-02 | — | — | US | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100298216-A1 | Casein Derived Peptides And Uses Thereof in Therapy | SIDELMAN ZVI | 2010-11-25 | — | — | US | disclosed |
| US-20100298226-A1 | POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA | VASCULAR BIOGENICS LTD. (IL) | 2010-11-25 | — | — | US | disclosed |
| US-20100297150-A1 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS | HILLMAN YITZCHAK | 2010-11-25 | — | — | US | disclosed |
| US-20100298528-A1 | Cystine knot molecules | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100292200-A1 | Methods for Modulating Apoptosis in Platelets | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-11-18 | — | — | US | disclosed |
| US-20100292152-A9 | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERSALEM (IL) | 2010-11-18 | — | — | US | disclosed |
| US-20100291828-A1 | PEPTIDE NANOSTRUCTURES CONTAINING END-CAPPING MODIFIED PEPTIDES AND METHODS OF GENERATING AND USING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-11-18 | — | — | US | disclosed |
| US-7833974-B2 | Polypeptide biodrugs with given amino acid sequence which includes phosphorylated serine or threonine conjugated to a hydrophobic moiety such as a fatty acid; treating disorders such as Type II Diabetes, neurodegenerative diseases and psychological disorders | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-11-16 | — | — | US | disclosed |
| US-7834248-B2 | comprising 12,13-epoxy-9-octadecenoic acid; generation of preferential coatings, resins, glues, plastics, surfactants and lubricants from renewable plant sources | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-11-16 | — | — | US | disclosed |
| WO-2010127399-A1 | GENE EXPRESSION PROFILES AND USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286375-A1 | Carrier molecules | AGEN BIOMEDICAL LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20100278807-A1 | Novel antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| US-20100279943-A1 | CYTOPLASMIC MALATE DEHYDROGENASE (MDH1) TARGETED TREATMENT FOR NEURODEGENERATIVE DISEASES | RAMAT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| US-7825217-B2 | Polypeptides for bone mineralization | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2242495-A2 | USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS | Technion Research and Development Foundation, Ltd. (IL) | 2010-10-27 | — | — | EP | disclosed |
| US-7820786-B2 | Synthetic peptides and uses therefore | SAVINE THERAPEUTICS PTY LTD (AU) | 2010-10-26 | — | — | US | disclosed |
| WO-2010117977-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100247516-A1 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF | Rappaport Family Institute for Research Research in the Medical Sciences (IL) | 2010-09-30 | — | — | US | disclosed |
| US-20100248270-A1 | Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Cardiac Disease | COMPUGEN LTD (IL) | 2010-09-30 | — | — | US | disclosed |
| US-20100240538-A1 | Programmable iterated elongation: a method for manufacturing synthetic genes and combinatorial dna and protein libraries | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-09-23 | — | — | US | disclosed |
| US-20100233120-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-16 | — | — | US | disclosed |
| US-20100233120-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-16 | — | — | US | disclosed |
| US-20100233188-A1 | ANTIBODIES AND PHARAMCETICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-09-16 | — | — | US | disclosed |
| US-7795247-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | disclosed |
| US-7795241-B2 | Derivative prodrugs of ethinyl estradiol | WARNER CHILCOTT COMPANY, LLC (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100227805-A1 | Molecules and Methods of Using Same for Treating CCR5/CCR5 Ligands Associated Diseases | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2010-09-09 | — | — | US | disclosed |
| US-20100227315-A1 | Biosensor Using Whispering Gallery Modes in Microspheres | Mulvaney, Paul | 2010-09-09 | — | — | US | disclosed |
| CN-101820897-A | Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseases | UNIV RAMOT | 2010-09-01 | — | — | CN | disclosed |
| US-7786279-B2 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-31 | — | — | US | disclosed |
| US-7786260-B1 | immunogenic; treating or preventing Helicobacter infection in a mammalian host; gastroduodenal disease | CSL LIMITED (AU) | 2010-08-31 | — | — | US | disclosed |
| US-7786086-B2 | at least one aromatic amino acid (phenylalanine); hollow and fibrillar peptide; macroscopic and microscopic articles; self-assembled; 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz); slow release of drug, nucleic acid molecule or a polypeptide; antibody | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-08-31 | — | — | US | disclosed |
| US-20100216701-A1 | Protein Kinase C Inhibitors for Prevention of Insulin Resistance and Type 2 Diabetes | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2010-08-26 | — | — | US | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-7781396-B2 | Peptides directed for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-08-24 | — | — | US | disclosed |
| US-20100209385-A1 | TREATMENT OF OBESITY | BAKER MEDICAL RESEARCH INSTITUTE (AU) | 2010-08-19 | — | — | US | disclosed |
| US-20100203609-A1 | PHOTOCATALYTIC HYDROGEN PRODUCTION AND POLYPEPTIDES CAPABLE OF SAME | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100196874-A1 | METHOD OF DRUG DESIGN | PICORAL PTY LTD (AU) | 2010-08-05 | — | — | US | disclosed |
| US-20100199368-A1 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-08-05 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100189652-A1 | NOVEL DIAGNOSTIC MARKERS, ESPECIALLY FOR IN VIVO IMAGING, AND ASSAYS AND METHODS OF USE THEREOF | COMPUGEN LTD. | 2010-07-29 | — | — | US | disclosed |
| WO-2010083573-A1 | THE TREATMENT OR PROPHYLAXIS OF ORGAN AND TISSUE FIBROSIS VIA MODULATION OF CELL DIVISION AUTOANTIGEN (CDA1) | BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010081683-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2010-07-22 | — | — | WO | disclosed |
| EP-1677813-B1 | ANGIOGENIC PEPTIDES AND USES THEREOF | UNIV RAMOT (IL) | 2010-07-21 | — | — | EP | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
| CN-101784522-A | Proton acceptor iminium/carbocationic coupling agents | LUXEMBOURG BIOTECHNOLOGIES LTD | 2010-07-21 | — | — | CN | disclosed |
| US-7759495-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100173832-A1 | ANTICANCEROUS POLYMERIC AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-07-08 | — | — | US | disclosed |
| US-7745636-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745636-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-7741433-B2 | Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof | COMPUGEN LTD. (IL) | 2010-06-22 | — | — | US | disclosed |
| US-7741347-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741347-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741274-B2 | Casein derived peptides and uses thereof in therapy | PEPTERA PHARMACEUTICALS LTD. (IL) | 2010-06-22 | — | — | US | disclosed |
| US-20100152420-A1 | PEPTIDE NETWORKS | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20100144588-A1 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS | LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100143964-A1 | COMPOSITIONS AND METHODS FOR CONCENTRATING AND DEPLETING MICROORGANISMS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| EP-1611251-B1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS | MURDOCH CHILDRENS RES INST (AU) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010060155-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | NEXPEP PTY LTD (AU) | 2010-06-03 | — | — | WO | disclosed |
| US-20100135903-A1 | USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER | MEDVET SCIENCE PTY. LTD. (AU) | 2010-06-03 | — | — | US | disclosed |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
| US-20100129344-A1 | MEDICAL USES AND THERAPIES BASED UPON THE ACTION OF AZUROCIDIN ON IGFBP-1 | LEWITT MOIRA SALLY | 2010-05-27 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7723034-B2 | Method of screening for neuronal ceroid lipfuscinosis in canine by detecting a mutation in ceroid lipofuscinosis neuornal 5 (CLN5) gene | MELVILLE SCOTT ANDREW | 2010-05-25 | — | — | US | disclosed |
| US-20100124786-A1 | Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of use Thereof for Diagnosis of Ovarian Cancer | COMPUGEN LTD (IL) | 2010-05-20 | — | — | US | disclosed |
| US-20100120671-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-05-13 | — | — | US | disclosed |
| US-20100120670-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-05-13 | — | — | US | disclosed |
| US-7714100-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease | COMPUGEN LTD (IL) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100111980-A1 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2010-05-06 | — | — | US | disclosed |
| CN-101702906-A | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins | YEDA RES & DEV | 2010-05-05 | — | — | CN | disclosed |
| US-20100105608-A1 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104607-A1 | ANTI-BACTERIAL PEPTIDES AND METHODS OF TREATING DISEASES USING SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-04-29 | — | — | US | disclosed |
| US-7704992-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704992-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100099627-A1 | NUCLEAR TARGETING SEQUENCES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-04-22 | — | — | US | disclosed |
| US-7700826-B2 | Genes encoding wheat starch synthases and uses thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESSEARCH ORGANIZATION (AU) | 2010-04-20 | — | — | US | disclosed |
| US-7700271-B2 | Method of diagnosis and treatment and agents useful for same | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-04-20 | — | — | US | disclosed |
| US-20100093600-A1 | REGULATION OF NEUROTRANSMITTERS SEQUESTRATION AND RELEASE THROUGH MANIPULATION OF THE VESICULAR FUNCTIONS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| WO-2010037181-A1 | CELL THERAPY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-04-08 | — | — | WO | disclosed |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| WO-2010037124-A1 | TUMOR VASCULAR MARKER-TARGETED VACCINES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7687457-B2 | Cyclic molecular framework and derivatives thereof | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-03-30 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100075891-A1 | Novel polynucleotides encoding polypeptides and methods using same | COMPUGEN LTD. (IL) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074908-A1 | Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-03-25 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068736-A1 | Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Lung Cancer | COMPUGEN LTD. (IL) | 2010-03-18 | — | — | US | disclosed |
| US-7678374-B2 | Viral vectors expressing fusion of viral large envelope protein and protein of interest | HEPGENICS PTY LTD (AU) | 2010-03-16 | — | — | US | disclosed |
| WO-2010026096-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010025510-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010023670-A2 | METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20100048863-A1 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2010-02-25 | — | — | US | disclosed |
| WO-2010019995-A1 | THE ERG TRANSCRIPTION FACTOR MODULATION OF VASCULAR DEVELOPMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-02-25 | — | — | WO | disclosed |
| CN-101653602-A | Treatment, prophylaxis and diagnostic reagent of hepatitis b | MELBOURNE HEALTH CARE LTD | 2010-02-24 | — | — | CN | disclosed |
| US-7666996-B2 | Casein derived peptides and uses thereof | PEPTERA PHARMACEUTICALS LTD (IL) | 2010-02-23 | — | — | US | disclosed |
| US-7667001-B1 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer | COMPUGEN LTD. (IL) | 2010-02-23 | — | — | US | disclosed |
| EP-2152289-A1 | NOVEL ANTIMICROBIAL AGENTS | Technion Research & Development Foundation Ltd. (IL) | 2010-02-17 | — | — | EP | disclosed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20100035808-A1 | Methods and compositions for promoting organ development | KINTAN PTY LTD. (AU) | 2010-02-11 | — | — | US | disclosed |
| US-7659270-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659270-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100022459-A1 | Peptides directed for diagnosis and treatment of amyloid-associated diseases | Tel Aviv University Future Technology Development L.P (IL) | 2010-01-28 | — | — | US | disclosed |
| US-20100021489-A1 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-01-28 | — | — | US | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| EP-1226166-B1 | IMMUNO-INTERACTIVE FRAGMENTS OF THE ALPHA C SUBUNIT OF INHIBIN | PRINCE HENRYS INST MED RES (AU) | 2010-01-27 | — | — | EP | disclosed |
| EP-2142256-A1 | TREATMENT OF OBESITY | Baker Medical Research Institute (AU) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142257-A2 | ANTICANCEROUS POLYMERIC AGENTS | Technion Research & Development Foundation Ltd. (IL) | 2010-01-13 | — | — | EP | disclosed |
| US-20100003262-A1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B | MELBOURNE HEALTH (AU) | 2010-01-07 | — | — | US | disclosed |
| WO-2009158633-A1 | DRUG CONJUGATES | CURATORS OF THE UNIVERSITY OF MISSOURI ON BEHALF OF THE UNIVERSITY OF MISSOURI-KANSAS CITY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318339-A1 | Biodegradable polymers having a pre-determined chirality | Yissum Research Development Company of The Hebrew Univerisity of Jerusalem (IL) | 2009-12-24 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM | 2009-12-17 | — | — | US | disclosed |
| EP-1261360-B1 | CASEIN DERIVED PEPTIDES AND USES THEREOF IN THERAPY | PEPTERA PHARMACEUTICALS LTD (IL) | 2009-12-16 | — | — | EP | disclosed |
| US-20090305970-A1 | Toxin-Like Polypeptides, Polynucleotides Encoding Same and Uses Thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-12-10 | — | — | US | disclosed |
| US-20090305294-A1 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES | MEDIMOLECULAR PTY LTD (AU) | 2009-12-10 | — | — | US | disclosed |
| CN-101595577-A | Photovoltaic device and method for manufacturing same | UNIV RAMOT (IL) | 2009-12-02 | — | — | CN | disclosed |
| US-20090286957-A1 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF BREAST CANCER | COMPUGEN LTD (IL) | 2009-11-19 | — | — | US | disclosed |
| EP-2119728-A1 | Therapeutic and diagnostic agents | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281042-A1 | COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION OF VIRUSES | MND DIAGNOSTICS LTD. (IL) | 2009-11-12 | — | — | US | disclosed |
| US-20090275498-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-11-05 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| CN-101573377-A | Molecules for treatment of CCR5/CCR5 ligand-related diseases and methods of using such molecules for treatment of such diseases | RAPPAPORT FAMILY INST FOR RES (IL) | 2009-11-04 | — | — | CN | disclosed |
| US-20090269355-A1 | Catalytic antibodies and a method of producing same | Koentgen, Frank (AU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270591-A1 | NOVEL SURFACE ANTIGEN | UNIVERSITY OF QUEENSLAND (AU) | 2009-10-29 | — | — | US | disclosed |
| EP-2112159-A2 | Immuno-interactive fragments of the alpha C subunit of inhibin | Prince Henry's Institute of Medical Research (AU) | 2009-10-28 | — | — | EP | disclosed |
| US-7604958-B2 | Synthetic mammalian α-N-acetylglucosaminidase and genetic sequences encoding same | CENTRAL NORTHERN ADELAIDE HEALTH SERVICE (AU) | 2009-10-20 | — | — | US | disclosed |
| EP-1871798-B1 | MOLECULES AND METHODS OF USING SAME FOR TREATING MCP-1/CCR2 ASSOCIATED DISEASES | RAPPAPORT FAMILY INST FOR RES (IL) | 2009-10-14 | — | — | EP | disclosed |
| US-20090252735-A1 | Novel Peptides for Development of Diagnostic and Therapeutic Agents and Methods of Using Same | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-10-08 | — | — | US | disclosed |
| EP-0907730-B1 | HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | ZENYTH OPERATIONS PTY LTD (AU) | 2009-10-07 | — | — | EP | disclosed |
| CN-101553581-A | Compositions for detecting of influenza viruses and kits and methods using same | MND DIAGNOSTIC LTD (IL) | 2009-10-07 | — | — | CN | disclosed |
| US-20090242879-A1 | Optoelectronic device and method of fabricating the same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-10-01 | — | — | US | disclosed |
| US-20090238819-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2009-09-24 | — | — | US | disclosed |
| EP-1542528-B1 | A METHOD OF TREATMENT AND PROPHYLAXIS | INST MEDICAL W & E HALL (AU) | 2009-09-23 | — | — | EP | disclosed |
| US-20090232808-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-7589253-B2 | Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-09-15 | — | — | US | disclosed |
| US-20090221478-A1 | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERSALEM (IL) | 2009-09-03 | — | — | US | disclosed |
| US-20090221494-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREIN | THE UNIVERSITY OF SYDNEY (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090220941-A1 | COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND KITS AND METHODS USING SAME | MND DIAGNOSTIC LTD (IL) | 2009-09-03 | — | — | US | disclosed |
| US-7582439-B2 | Therapeutic molecules | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-09-01 | — | — | US | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| US-20090215042-A1 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS | COMPUGEN LTD. | 2009-08-27 | — | — | US | disclosed |
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | disclosed |
| EP-2092937-A2 | Immunotherapeutic and immunoprophylactic reagents | Circassia Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-2092071-A2 | COMPOSITIONS AND METHODS FOR CONCENTRATING AND DEPLETING MICROORGANISMS | Technion Research & Development Foundation Ltd. (IL) | 2009-08-26 | — | — | EP | disclosed |
| EP-2091967-A1 | CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR | St. Vincent's Institute of Medical Research (AU) | 2009-08-26 | — | — | EP | disclosed |
| CN-101516902-A | Polypeptides and polynucleotides encoding same and their use in treating medical conditions associated with ischemia | VASCULAR BIOGENICS LTD (IL) | 2009-08-26 | — | — | CN | disclosed |
| US-20090209041-A1 | Peptides and methods for inhibiting amyloid formation | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2009-08-20 | — | — | US | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102325-A1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102694-A1 | HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102318-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-1078003-B1 | PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE, PSEUDONAJA TEXTILIS TEXTILIS | UNIV QUEENSLAND (AU) | 2009-08-19 | — | — | EP | disclosed |
| US-20090202991-A1 | NOVEL DIAGNOSTIC MARKERS, ESPECIALLY FOR IN VIVO IMAGING AND ASSAYS AND METHODS OF USE THEREOF | COMPUGEN LTD. (IL) | 2009-08-13 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-7572900-B2 | Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-08-11 | — | — | US | disclosed |
| US-20090197810-A1 | ALPHA CONOTOXIN PEPTIDES WITH ANALGESIC PROPERTIES | LIVETT BRUCE GRAYSON | 2009-08-06 | — | — | US | disclosed |
| CN-101500591-A | Composition for detecting virus and method for detecting virus using the same | MND DIAGNOSTIC LTD (IL) | 2009-08-05 | — | — | CN | disclosed |
| US-7569665-B2 | Comprises von willebrand factor a-related protein for use as diagnostic toll in diagnosis of autoimmune, arthritic and bone disorders | MURDOCH CHILDRENS RESEARCH INSTITUTE ROYAL CHILDREN'S HOSPITAL (AU) | 2009-08-04 | — | — | US | disclosed |
| US-7569662-B2 | Novel markers for lung cancer that are both sensitive and accurate; show a high degree of differential detection between lung cancer and non-cancerous states | COMPUGEN LTD (IL) | 2009-08-04 | — | — | US | disclosed |
| US-20090192081-A1 | Casein derived peptides and uses thereof | SIDELMAN ZVI | 2009-07-30 | — | — | US | disclosed |
| EP-2082235-A1 | A METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME | MEDVET SCIENCE PTY. LTD. (AU) | 2009-07-29 | — | — | EP | disclosed |
| US-20090188010-A1 | Insect Chymotrypsin and Inhibitors Thereof | HEXIMA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
| WO-2009090648-A2 | USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-07-23 | — | — | WO | disclosed |
| EP-1863846-B1 | HUMAN SYNTHETIC SINGLE-CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND THEIR USES | UNIV RAMOT (IL) | 2009-07-22 | — | — | EP | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090175785-A1 | Self-Assembled Fmoc-Ff Hydrogels | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-07-09 | — | — | US | disclosed |
| EP-1765384-A4 | METHOD OF MODULATING CELLULAR ACTIVITY INVOLVING SPHINGOSINE KINASE AND AGENTS FOR SAME, AND SPHINGOSINE KINASE VARIANTS | MEDVET SCIENCE PTY LTD (AU) | 2009-07-08 | — | — | EP | disclosed |
| US-20090169520-A1 | Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-07-02 | — | — | US | disclosed |
| EP-2073899-A1 | THE USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER | MEDVET SCIENCE PTY. LTD. (AU) | 2009-07-01 | — | — | EP | disclosed |
| US-7553928-B2 | Use of des-Aspartate-angiotensin I as an agent for the treatment and prevention of glomerulosclerosis and renal failure | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2009-06-30 | — | — | US | disclosed |
| US-7553948-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer | COMPUGEN LTD (IL) | 2009-06-30 | — | — | US | disclosed |
| US-20090163405-A1 | Angiogenic peptides and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
| US-20090156471-A1 | Use of anti-amyloid agents for treating and typing pathogen infections | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1390408-A4 | A MOLECULAR MARKER | MURDOCH CHILDRENS RES INST (AU) | 2009-06-17 | — | — | EP | disclosed |
| US-7547441-B2 | PAI-2 conjugates for the treatment and imaging of cancer | PAI-2 PTY LIMITED (AU) | 2009-06-16 | — | — | US | disclosed |
| WO-2009073056-A1 | NOVEL TETRACYCLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143571-A1 | NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE | AUTOGEN RESEARCH PTY LTD (AU) | 2009-06-04 | — | — | US | disclosed |
| US-20090136546-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-05-28 | — | — | US | disclosed |
| WO-2009065181-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-05-28 | — | — | WO | disclosed |
| US-20090136421-A1 | PAI-2 conjugates for the treatment and imaging of cancer | UNIVERSITY OF WOLLONGONG | 2009-05-28 | — | — | US | disclosed |
| EP-1844069-A4 | MOLECULES AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LTD (AU) | 2009-05-20 | — | — | EP | disclosed |
| EP-1910535-A4 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME | INST MEDICAL W & E HALL (AU) | 2009-05-20 | — | — | EP | disclosed |
| US-20090121709-A1 | Peptide nanostructures encapsulating A foreign material and method of manufacturing same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| US-20090123553-A1 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| EP-2058275-A1 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | Ramot at Tel-Aviv University Ltd. (IL) | 2009-05-13 | — | — | EP | disclosed |
| US-7531575-B2 | Method of modulating cellular activity and agents useful for same | Eberhard-Karls-Universität Tübingin (DE) | 2009-05-12 | — | — | US | disclosed |
| EP-2054121-A1 | METHODS FOR MODULATING APOPTOSIS IN PLATELETS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2009-05-06 | — | — | EP | disclosed |
| EP-1910525-A4 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY LTD (AU) | 2009-05-06 | — | — | EP | disclosed |
| US-7528243-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer | COMPUGEN LTD (IL) | 2009-05-05 | — | — | US | disclosed |
| US-20090111776-A1 | Novel tetracycline derivatives as antibacterial agents | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-04-30 | — | — | US | disclosed |
| US-20090111776-A1 | Novel tetracycline derivatives as antibacterial agents | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-04-30 | — | — | US | disclosed |
| US-7524654-B2 | Isomaltulose synthases, polynucleotides encoding them and uses therefor | THE UNIVERSITY OF QUEENSLAND OF ST. LUCIA (AU) | 2009-04-28 | — | — | US | disclosed |
| US-7524929-B2 | polypeptides comprising an amino acid sequence of a photocatalytic unit of a photosynthetic microorganism, capable of maintaining photocatalytic activity when attached to solid surfaces of electrooptic devices | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-04-28 | — | — | US | disclosed |
| US-20090105129-A1 | Combination therapy | XENOME LTD (AU) | 2009-04-23 | — | — | US | disclosed |
| EP-1677816-A4 | THERAPEUTIC METHOD | UNIV MONASH (AU) | 2009-04-22 | — | — | EP | disclosed |
| EP-1778253-A4 | GLYCOSYLPHOSPHATIDYLINOSITOL GLYCAN SIGNALLING VIA INTEGRINS FUNCTIONING AS GLYCAN SPECIFIC RECEPTORS | INST MEDICAL W & E HALL (AU) | 2009-04-22 | — | — | EP | disclosed |
| CN-101415724-A | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2009-04-22 | — | — | CN | disclosed |
| US-20090098127-A1 | Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment | MEDICAL RESEARCH FUND OF TEL AVIV SOURASKY MEDICAL CENTER (IL) | 2009-04-16 | — | — | US | disclosed |
| WO-2009046483-A1 | THERAPEUTIC PROTOCOL FOR THE TREATMENT OR PREVENTION OF THROMBOCYTOPENIA | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-04-16 | — | — | WO | disclosed |
| EP-2048235-A2 | Synthetic Mammalian Alpha-N-Acetylglucosaminidase and Genetic Sequences Encoding Same | WOMEN'S AND CHILDREN'S HOSPITAL (AU) | 2009-04-15 | — | — | EP | disclosed |
| US-20090092546-A1 | Carrier molecules | AGEN BIOMEDICAL LIMITED (AU) | 2009-04-09 | — | — | US | disclosed |
| US-20090088389-A1 | NOVEL X-CONOTOXIN PEPTIDES (-II) | XENOME LTD. (AU) | 2009-04-02 | — | — | US | disclosed |
| EP-1910524-A4 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY LTD (AU) | 2009-04-01 | — | — | EP | disclosed |
| US-7511123-B2 | Immuno-interactive fragments of the alpha-C subunit of inhibin | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-03-31 | — | — | US | disclosed |
| US-20090081248-A1 | Non-hemolytic LLO fusion proteins and methods of utilizing same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-26 | — | — | US | disclosed |
| EP-1583713-B1 | PEPTIDE NANOSTRUCTURES ENCAPSULATING A FOREIGN MATERIAL AND METHOD OF MANUFACTURING SAME | UNIV RAMOT (IL) | 2009-03-25 | — | — | EP | disclosed |
| US-7507717-B2 | Type II chi-conotoxin peptides (noradrenaline transporter inhibitors) | XENOME LTD. (AU) | 2009-03-24 | — | — | US | disclosed |
| US-20090077677-A1 | MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS | MELBOURNE HEALTH (AU) | 2009-03-19 | — | — | US | disclosed |
| US-7504381-B2 | Antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-7504383-B2 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090062180-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2009-03-05 | — | — | US | disclosed |
| US-20090062197-A1 | Sp1 Polypeptides, Modified Sp1 Polypeptides and Uses Thereof | FULCRUM SP LTD. (IL) | 2009-03-05 | — | — | US | disclosed |
| EP-1603543-A4 | THERAPEUTIC COMPOSITIONS | FLOREY HOWARD INST (AU) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054307-A1 | PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-02-26 | — | — | US | disclosed |
| US-20090054342-A1 | Bioactive peptides and method of using same | COMPUGEN LTD (IL) | 2009-02-26 | — | — | US | disclosed |
| US-20090054322-A1 | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-02-26 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048164-A1 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | US | disclosed |
| US-7491699-B2 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2009-02-17 | — | — | US | disclosed |
| WO-2009018623-A1 | MOLECULAR MARKERS AND METHODS RELATED THERETO | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-0879244-B1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE AND VACCINES | UNIV MELBOURNE (AU) | 2009-02-11 | — | — | EP | disclosed |
| US-7488813-B2 | Diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof | COMPUGEN, LTD. (IL) | 2009-02-10 | — | — | US | disclosed |
| US-20090035287-A1 | ATRIAL NATRIURETIC PEPTIDE (ANP) SPLICE VARIANTS AND METHODS OF USING SAME | COMPUGEN LTD. (IL) | 2009-02-05 | — | — | US | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
| EP-2015766-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-01-21 | — | — | EP | disclosed |
| EP-1858914-A4 | PEPTIDE NETWORKS | UNIV QUEENSLAND (AU) | 2009-01-14 | — | — | EP | disclosed |
| US-7473682-B2 | Angiogenic peptides and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-01-06 | — | — | US | disclosed |
| US-20090004648-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer | COMPUGEN LTD. (IL) | 2009-01-01 | — | — | US | disclosed |
| EP-1620089-A4 | THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS AND USES THEREFOR | CRC FOR ASTHMA LTD (AU) | 2008-12-24 | — | — | EP | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080305471-A1 | polypeptides comprising an amino acid sequence of a photocatalytic unit of a photosynthetic microorganism, capable of maintaining photocatalytic activity when attached to solid surfaces of electrooptic devices | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-12-11 | — | — | US | disclosed |
| EP-1656445-A4 | A METHOD AND AGENTS FOR IMPROVING PLANT PRODUCTIVITY INVOLVING ENDOPHYTIC ACTINOMYCETES AND METABOLITES THEREOF | FLINDERS TECHNOLOGIES PTY LTD (AU) | 2008-12-10 | — | — | EP | disclosed |
| US-7462695-B2 | Insect chymotrypsin and inhibitors thereof | HEXIMA LIMITED (AU) | 2008-12-09 | — | — | US | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-7459143-B2 | Monoclonal antibodies; determination blood coagulation; dissolving clots; administering deimmunized immunointeractive molecules; using planar or computer assisted tomographic nuclear medicine scan to visualize a clot | AGEN BIOMEDICAL LTD. (AU) | 2008-12-02 | — | — | US | disclosed |
| US-7456148-B2 | Method of producing an anticoagulation effect | HEALTHLINX LIMITED (AU) | 2008-11-25 | — | — | US | disclosed |
| CN-100434519-C | Curing and preventing method | WALTER & ELESARHOL MEDICAL ACA (AU) | 2008-11-19 | — | — | CN | disclosed |
| US-20080279841-A1 | Novel Therapeutic Molecular Variants And Uses Thereof | MEDVET SCIENCE PTY LTD. (AU) | 2008-11-13 | — | — | US | disclosed |
| US-20080279897-A1 | Method of Treating Cellular Damage | MEDVET SCIENCE PTY. LTD. (AU) | 2008-11-13 | — | — | US | disclosed |
| EP-1988915-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREIN | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008132738-A2 | ANTICANCEROUS POLYMERIC AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2008-11-06 | — | — | WO | disclosed |
| US-20080274973-A1 | NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | WILLSON TRACY | 2008-11-06 | — | — | US | disclosed |
| WO-2008132737-A1 | NOVEL ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2008-11-06 | — | — | WO | disclosed |
| US-7446092-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-11-04 | — | — | US | disclosed |
| EP-1545589-A4 | A METHOD OF MODULATING ENDOTHELIAL CELL ACTIVITY | MEDVET SCIENCE PTY LTD (AU) | 2008-10-29 | — | — | EP | disclosed |
| EP-1737884-A4 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | UNIV QUEENSLAND (AU) | 2008-10-29 | — | — | EP | disclosed |
| CN-101291943-A | Novel coupler and application thereof | LUXEMBOURG INDUSTRY LTD (IL) | 2008-10-22 | — | — | CN | disclosed |
| US-20080254023-A1 | Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-10-16 | — | — | US | disclosed |
| US-20080255044-A1 | Method of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2008-10-16 | — | — | US | disclosed |
| EP-0870036-B1 | SYNTHETIC MAMMALIAN ALPHA-N-ACETYLGLUCOSAMINIDASE AND GENETIC SEQUENCES ENCODING SAME | WOMENS & CHILDRENS HOSPITAL (AU) | 2008-10-15 | — | — | EP | disclosed |
| US-7435716-B2 | Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-10-14 | — | — | US | disclosed |
| US-20080248067-A1 | Immunomodulating Compositions and Uses Therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-10-09 | — | — | US | disclosed |
| US-20080248008-A1 | Inhibitors of Protein Kinase a Anchoring | CARLSON CATHRINE REIN | 2008-10-09 | — | — | US | disclosed |
| US-20080249015-A1 | Use of Des-Aspartate-Angiotensin 1 | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-10-09 | — | — | US | disclosed |
| WO-2008119110-A1 | TREATMENT OF OBESITY | BAKER MEDICAL RESEARCH INSTITUTE (AU) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242598-A1 | Alpha Helical Mimics, Their Uses and Methods For Their Production | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-10-02 | — | — | US | disclosed |
| EP-1975234-A2 | Therapeutic and diagnotics agents capable of modulating cellular responsiveness to cytokines | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-10-01 | — | — | EP | disclosed |
| EP-1572725-A4 | NOVEL CHI-CONOTOXIN PEPTIDES (-I) | XENOME LTD (AU) | 2008-09-24 | — | — | EP | disclosed |
| EP-1578787-A4 | NOVEL CHI-CONOTOXIN PEPTIDES (-II) | XENOME LTD (AU) | 2008-09-24 | — | — | EP | disclosed |
| EP-1968976-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-17 | — | — | EP | disclosed |
| EP-1638992-A4 | VIRAL POLYMERASE AND MODULATION THEREOF | MELBOURNE HEALTH (AU) | 2008-09-17 | — | — | EP | disclosed |
| EP-1121434-B1 | POLYPEPTIDES FOR MODULATING CELL SURVIVAL | UNIV QUEENSLAND (AU) | 2008-09-17 | — | — | EP | disclosed |
| EP-0956039-B1 | IL-11 signalling for enhancing fertility | INST MEDICAL W & E HALL (AU) | 2008-09-10 | — | — | EP | disclosed |
| US-7422890-B2 | Therapeutic and prophylactic agents and methods of using the same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-09-09 | — | — | US | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008098280-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN GROWTH HORMONE PEPTIDES | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2008-08-21 | — | — | WO | disclosed |
| EP-1685102-A4 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20080193941-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease | COMPUGEN LTD. (IL) | 2008-08-14 | — | — | US | disclosed |
| EP-1951914-A2 | DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS | Cheng Si Yuan (China-International) Hepatitis Research Foundation (CN) | 2008-08-06 | — | — | EP | disclosed |
| US-7408048-B2 | Mammalian grainyhead transcription factors | MELBOURNE HEALTH (AU) | 2008-08-05 | — | — | US | disclosed |
| US-20080182299-A1 | Polynucleotide variants of brain natriuretic peptides used as diagnostic markers for cardiovascular diseases including myocardial infarct, acute coronary syndrome, angina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure; kits; monitoring disease progression , relapse | COMPUGENT LTD. (IL) | 2008-07-31 | — | — | US | disclosed |
| WO-2008086573-A1 | USE OF GALANIN IN A METHOD OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2008-07-24 | — | — | WO | disclosed |
| EP-1406648-A4 | THE USE OF ANGIOTENSIN I DERIVATIVE AS AN AGENT FOR THE TREATMENT AND PREVENTION OF INFARCTION-RELATED CARDIAC INJURIES AND DISORDERS | UNIV SINGAPORE (SG) | 2008-07-23 | — | — | EP | disclosed |
| CN-101228187-A | Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses | UNIV RAMOT (IL) | 2008-07-23 | — | — | CN | disclosed |
| US-20080171702-A1 | NOVEL GENE AND USES THEREFOR | INTERNATIONAL DIABETES INSTITUTE (AU) | 2008-07-17 | — | — | US | disclosed |
| US-20080171313-A1 | Viral variants | MELBOURNE HEALTH (AU) | 2008-07-17 | — | — | US | disclosed |
| US-20080166730-A1 | Therapeutic and diagnostic proteins comprising a SOCS box | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-07-10 | — | — | US | disclosed |
| EP-1765990-A4 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B | MELBOURNE HEALTH (AU) | 2008-07-09 | — | — | EP | disclosed |
| EP-0932674-B1 | A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES | INST MEDICAL W & E HALL (AU) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | disclosed |
| US-20080160582-A1 | Isomaltulose synthases, polynucleotides encoding them and uses therefor | THE UNIVERSITY OF QUEENSLAND OF ST. LUCIA (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161231-A1 | Methods and compositions for promoting organ development | KINTAN PTY. LTD. (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080153159-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080153747-A1 | PROTEINACEOUS COMPOUNDS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-06-26 | — | — | US | disclosed |
| EP-1781685-A4 | THERAPEUTIC AND DIAGNOSTIC AGENTS | INST MEDICAL W & E HALL (AU) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008070924-A1 | A METHOD OF DRUG DESIGN | PICORAL PTY LTD (AU) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008072242-A2 | COMPOSITIONS AND METHODS FOR CONCENTRATING AND DEPLETING MICROORGANISMS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080146502-A1 | Methods for modulating the sensation of satiety perception and agents useful for same | AUTOGEN RESEARCH PTY LTD. (AU) | 2008-06-19 | — | — | US | disclosed |
| EP-1931370-A1 | USE OF DES-ASPARTATE-ANGIOTENSIN I | National University of Signapore (SG) | 2008-06-18 | — | — | EP | disclosed |
| EP-1129106-B1 | CYCLISED CONOTOXIN PEPTIDES | UNIV QUEENSLAND (AU) | 2008-06-18 | — | — | EP | disclosed |
| EP-0948522-B1 | THERAPEUTIC AND DIAGNOSTIC AGENTS CAPABLE OF MODULATING CELLULAR RESPONSIVENESS TO CYTOKINES | INST MEDICAL W & E HALL (AU) | 2008-06-11 | — | — | EP | disclosed |
| EP-1928896-A2 | ANCHORING DISRUPTION MOLECULES | University of Oslo (NO) | 2008-06-11 | — | — | EP | disclosed |
| US-7384958-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384958-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080131406-A1 | Angiotensin I Derivatives | NATIONAL UNVERSITY OF SINGAPORE (SG) | 2008-06-05 | — | — | US | disclosed |
| EP-1549335-A4 | A METHOD OF MODULATING CELLULAR ACTIVITY AND MOLECULES FOR USE THEREIN | UNIV MONASH (AU) | 2008-06-04 | — | — | EP | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008058332-A1 | DIAGNOSTIC PROTOCOLS FOR DIABETES | AUTOGEN RESEARCH PTY LTD (AU) | 2008-05-22 | — | — | WO | disclosed |
| EP-1242111-B1 | AN ANIMAL MODEL FOR STUDYING HORMONE SIGNALLING AND METHOD OF MODULATING THE SIGNALLING | INST MEDICAL W & E HALL (AU) | 2008-05-21 | — | — | EP | disclosed |
| EP-1919506-A1 | PEPTIDE CONJUGATE FOR ORAL DELIVERY OF HYDROPHILIC PEPTIDE ANALGESICS | Metabolic Pharmaceuticals Ltd. (AU) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052277-A1 | CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR | ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-05-08 | — | — | WO | disclosed |
| EP-1701736-A4 | THERAPEUTIC AGENTS AND USES THEREFOR | INST MEDICAL W & E HALL (AU) | 2008-05-07 | — | — | EP | disclosed |
| US-7368548-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer | COMPUGEN LTD. (IL) | 2008-05-06 | — | — | US | disclosed |
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | EBERHARD-KARLS-UNIVERSITAT TUBINGEN (DE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008043153-A1 | A METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME | MEDVET SCIENCE PTY. LTD. (AU) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043148-A1 | THE USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER | MEDVET SCIENCE PTY. LTD. (AU) | 2008-04-17 | — | — | WO | disclosed |
| EP-1910525-A1 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910523-A1 | MODULATION OF EGFR SIGNALLING BY MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910524-A1 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910535-A1 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-04-16 | — | — | EP | disclosed |
| CN-101163793-A | Molecular optoelectronic device and method of fabricating the same | UNIV RAMOT (IL) | 2008-04-16 | — | — | CN | disclosed |
| WO-2008040087-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-04-10 | — | — | WO | disclosed |
| EP-1692514-A4 | BINDING ASSAY COMPONENTS | HEPGENICS PTY LTD (AU) | 2008-04-09 | — | — | EP | disclosed |
| CN-101160323-A | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases | ICAL SCIENCES RAPPAPORT FAMILY (IL) | 2008-04-09 | — | — | CN | disclosed |
| US-20080076717-A1 | Polypeptides for bone mineralization | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-27 | — | — | US | disclosed |
| US-20080075725-A1 | Novel Immunointeractive Molecules and uses Thereof | MONASH UNIVERSITY (AU) | 2008-03-27 | — | — | US | disclosed |
| EP-1902084-A2 | BIODEGRADABLE POLYMERS HAVING A PRE-DETERMINED CHIRALITY | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2008-03-26 | — | — | EP | disclosed |
| US-7348400-B2 | α-conotoxin peptides with analgesic properties | Livett, Bruce Grayson (AU) | 2008-03-25 | — | — | US | disclosed |
| WO-2008033488-A2 | POLYPEPTIDES FOR BONE MINERALIZATION | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7345142-B2 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease | COMPUGEN LTD. (IL) | 2008-03-18 | — | — | US | disclosed |
| WO-2008028250-A1 | THERAPEUTIC AGENTS, TARGETS AND DIAGNOSTICS | AUTOGEN RESEARCH PTY LTD (AU) | 2008-03-13 | — | — | WO | disclosed |
| US-7341997-B2 | Method of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-11 | — | — | US | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20080057517-A1 | Methods of regulating cytokine signalling | THE WALTER AND ELIZA INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | US | disclosed |
| US-20080060087-A1 | Transgenic cells/animal comprising positive regulatory domain I element (PRDM-1) gene for use as model in identifying hematopoietic cells of particular lineages and their stage of differentiation | Cave, Davies Collison (AU) | 2008-03-06 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044377-A1 | Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine | VIRAX DEVELOPMENT PTY LTD (AU) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044428-A1 | Glycosylphosphatidylinositol Glycan Signalling Via Integrins Functioning as Glycan Specific Receptors | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RES (AU) | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| EP-1511474-A4 | A METHOD OF TREATMENT | INST MEDICAL W & E HALL (AU) | 2008-02-20 | — | — | EP | disclosed |
| US-7332569-B2 | Brain natriuretic peptide spliced variant | COMPUGEN LTD. (IL) | 2008-02-19 | — | — | US | disclosed |
| WO-2008017121-A1 | METHODS FOR MODULATING APOPTOSIS IN PLATELETS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017123-A1 | METHODS FOR MODULATING APOPTOSIS IN PLATELETS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-02-14 | — | — | WO | disclosed |
| US-20080039364-A1 | Modulating serum amyloid a interaction with tanis and agents useful for same | AUTOGEN RESEARCH PTY LTD (AU) | 2008-02-14 | — | — | US | disclosed |
| CN-101124261-A | Casein derived peptides and therapeutic uses thereof | PEPTERA PHARMACEUTICALS LTD (IL) | 2008-02-13 | — | — | CN | disclosed |
| US-7326682-B2 | Conotoxin peptides | XENOME LIMITED (AU) | 2008-02-05 | — | — | US | disclosed |
| US-20080027145-A1 | Therapeutic Molecules and Methods for Generating and/or Selecting Same | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-01-31 | — | — | US | disclosed |
| US-20080027003-A1 | Peptides Useful for Treating Gnrh Associated Diseases | CUREPEPTIDE LTD. (IL) | 2008-01-31 | — | — | US | disclosed |
| US-20080014590-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer | COMPUGEN LTD. (IL) | 2008-01-17 | — | — | US | disclosed |
| US-20080009444-A1 | Biologically active complex of NR6 and cardiotrophin-like-cytokine | ZENYTH OPERATIONS PTY LTD (AU) | 2008-01-10 | — | — | US | disclosed |
| US-20080009434-A1 | at least one aromatic amino acid (phenylalanine); hollow and fibrillar peptide; macroscopic and microscopic articles; self-assembled; 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz); slow release of drug, nucleic acid molecule or a polypeptide; antibody | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-01-10 | — | — | US | disclosed |
| EP-1793854-A4 | TREATING GLIOSIS, GLIAL SCARRING, INFLAMMATION OR INHIBITION OF AXONAL GROWTH IN THE NERVOUS SYSTEM BY MODULATING EPH RECEPTOR | UNIV QUEENSLAND (AU) | 2008-01-02 | — | — | EP | disclosed |
| US-20070299645-A1 | Autonomous Molecular Computer Diagnoses Molecular Disease Markers and Administers Requisite Drug in Vitro | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-12-27 | — | — | US | disclosed |
| US-20070298432-A1 | Binding Assay Components | HEP-GENICS PTY LTD (AU) | 2007-12-27 | — | — | US | disclosed |
| US-7312195-B2 | Cyclised conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-12-25 | — | — | US | disclosed |
| US-20070287662-A1 | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-12-13 | — | — | US | disclosed |
| EP-1673458-A4 | POXVIRUS VECTOR ENCODING RETROVIRUS (EG HIV) AND CYTOKINE | VIRAX DEV PTY LTD (AU) | 2007-12-12 | — | — | EP | disclosed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | disclosed |
| US-7306920-B2 | Gene associated with regulation of energy balance, obesity and diabetes and uses therefor | INTERNATIONAL DIABETES INSTITUTE (AU) | 2007-12-11 | — | — | US | disclosed |
| US-20070281986-A1 | Methods and Compositions for Modulating Satiety | COLLIER GREGORY R | 2007-12-06 | — | — | US | disclosed |
| EP-0931149-B1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY LTD (AU) | 2007-12-05 | — | — | EP | disclosed |
| US-7304163-B2 | Benzotriazole-1-yl-N-oxy phosphonium coupling agent | LUXEMBOURG INDUSTRIES LTD. (IL) | 2007-12-04 | — | — | US | disclosed |
| US-20070275916-A1 | Methods of Identifying Compounds Which Modulate Granulocite-Colony Stimulating Factor (G-Csf) Dependent Processes by Modulation of the Levels of Suppressor of Cytokine Signaling (Socs) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2007-11-29 | — | — | US | disclosed |
| EP-1858914-A1 | PEPTIDE NETWORKS | The University of Queensland (AU) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007131286-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-11-22 | — | — | WO | disclosed |
| US-20070269436-A1 | Method of Antibody Production | APOLLO LIFE SCIENCE LIMITED (AU) | 2007-11-22 | — | — | US | disclosed |
| US-20070270352-A1 | Method of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-11-22 | — | — | US | disclosed |
| WO-2007131280-A1 | HEMATOPOIESIS AND REGULATION THEREOF BY ETS RELATED GENE (Erg) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-11-22 | — | — | WO | disclosed |
| EP-1599226-A4 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY LTD (AU) | 2007-11-21 | — | — | EP | disclosed |
| US-20070264284-A1 | Therapeutic, Prophylactic and Diagnostic Agents for Hepatitis B | MELBOURNE HEALTH (AU) | 2007-11-15 | — | — | US | disclosed |
| WO-2007128080-A1 | AN ASSAY FOR MODULATORS OF APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-11-15 | — | — | WO | disclosed |
| US-20070265196-A1 | Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein | MEDVET SCIENCE PTY., LTD. (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259386-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer | COMPUGEN LTD. (IL) | 2007-11-08 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7291453-B1 | Viral variants | MELBOURNE HEALTH (AU) | 2007-11-06 | — | — | US | disclosed |
| EP-1192247-B9 | SPHINGOSINE KINASE ENZYME | JOHNSON & JOHNSON PHARM RES (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7288398-B2 | Molecules | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-10-30 | — | — | US | disclosed |
| US-20070248584-A1 | Immunomodulating Compositions, Uses Therefore and Processes for Their Production | THE UNIVERSITY OF MELBOURNE (AU) | 2007-10-25 | — | — | US | disclosed |
| WO-2007118270-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-10-25 | — | — | WO | disclosed |
| US-20070248609-A1 | Therapeutic Method | MONASH UNIVERSITY OF CLAYTON (AU) | 2007-10-25 | — | — | US | disclosed |
| EP-1845971-A1 | A METHOD OF TREATING CELLULAR DAMAGE | MEDVET SCIENCE PTY. LTD. (AU) | 2007-10-24 | — | — | EP | disclosed |
| EP-1846017-A1 | ANGIOTENSIN I DERIVATIVES | National University of Signapore (SG) | 2007-10-24 | — | — | EP | disclosed |
| EP-1408995-A4 | MODULATING SERUM AMYLOID A INTERACTION WITH TANIS AND AGENTS USEFUL FOR SAME | AUTOGEN RES PTY LTD (AU) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844069-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | Apollo Life Sciences Limited (AU) | 2007-10-17 | — | — | EP | disclosed |
| US-7279557-B2 | Therapeutic and diagnostic agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-10-09 | — | — | US | disclosed |
| EP-1222255-B1 | POLYPEPTIDE FRAGMENTS COMPRISING C-TERMINAL PORTION OF HELICOBACTER CATALASE | CSL LTD (AU) | 2007-09-26 | — | — | EP | disclosed |
| EP-1723235-A4 | MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME | INST MEDICAL W & E HALL (AU) | 2007-09-26 | — | — | EP | disclosed |
| EP-1836216-A1 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2007-09-26 | — | — | EP | disclosed |
| US-20070219147-A1 | Insect Chymotrypsin and Inhibitors Thereof | HEXIMA LIMITED (AU) | 2007-09-20 | — | — | US | disclosed |
| US-20070212769-A1 | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same | CENTRAL NORTHERN ADELAIDE HEALTH SERVICE (AU) | 2007-09-13 | — | — | US | disclosed |
| US-20070209092-A1 | Plant seed comprising vernolic acid | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, BASF PLANT SCIENCE, GMBH | 2007-09-06 | — | — | US | disclosed |
| US-20070207161-A1 | Immunomodulating Compositions and uses Therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2007-09-06 | — | — | US | disclosed |
| EP-1830187-A1 | Methods of and compositions for modulating hair growth via p-cadherin modulators | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2007-09-05 | — | — | EP | disclosed |
| US-20070203060-A1 | Casein Derived Peptides And Therapeutic Uses Thereof | SIDELMAN ZVI | 2007-08-30 | — | — | US | disclosed |
| US-7262027-B2 | Polypeptide and DNA immunization against Coccidioides spp. infections | MEDICAL COLLEGE OF OHIO (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| EP-0956353-B1 | MANIPULATION OF CELLULOSE. | UNIV AUSTRALIAN (AU) | 2007-08-22 | — | — | EP | disclosed |
| US-7256007-B2 | Methods of regulating cytokine signalling | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-14 | — | — | US | disclosed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | disclosed |
| WO-2007087689-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREIN | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2007-08-09 | — | — | WO | disclosed |
| US-7250282-B2 | Isomaltulose synthases, polynucleotides encoding them and uses therefor | THE UNIVERSITY OF QUEENSLAND OF ST. LUCIA (AU) | 2007-07-31 | — | — | US | disclosed |
| WO-2007081540-A2 | TYLOPHORINE ANALOGS AS ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070161557-A1 | Casein derived peptides and uses thereof in therapy | SIDELMAN ZVI | 2007-07-12 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-7238800-B2 | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070148129-A1 | Therapeutic agents and uses therefor | THE WALTER AND ELIZA HALL INSTIUTE OF MEDICAL RESEARCH (AU) | 2007-06-28 | — | — | US | disclosed |
| EP-1799702-A2 | INHIBITORS OF PROTEIN KINASE A ANCHORING | The University of Oslo (NO) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142226-A1 | Method and agents for improving plant productivity involving endophytic actinomycetes and metabolites thereof | FLINDERS TECHNOLOGIES PTY LTD (AU) | 2007-06-21 | — | — | US | disclosed |
| US-20070138007-A1 | Peptide nanostructure-coated electrodes | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-06-21 | — | — | US | disclosed |
| US-20070135334-A1 | Peptides and methods using same for diagnosing and treating amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135336-A1 | Follistatin isoforms and uses thereof | MONASH UNIVERSITY (AU) | 2007-06-14 | — | — | US | disclosed |
| EP-1793837-A2 | FATTY ACID MODIFIED POLYLYSINES AS ANTIMICROBIAL AGENTS | Technion Research & Development Foundation Limited (IL) | 2007-06-13 | — | — | EP | disclosed |
| EP-1793854-A1 | TREATING GLIOSIS, GLIAL SCARRING, INFLAMMATION OR INHIBITION OF AXONAL GROWTH IN THE NERVOUS SYSTEM BY MODULATING EPH RECEPTOR | The University of Queensland (AU) | 2007-06-13 | — | — | EP | disclosed |
| CN-1981033-A | Therapeutic, prophylactic and diagnostic agent for hepatitis B | MELBOURNE HEALTH (AU) | 2007-06-13 | — | — | CN | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| US-20070128586-A1 | Therapeutic, prophylactic and diagnostic agents | SOUTH EASTERN SYDNEY AND ILLAWARRA AREA HEALTH SERVICE (AU) | 2007-06-07 | — | — | US | disclosed |
| WO-2007059569-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2007-05-31 | — | — | WO | disclosed |
| CN-1973041-A | Therapeutic molecules and methods of producing and/or selecting the same | INST MEDICAL W & E HALL (AU) | 2007-05-30 | — | — | CN | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070116687-A1 | Method of modulating cellular transmigration and agents for use therein | MEDVET SCIENCE PTY, LTD. | 2007-05-24 | — | — | US | disclosed |
| US-7220828-B2 | Haemopoietin receptor and genetic sequence encoding same | ZENYTH OPERATIONS PTY LTD (AU) | 2007-05-22 | — | — | US | disclosed |
| WO-2007056527-A2 | DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS | CHENG SI YUAN (CHINA-INTERNATIONAL) HEPATITIS RESEARCH FOUNDATION (CN) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112013-A1 | Method of modulating ion channel functional activity | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2007-05-17 | — | — | US | disclosed |
| US-20070110712-A1 | Method of modulating fertility in animals | ROBB LORRAINE G | 2007-05-17 | — | — | US | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781685-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099262-A1 | Viral vectors expressing fusion of viral large envelope protein and protein of interest | ANDERSON DAVID A | 2007-05-03 | — | — | US | disclosed |
| EP-1778253-A1 | GLYCOSYLPHOSPHATIDYLINOSITOL GLYCAN SIGNALLING VIA INTEGRINS FUNCTIONING AS GLYCAN SPECIFIC RECEPTORS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-02 | — | — | EP | disclosed |
| EP-1620558-A4 | VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN AND PROTEIN OF INTEREST | HEPGENICS PTY LTD (AU) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007045873-A2 | MEDICAL USES AND THERAPIES BASED UPON THE ACTION OF AZUROCIDIN ON IGFBP-1 | RUTHERFORD, JODIE (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20070082849-A1 | Angiogenic peptides and uses thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2007-04-12 | — | — | US | disclosed |
| US-20070077569-A1 | Isomaltulose synthases, polynucleotides encoding them and uses therefor | THE UNIVERSITY OF QUEENSLAND OF ST. LUCIA (AU) | 2007-04-05 | — | — | US | disclosed |
| WO-2006026820-A9 | TREATING GLIOSIS, GLIAL SCARRING, INFLAMMATION OR INHIBITION OF AXONAL GROWTH IN THE NERVOUS SYSTEM BY MODULATING EPH RECEPTOR | UNIV QUEENSLAND (AU) | 2007-04-05 | — | — | WO | disclosed |
| US-20070077628-A1 | Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-04-05 | — | — | US | disclosed |
| US-20070071752-A1 | Sphingosine kinase enzyme | JOHNSON & JOHNSON PHARMACEUTICAL R AND D LLC (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1765990-A1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B | Melbourne Health (AU) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765384-A1 | METHOD OF MODULATING CELLULAR ACTIVITY INVOLVING SPHINGOSINE KINASE AND AGENTS FOR SAME, AND SPHINGOSINE KINASE VARIANTS | MEDVET SCIENCE PTY. LTD. (AU) | 2007-03-28 | — | — | EP | disclosed |
| US-20070065915-A1 | Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals | AUTOGEN RESEARCH PTY LTD (AU) | 2007-03-22 | — | — | US | disclosed |
| US-7192576-B1 | Biologically active complex of NR6 and cardiotrophin-like-cytokine | ZENYTH OPERATIONS PTY LTD. (AU) | 2007-03-20 | — | — | US | disclosed |
| US-20070059806-A1 | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection | YEDA RESEARCH AND DEVELOPMENT CO., LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2007-03-15 | — | — | US | disclosed |
| WO-2007030082-A1 | USE OF DES-ASPARTATE-ANGIOTENSIN I | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2007-03-15 | — | — | WO | disclosed |
| US-20070059756-A1 | Immunointeractive molecules and their uses in treating subjects suffering from Hev b 5 allergies | O'HEHIR ROBYN | 2007-03-15 | — | — | US | disclosed |
| WO-2007028969-A2 | ANCHORING DISRUPTION MOLECULES | UNIVERSITY OF OSLO (NO) | 2007-03-15 | — | — | WO | disclosed |
| EP-1434878-A4 | NUCLEIC ACID CONSTRUCTS CAPABLE OF HIGH EFFICIENCY DELIVERY OF POLYNUCLEOTIDES INTO DNA CONTAINING ORGANELLES AND METHODS OF UTILIZING SAME | YEDA RES & DEV (IL) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007025347-A1 | PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007022557-A1 | MIMOTOPES OF EPSTEIN-BARR VIRUS (EBV) EPITOPES | DIATECH PTY LTD (AU) | 2007-03-01 | — | — | WO | disclosed |
| EP-1530484-A4 | A METHOD OF IMMUNOMODULATION | ORDER SISTERS OF MERCY QUEENSL (AU) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756272-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756548-A1 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES | Genera Biosystems Pty Ltd (AU) | 2007-02-28 | — | — | EP | disclosed |
| US-20070042432-A1 | Method of diagnosis and treatment | MEDVET SCIENCE PTY.LTD (AU) | 2007-02-22 | — | — | US | disclosed |
| US-20070043207-A1 | Novel coupling agent and uses thereof | LUXEMBOURG INDUSTRIES LTD. (IL) | 2007-02-22 | — | — | US | disclosed |
| US-20070043512-A1 | Therapeutic and prophylactic compositions and uses therefor | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2007-02-22 | — | — | US | disclosed |
| US-7179803-B1 | Method of modulating ion channel functional activity | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2007-02-20 | — | — | US | disclosed |
| US-7179615-B1 | Method of prophylaxis and treatment | MENZIES SCHOOL OF HEALTH RESEARCH (AU) | 2007-02-20 | — | — | US | disclosed |
| US-20070037883-A1 | Therapeutic compositions | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY & MEDICINE (AU) | 2007-02-15 | — | — | US | disclosed |
| US-20070031835-A1 | Diagnosis of advanced cancer | PROSTATE DIAGNOSTICS PTY LTD (AU) | 2007-02-08 | — | — | US | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| US-20070032642-A1 | Novel genes and their use in the modulation of obesity, diabetes and energy imbalance | COLLIER GREGORY | 2007-02-08 | — | — | US | disclosed |
| US-20070032428-A1 | Novel antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-02-08 | — | — | US | disclosed |
| WO-2007014432-A1 | PEPTIDE CONJUGATE FOR ORAL DELIVERY OF HYDROPHILIC PEPTIDE ANALGESICS | METABOLIC PHARMACEUTICALS LIMITED (AU) | 2007-02-08 | — | — | WO | disclosed |
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7172879-B2 | Detection of sphingosine kinase activity and sphingosine kinase agonist or antagonist activity | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT LLP (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070021589-A1 | Obesity-related genes | DEAKIN UNIVERSITY (AU) | 2007-01-25 | — | — | US | disclosed |
| US-20070021345-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2007-01-25 | — | — | US | disclosed |
| CN-1902496-A | Binding assay components | HEPGENICS PTY LTD (AU) | 2007-01-24 | — | — | CN | disclosed |
| US-7166698-B2 | Genetic engineering; delay cell cycle | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-01-23 | — | — | US | disclosed |
| US-20070015196-A1 | Growth factor with acts through Erb B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-01-18 | — | — | US | disclosed |
| US-20070015741-A1 | Novel prodrugs of estradiol | WARNER CHILCOTT COMPANY LLC (PR) | 2007-01-18 | — | — | US | disclosed |
| US-20070015740-A1 | Derivative prodrugs of ethinyl estradiol | Allergan Therapeutics LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070010467-A1 | Targeted double stranded rna mediated cell killing | TARGIMMUNE THERAPEUTICS AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1196562-A4 | NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE | AUTOGEN RES PTY LTD (AU) | 2007-01-10 | — | — | EP | disclosed |
| EP-1599489-A4 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES | MEDIMOLECULAR PTY LTD (AU) | 2007-01-03 | — | — | EP | disclosed |
| EP-1620553-A4 | INSECT CHYMOTRYPSIN AND INHIBITORS THEREOF | HEXIMA LTD (AU) | 2007-01-03 | — | — | EP | disclosed |
| EP-1737884-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | The University of Queensland (AU) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006135968-A1 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2006-12-28 | — | — | WO | disclosed |
| US-20060292153-A1 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-12-28 | — | — | US | disclosed |
| WO-2006135967-A1 | MODULATION OF EGFR SIGNALLING BY MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006135969-A1 | MODULATION OF SPHINGOSINE KINASE SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006135985-A1 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-12-28 | — | — | WO | disclosed |
| US-20060294608-A1 | Novel haemopoietin receptor and genetic sequences encoding same | ZENYTH OPERATIONS PTY LTD (AU) | 2006-12-28 | — | — | US | disclosed |
| US-7154026-B2 | Manipulation of cellulose and/or β-1,4,-glucan | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-12-26 | — | — | US | disclosed |
| US-20060287229-A1 | Novel CD40 variants | COMPUGEN LTD (IL) | 2006-12-21 | — | — | US | disclosed |
| US-20060281672-A1 | Dec-205 (ly 75)/dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof | TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND, THE CORPORATION OF (AU) | 2006-12-14 | — | — | US | disclosed |
| US-20060275313-A1 | Therapeutic and diagnostic agents | CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY, THE (AU) | 2006-12-07 | — | — | US | disclosed |
| WO-2006129320-A2 | BIODEGRADABLE POLYMERS HAVING A PRE-DETERMINED CHIRALITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-12-07 | — | — | WO | disclosed |
| EP-1616190-A4 | DIAGNOSIS OF ADVANCED CANCER | UNIV MONASH (AU) | 2006-12-06 | — | — | EP | disclosed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | disclosed |
| US-20060270832-A1 | Novel x-conotoxin peptides (-II) | XENOME LIMITED (AU) | 2006-11-30 | — | — | US | disclosed |
| EP-1587827-A4 | OBESITY-RELATED GENES | AUTOGEN RES PTY LTD (AU) | 2006-11-29 | — | — | EP | disclosed |
| EP-1611251-A4 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS | MURDOCH CHILDRENS RES INST (AU) | 2006-11-29 | — | — | EP | disclosed |
| US-20060264362-A1 | Method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling | MEDVET SCIENCE PTY. LTD. (AT) | 2006-11-23 | — | — | US | disclosed |
| WO-2006122363-A1 | THERAPEUTIC AGENTS AND TARGETS | AUTOGEN RESEARCH PTY LTD (AU) | 2006-11-23 | — | — | WO | disclosed |
| US-20060263365-A1 | Method of immunomodulation | HART DEREK | 2006-11-23 | — | — | US | disclosed |
| EP-1723235-A1 | MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-11-22 | — | — | EP | disclosed |
| EP-1576156-A4 | DEC-205 (LY 75) / DCL-1 INTERGENIC SPLICE VARIANTS ASSOCIATED WITH HODKIN'S DISEASE, AND USES THEREOF | ORDER SISTERS OF MERCY QUEENSL (AU) | 2006-11-22 | — | — | EP | disclosed |
| US-7138421-B2 | Anti-androgenic pyrrolidines with tumor-inhibiting action | SCHRING AKTIENGESELLSCHAFT (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20060258856-A1 | Method of isolating nucleic acids from stool samples | MEDIMOLECULAR PTY. LTD. (AU) | 2006-11-16 | — | — | US | disclosed |
| US-20060257896-A1 | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof | COMPUGEN LTD. (IL) | 2006-11-16 | — | — | US | disclosed |
| EP-1718748-A1 | THERAPEUTIC MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | disclosed |
| US-7128922-B1 | Compositions of leukaemia inhibitory factor | AMRAD OPERATIONS PTY LTD (AU) | 2006-10-31 | — | — | US | disclosed |
| US-20060242718-A1 | SOCS-box containing peptides | WILLSON TRACY A | 2006-10-26 | — | — | US | disclosed |
| US-20060241130-A1 | Anti-inflammatory compositions and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-10-26 | — | — | US | disclosed |
| US-20060239912-A1 | Carrier molecules | AGEN BIOMEDICAL LIMITED (AU) | 2006-10-26 | — | — | US | disclosed |
| EP-1713462-A1 | A METHOD OF MODULATING PRO-INFLAMMATORY AND INFLAMMATORY ACTIVITY MEDIATED BY C-REACTIVE PROTEIN | MEDVET SCIENCE PTY. LTD. (AU) | 2006-10-25 | — | — | EP | disclosed |
| US-20060234290-A1 | Novel genes and expression products therefrom | CHUNG CHING M | 2006-10-19 | — | — | US | disclosed |
| US-20060233785-A1 | Immunointeractive molecules and uses thereof | COOPERATIVE RESEARCH CENTRE FOR ASTHMA (AU) | 2006-10-19 | — | — | US | disclosed |
| US-20060236428-A1 | Manipulation of cellulose and/or beta-1,4-glucan | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-10-19 | — | — | US | disclosed |
| US-20060234914-A1 | Fragments of proinsulin c-peptide | CREATIVE PEPTIDES SWEDEN AB (SE) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108211-A1 | FRAGMENTS OF VON WILLEBRAND FACTOR A-RELATED PROTEIN | THE MURDOCH CHILDRENS RESEARCH INSTITUTE (AU) | 2006-10-19 | — | — | WO | disclosed |
| US-20060234947-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | Tel Aviv University Future Technology Development L.P (IL) | 2006-10-19 | — | — | US | disclosed |
| WO-2006105602-A1 | ANIMAL MODELS AND CELLS WITH A MODIFIED GENE ENCODING TRANSTHYRETIN-RELATED PROTEIN AND APPLICATIONS THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-10-12 | — | — | WO | disclosed |
| US-20060228775-A1 | Differential expression of nucleic acid molecules | CHEMGENEX PHARMACEUTICALS LLIMITED | 2006-10-12 | — | — | US | disclosed |
| EP-0975765-B1 | PLANT FATTY ACID EPOXYGENASE GENES AND USES THEREFOR | COMMW SCIENT IND RES ORG (AU) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006099667-A1 | PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-09-28 | — | — | WO | disclosed |
| US-20060218653-A1 | Novel molecular variant and uses thereof | MELVILLE SCOTT A | 2006-09-28 | — | — | US | disclosed |
| EP-1572741-A4 | THERAPEUTIC AND DIAGNOSTIC AGENTS | ORDER SISTERS OF MERCY QUEENSL (AU) | 2006-09-27 | — | — | EP | disclosed |
| US-7112427-B2 | Sphingosine kinase enzyme | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1701736-A1 | THERAPEUTIC AGENTS AND USES THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-09-20 | — | — | EP | disclosed |
| US-20060205688-A1 | Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase | MEDVET SCIENCE PTY. LTD. (AU) | 2006-09-14 | — | — | US | disclosed |
| US-7105480-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2006-09-12 | — | — | US | disclosed |
| EP-1578794-A4 | A NOVEL PHOSPHOPROTEIN | INST MEDICAL W & E HALL (AU) | 2006-09-06 | — | — | EP | disclosed |
| US-7101849-B1 | ωconotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-09-05 | — | — | US | disclosed |
| WO-2006089364-A1 | PEPTIDE NETWORKS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-08-31 | — | — | WO | disclosed |
| US-20060194233-A1 | Ligand of the protein \"beacon\ | COLLIER GREG | 2006-08-31 | — | — | US | disclosed |
| US-20060190186-A1 | Viral polymerase and modulation thereof | MELBOURNE HEALTH (AU) | 2006-08-24 | — | — | US | disclosed |
| EP-1692514-A1 | BINDING ASSAY COMPONENTS | Hepgenics Pty Ltd (AU) | 2006-08-23 | — | — | EP | disclosed |
| US-7094882-B2 | Neuregulin-4; for treating or preventing a disease, condition or syndrome associated with disregulation of an endogenous protein affecting receptor activity | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-08-22 | — | — | US | disclosed |
| US-7094575-B2 | Therapeutic and prophylactic agents and methods of using same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2006-08-22 | — | — | US | disclosed |
| US-20060182768-A1 | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060183131-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer | COMPUGEN LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183687-A1 | Novel therapeutic molecules | CORY SUZANNE | 2006-08-17 | — | — | US | disclosed |
| EP-1117682-B1 | Chi-Conotoxin Peptides as INhibitors of Neuronal Amine Transporters | XENOME LTD (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-1412388-A4 | HUMANIZED ANTIBODIES DERIVED FROM DD-3B6/22, SPECIFIC FOR THE D-DIMER FRAGMENT OF FIBRIN | AGEN BIOMEDICAL LTD (AU) | 2006-08-09 | — | — | EP | disclosed |
| EP-1613765-A4 | A METHOD OF MODULATING SMOOTH MUSCLE CELL FUNCTIONING BY MODULATING SPHINGOSINE KINASE MEDIATED SIGNALLING | MEDVET SCIENCE PTY LTD (AU) | 2006-08-09 | — | — | EP | disclosed |
| US-7087724-B2 | Carrier molecules | AGEN BIOMEDICAL LTD (AU) | 2006-08-08 | — | — | US | disclosed |
| US-20060172347-A1 | Method of diagnosis, treatment and useful agents for conditions characterised by modulation in the level of activin ssc | MONASH UNIVERSITY (AU) | 2006-08-03 | — | — | US | disclosed |
| US-20060172311-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease | COMPUGEN LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
| WO-2006079176-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LIMITED (AU) | 2006-08-03 | — | — | WO | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060166917-A1 | Differentiation and/or proliferation modulating agents and uses therefor | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-07-27 | — | — | US | disclosed |
| WO-2006076767-A1 | A METHOD OF TREATING CELLULAR DAMAGE | MEDVET SCIENCE PTY. LTD. (AU) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078223-A1 | ANGIOTENSIN I DERIVATIVES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2006-07-27 | — | — | WO | disclosed |
| EP-1579213-A4 | METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN BETA C | UNIV MONASH (AU) | 2006-07-26 | — | — | EP | disclosed |
| US-20060162001-A1 | Mammalian grainyhead transcription factors | MONASH UNIVERSITY (AU) | 2006-07-20 | — | — | US | disclosed |
| US-7078037-B2 | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2006-07-18 | — | — | US | disclosed |
| US-7078174-B1 | Screening methods using SOCS box-containing peptides | THE WALTER & ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-07-18 | — | — | US | disclosed |
| US-20060153843-A1 | Method of immunomodulation | The Corporation of The Trustees of The Sisters of Mercy in Queensland of South Brisbane (AU) | 2006-07-13 | — | — | US | disclosed |
| US-20060155111-A9 | Novel genes and their use in the modulation of obesity, diabetes and energy imbalance | AUTOGEN RESEARCH PTY LTD. (AU) | 2006-07-13 | — | — | US | disclosed |
| EP-1677816-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2006-07-12 | — | — | EP | disclosed |
| US-20060147946-A1 | Novel calcium channel variants and methods of use thereof | AKIVA PINCHAS | 2006-07-06 | — | — | US | disclosed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| US-20060148032-A1 | Novel phosphoprotein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RES (AU) | 2006-07-06 | — | — | US | disclosed |
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | disclosed |
| US-20060142201-A1 | Novel x-conotoxin peptides (-1) | XENOME LIMITED (AU) | 2006-06-29 | — | — | US | disclosed |
| EP-1673458-A1 | POXVIRUS VECTOR ENCODING RETROVIRUS (EG HIV) AND CYTOKINE | Virax Development Pty Ltd. (AU) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135408-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT (IL) | 2006-06-22 | — | — | US | disclosed |
| US-7064193-B1 | New member of the Bcl-2 family of proteins, useful, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-06-20 | — | — | US | disclosed |
| WO-2006060871-A1 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2006-06-15 | — | — | WO | disclosed |
| EP-1667516-A1 | METHOD OF SELECTING ANIMAL MODELS FROM ANIMALS WHICH HAVE BEEN SUBJECT TO MUTAGENESIS, AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING | The Walter and Eliza Hall Institute of Medical Research (AU) | 2006-06-14 | — | — | EP | disclosed |
| US-20060121083-A1 | Anti-microbial medical implants and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-06-08 | — | — | US | disclosed |
| US-20060122107-A1 | Method of modulating cellular activity and molecules for use therein | MONASH UNIVERSITY (AU) | 2006-06-08 | — | — | US | disclosed |
| EP-1534833-A4 | MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS | MELBOURNE HEALTH (AU) | 2006-06-07 | — | — | EP | disclosed |
| US-20060115480-A1 | Disease treatment via antimicrobial peptide inhibitors | HILLMAN YITZCHAK | 2006-06-01 | — | — | US | disclosed |
| WO-2006056009-A1 | PEPTIDES HAVING ADHESIVE PROPERTIES FOR USE IN SOLID PHASE ASSAY AND CHEMICAL POLYMER SYNTHESIS REGIMES. | HEPGENICS PTY LTD (AU) | 2006-06-01 | — | — | WO | disclosed |
| EP-1438063-A4 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME | MENTAL HEALTH RES INST OF VICT (AU) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660113-A1 | A METHOD OF PRODUCING AN ANTICOAGULATION EFFECT | Cryptome Pharmaceuticals Ltd. (AU) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111286-A1 | Method of modulating endothelial cell activity | MEDVET SCIENCE PTY LTD (AU) | 2006-05-25 | — | — | US | disclosed |
| US-7049418-B2 | Therapeutic and diagnostic agents comprising a SOCS box | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-05-23 | — | — | US | disclosed |
| EP-1656445-A1 | A METHOD AND AGENTS FOR IMPROVING PLANT PRODUCTIVITY INVOLVING ENDOPHYTIC ACTINOMYCETES AND METABOLITES THEREOF | Flinders Technologies PTY. Ltd. (AU) | 2006-05-17 | — | — | EP | disclosed |
| CN-1774243-A | Therapeutic compositions | FLOREY HOWARD INST (AU) | 2006-05-17 | — | — | CN | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
| EP-1438407-A4 | OBESITY RELATED GENES EXPRESSED AT LEAST IN THE HYPOTALAMUS, LIVER OR PANCREAS | AUTOGEN RES PTY LTD (AU) | 2006-05-10 | — | — | EP | disclosed |
| US-20060093604-A1 | Method of treatment and prophylaxis | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-05-04 | — | — | US | disclosed |
| US-20060084789-A1 | Immunotherapeutic and immunoprphylactic reagents | CIRCASSIA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| EP-1458406-A4 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | ORDER SISTERS OF MERCY QUEENSL (AU) | 2006-04-19 | — | — | EP | disclosed |
| CN-1761484-A | Methods of Diagnosis and Treatment | MEDVET SCIENCE PTY LTD (AU) | 2006-04-19 | — | — | CN | disclosed |
| US-20060078551-A1 | Novel therapeutic and prophylactic agents and methods of using the same | GOPALAKRISHNAKONE PONNAMPALAM | 2006-04-13 | — | — | US | disclosed |
| US-20060079455-A1 | Peptide nanostructures encapsulating a foreign material and method of manufacturing same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-04-13 | — | — | US | disclosed |
| US-20060079454-A1 | Peptide nanostructures and methods of generating and using the same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-04-13 | — | — | US | disclosed |
| EP-1192247-B1 | SPHINGOSINE KINASE ENZYME | JOHNSON & JOHNSON PHARM RES (US) | 2006-04-12 | — | — | EP | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| US-20060074021-A1 | Novel antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-04-06 | — | — | US | disclosed |
| WO-2006035431-A2 | FATTY ACID MODIFIED POLYLYSINES AS ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069023-A1 | Animal model for studying hormone signalling and method of modulating the signalling | ALEXANDER WARREN S | 2006-03-30 | — | — | US | disclosed |
| US-20060068472-A1 | Compositions to ameliorate protein misfolding and aggregation | CALDWELL GUY A | 2006-03-30 | — | — | US | disclosed |
| WO-2006032909-A2 | PKA II ANCHORING DISRUPTION POLYPEPTIDE | THE UNIVERSITY OF OSLO (NO) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006032923-A2 | INHIBITORS OF PROTEIN KINASE A ANCHORING | UNIVERSITY OF OSLO (NO) | 2006-03-30 | — | — | WO | disclosed |
| EP-1638992-A1 | VIRAL POLYMERASE AND MODULATION THEREOF | Melbourne Health (AU) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006029462-A1 | A NUCLEIC ACID MOLECULE DIFFERENTIALLY EXPRESSED IN A MOUSE BEHAVIOURAL MODEL SYSTEM AND USES THEREOF | AUTOGEN RESEARCH PTY LTD (AU) | 2006-03-23 | — | — | WO | disclosed |
| US-20060057665-A1 | Galectin-14 therapeutic molecule and uses thereof | THE UNIVERSITY OF MELBOURNE (AU) | 2006-03-16 | — | — | US | disclosed |
| WO-2006026820-A1 | TREATING GLIOSIS, GLIAL SCARRING, INFLAMMATION OR INHIBITION OF AXONAL GROWTH IN THE NERVOUS SYSTEM BY MODULATING EPH RECEPTOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-03-16 | — | — | WO | disclosed |
| EP-1438427-A4 | NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM AND/OR ADENOMA | ENTERIX PTY LTD (AU) | 2006-03-15 | — | — | EP | disclosed |
| CN-1245161-C | Method for modulating ion channel functional activity | UNIV AUSTRALIAN (AU) | 2006-03-15 | — | — | CN | disclosed |
| US-20060051774-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer | COMPUGEN LTD. (IL) | 2006-03-09 | — | — | US | disclosed |
| CN-1745299-A | Diagnostic, therapeutic methods and useful agents for conditions characterized by modulation of activin β c levels | UNIV MONASH (AU) | 2006-03-08 | — | — | CN | disclosed |
| US-20060040278-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer | COMPUGEN LTD. (IL) | 2006-02-23 | — | — | US | disclosed |
| US-7001883-B1 | Cyclized conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-21 | — | — | US | disclosed |
| US-7001771-B1 | Genes encoding wheat starch synthases and uses thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2006-02-21 | — | — | US | disclosed |
| US-20060035379-A1 | Genes encoding wheat starch synthases and uses thereof | Commonwealth and Scientific and Industrial Research Organisation ("CSIRO") | 2006-02-16 | — | — | US | disclosed |
| US-20060035819-A1 | Novel molecule | CRAIK DAVID J | 2006-02-16 | — | — | US | disclosed |
| EP-1620089-A1 | THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS AND USES THEREFOR | CRC For Asthma Limited (AU) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620558-A1 | VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN AND PROTEIN OF INTEREST | Hepgenics Pty Ltd (AU) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620553-A1 | INSECT CHYMOTRYPSIN AND INHIBITORS THEREOF | Hexima Ltd. (AU) | 2006-02-01 | — | — | EP | disclosed |
| CN-1729014-A | Methods of treating diseases by antimicrobial peptide inhibitors | YITZCHAK HILLMAN (IL) | 2006-02-01 | — | — | CN | disclosed |
| WO-2006007667-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-26 | — | — | WO | disclosed |
| EP-1135476-A4 | BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR | MELBOURNE HEALTH (AU) | 2006-01-25 | — | — | EP | disclosed |
| EP-1230263-A4 | A NOVEL MOLECULE | UNIV QUEENSLAND (AU) | 2006-01-25 | — | — | EP | disclosed |
| US-20060014166-A1 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis | COMPUGEN LTD. (IL) | 2006-01-19 | — | — | US | disclosed |
| EP-1616190-A1 | DIAGNOSIS OF ADVANCED CANCER | Prostate Diagnostics Pty Ltd (AU) | 2006-01-18 | — | — | EP | disclosed |
| US-20060008464-A1 | Histone conjugates and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-01-12 | — | — | US | disclosed |
| US-20060009378-A1 | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-01-12 | — | — | US | disclosed |
| EP-1613765-A1 | A METHOD OF MODULATING SMOOTH MUSCLE CELL FUNCTIONING BY MODULATING SPHINGOSINE KINASE MEDIATED SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2006-01-11 | — | — | EP | disclosed |
| EP-1290182-A4 | SPHINGOSINE KINASE AND USES THEREOF | MEDVET SCIENCE PTY LTD (AU) | 2006-01-11 | — | — | EP | disclosed |
| US-20060003377-A1 | Therapeutic and diagnostic proteins comprising a SOCS box | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| EP-1611251-A1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS | Murdoch Childrens Research Institute (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005123115-A1 | METHODS OF MODULATING CELLULAR ACTIVITY INVOLVING SPHINGOSINE KINASE AND AGENTS FOR SAME, AND SPHINGOSINE KINASE VARIANTS | MEDVET SCIENCE PTY. LTD. (AU) | 2005-12-29 | — | — | WO | disclosed |
| EP-1609865-A2 | Hepatitis B virus (HBV) variants | Melbourne Health (AU) | 2005-12-28 | — | — | EP | disclosed |
| EP-1499343-A4 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY LTD (AU) | 2005-12-28 | — | — | EP | disclosed |
| EP-1542528-A4 | A METHOD OF TREATMENT AND PROPHYLAXIS | INST MEDICAL W & E HALL (AU) | 2005-12-28 | — | — | EP | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-20050281815-A1 | CD40 splice variants and their uses | ESHEL DANI | 2005-12-22 | — | — | US | disclosed |
| WO-2005120519-A1 | GLYCOSYLPHOSPHATIDYLINOSITOL GLYCAN SIGNALLING VIA INTEGRINS FUNCTIONING AS GLYCAN SPECIFIC RECEPTORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121166-A1 | NOVEL IMMUNOINTERACTIVE MOLECULES AND USES THEREOF | MONASH UNIVERSITY (AU) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277156-A1 | Novel brain natriuretic peptide variants and methods of use thereof | COMPUGEN LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
| EP-1015494-B1 | METHOD OF PRODUCING CATALYTIC ANTIBODIES | KOENTGEN FRANK (AU) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603543-A1 | THERAPEUTIC COMPOSITIONS | Howard Florey Institute of Experimental Physiology and Medicine (AU) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005116615-A1 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES | GENERA BIOSYSTEMS PTY LTD (AU) | 2005-12-08 | — | — | WO | disclosed |
| US-20050265964-A1 | Compositions of leukaemia inhibitory factor | CHARMAN SUSAN A | 2005-12-01 | — | — | US | disclosed |
| EP-1599226-A1 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY. LTD. (AU) | 2005-11-30 | — | — | EP | disclosed |
| EP-1599489-A1 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES | Medimolecular Pty. Ltd. (AU) | 2005-11-30 | — | — | EP | disclosed |
| US-20050260770-A1 | Antigen array and diagnostic uses thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-11-24 | — | — | US | disclosed |
| WO-2005111199-A1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B | MELBOURNE HEALTH (AU) | 2005-11-24 | — | — | WO | disclosed |
| EP-1446414-A4 | DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES | AUTOGEN RES PTY LTD (AU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1499337-A4 | IMMUNOTHERAPEUTIC AND IMMUNOPROPHYLACTIC REAGENTS | UNIV MONASH (AU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1597350-A2 | NUCLEIC ACID MOLECULES, POLYPEPTIDES, ANTIBODIES AND COMPOSITIONS CONTAINING SAME USEFUL FOR TREATING AND DETECTING INFLUENZA VIRUS INFECTION | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2005-11-23 | — | — | EP | disclosed |
| US-20050256301-A1 | Cyclised conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-11-17 | — | — | US | disclosed |
| EP-1402021-A4 | A GENE AND USES THEREFOR | AUTOGEN RES PTY LTD (AU) | 2005-11-09 | — | — | EP | disclosed |
| CN-1694719-A | Casein derived peptides and therapeutic uses thereof | CHAY 13 MEDICAL RES GROUP N V (AN) | 2005-11-09 | — | — | CN | disclosed |
| CN-1691889-A | Curing and preventing method | WALTER & ELESARHOL MEDICAL ACA (AU) | 2005-11-02 | — | — | CN | disclosed |
| US-20050238657-A1 | Defective entities and uses therefor | UNIVERSITY OF SOUTHERN QUEENSLAND (AU) | 2005-10-27 | — | — | US | disclosed |
| EP-1587827-A1 | OBESITY-RELATED GENES | Autogen Research Pty. Ltd. (AU) | 2005-10-26 | — | — | EP | disclosed |
| US-20050232918-A1 | Differentially expressed genes associated with obesity and type 2 diabetes | INTERNATIONAL DIABETES INSTITUTE (AU) | 2005-10-20 | — | — | US | disclosed |
| EP-1412754-A4 | DIAGNOSTIC METHODS AND AGENTS | INST MEDICAL W & E HALL (AU) | 2005-10-19 | — | — | EP | disclosed |
| EP-1534333-A4 | A METHOD OF IMMUNOMODULATION | ORDER SISTERS OF MERCY QUEENSL (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095610-A1 | NUCLEIC ACID EXPRESSED IN THE HYPOTHALAMUS OR MUSCLE TISSUE AND USES THEREOF IN DIAGNOSES | AGT BIOSCIENCES LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |
| US-20050227279-A1 | Methods of using torsin proteins, to prevent protein misfolding and treat protein aggregation-associated disorders | UNIVERSITY OF ALABAMA | 2005-10-13 | — | — | US | disclosed |
| WO-2005090388-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215480-A1 | Alpha conotoxin peptides with analgesic properties | LIVETT BRUCE G | 2005-09-29 | — | — | US | disclosed |
| EP-1404364-A4 | SPHINGOSINE KINASE INTERACTS WITH TRAF2 AND MODULATES TUMOR NECROSIS FACTOR-INDUCED CELLULAR ACTIVITY | MEDVET SCIENCE PTY LTD (AU) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578787-A1 | NOVEL CHI-CONOTOXIN PEPTIDES (-II) | Xenome Ltd (AU) | 2005-09-28 | — | — | EP | disclosed |
| EP-1579213-A1 | METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN BETA C | Monash University (AU) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578794-A1 | A NOVEL PHOSPHOPROTEIN | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-09-28 | — | — | EP | disclosed |
| US-20050208521-A1 | Therapeutic and diagnostic agents | HILTON DOUGLAS J | 2005-09-22 | — | — | US | disclosed |
| US-20050208610-A1 | Method of producing an anticoagulation effect | CRYPTOME PHARMACEUTICALS LTD (AU) | 2005-09-22 | — | — | US | disclosed |
| EP-1576156-A1 | DEC-205 (LY 75) / DCL-1 INTERGENIC SPLICE VARIANTS ASSOCIATED WITH HODKIN'S DISEASE, AND USES THEREOF | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2005-09-21 | — | — | EP | disclosed |
| EP-1572951-A2 | NUCLEOTIDE SEQUENCES THAT CODE FOR TORSIN GENES, TORSIN PROTEINS, AND METHODS OF USING THE SAME TO TREAT PROTEIN-AGGREGATION | The Board of Trustees of the University of Alabama (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572741-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572065-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572725-A1 | NOVEL CHI-CONOTOXIN PEPTIDES (-I) | Xenome Ltd (AU) | 2005-09-14 | — | — | EP | disclosed |
| EP-1569956-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2005-09-07 | — | — | EP | disclosed |
| EP-1402032-A4 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | INST MEDICAL W & E HALL (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005078098-A1 | MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-08-25 | — | — | WO | disclosed |
| US-20050186600-A1 | Polynucleotides encoding novel UbcH10 polypeptides and kits and methods using same | COMPUGEN LTD. (IL) | 2005-08-25 | — | — | US | disclosed |
| US-20050181981-A1 | Method of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-08-18 | — | — | US | disclosed |
| WO-2005074966-A1 | A METHOD OF MODULATING CELLULAR UPTAKE AND MOLECULES USEFUL FOR SAME | ADELAIDE RESEARCH & INNOVATION PTY. LTD. (AU) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075645-A1 | THERAPEUTIC MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074923-A1 | METHODS AND COMPOSITIONS | AGT BIOSCIENCES LIMITED (AU) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005070409-A1 | A METHOD OF MODULATING PRO-INFLAMMATORY AND INFLAMMATORY ACTIVITY MEDIATED BY C-REACTIVE PROTEIN | MEDVET SCIENCE PTY LTD (AU) | 2005-08-04 | — | — | WO | disclosed |
| EP-1558736-A1 | A METHOD OF MODULATING EPITHELIAL CELL ACTIVITY BY MODULATING THE FUNCTIONAL LEVELS OF SPHINGOSINE KINASE | MEDVET SCIENCE PTY. LTD. (AU) | 2005-08-03 | — | — | EP | disclosed |
| US-20050163790-A1 | Method of treatment and agents useful for same | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2005-07-28 | — | — | US | disclosed |
| US-20050158309-A1 | Methods and pharmaceutical compositions for gnrh-II and gnrh-II modulation of t-cell activity, adhesion, migration and extravasation | KOCH, YITZHAK, PROF (IL) | 2005-07-21 | — | — | US | disclosed |
| WO-2005066337-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159468-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | disclosed |
| US-20050153286-A1 | Polynucleotides and polypeptides linked to cancer and/or tumorigenesis | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2005-07-14 | — | — | US | disclosed |
| US-20050148525-A1 | Obesity related genes expressed at least in the hypothalamus, liver or pancreas | AUTOGEN RESEARCH PTY LTD (AU) | 2005-07-07 | — | — | US | disclosed |
| WO-2005060992-A1 | THERAPEUTIC AGENTS AND USES THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-07-07 | — | — | WO | disclosed |
| EP-1315752-A4 | MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF | UNIV AUSTRALIAN (AU) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549335-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY AND MOLECULES FOR USE THEREIN | MONASH UNIVERSITY (AU) | 2005-07-06 | — | — | EP | disclosed |
| EP-1545589-A1 | A METHOD OF MODULATING ENDOTHELIAL CELL ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2005-06-29 | — | — | EP | disclosed |
| US-6911530-B1 | Haemopoietin receptor and genetic sequences encoding same | AMRAD OPERATIONS, PTY., LTD. (AU) | 2005-06-28 | — | — | US | disclosed |
| EP-1542528-A1 | A METHOD OF TREATMENT AND PROPHYLAXIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-06-22 | — | — | EP | disclosed |
| US-6905842-B1 | Therapeutic and diagnostic agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-06-14 | — | — | US | disclosed |
| US-20050123538-A1 | Polynucleotides encoding novel ErbB-2 polypeptides and kits and methods using same | COMPUGEN LTD. (IL) | 2005-06-09 | — | — | US | disclosed |
| US-20050118681-A1 | Novel regulatory molecule and genetic sequences encoding same | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-06-02 | — | — | US | disclosed |
| EP-1534333-A1 | A METHOD OF IMMUNOMODULATION | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2005-06-01 | — | — | EP | disclosed |
| EP-1366164-A4 | NUCLEIC ACID EXPRESSED IN THE HYPOTHALAMUS OR MUSCLE TISSUE IN OBESE ANIMALS | AUTOGEN RES PTY LTD (AU) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534833-A1 | MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS | Melbourne Health (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| EP-1436624-A4 | A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME | INST MEDICAL W & E HALL (AU) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005026358-A9 | POLYMORPHISMS IN SELENOPROTEIN S | AGT BIOSCIENCES LTD (AU) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005045439-A1 | BINDING ASSAY COMPONENTS | HEPGENICS PTY LTD (AU) | 2005-05-19 | — | — | WO | disclosed |
| EP-1530632-A2 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2005-05-18 | — | — | EP | disclosed |
| EP-1530589-A2 | FRAGMENTS OF PROINSULIN C-PEPTIDE | Creative Peptides Sweden AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1530632-A4 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RES & DEV (IL) | 2005-05-18 | — | — | EP | disclosed |
| EP-1530484-A1 | A METHOD OF IMMUNOMODULATION | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2005-05-18 | — | — | EP | disclosed |
| US-20050100547-A1 | Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity | PU XIA ETAL | 2005-05-12 | — | — | US | disclosed |
| EP-1169452-A4 | VIRAL VARIANTS | MELBOURNE HEALTH (AU) | 2005-05-11 | — | — | EP | disclosed |
| US-6887481-B1 | Bacterial-derived molecules and therapeutic and diagnostic uses therefor | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2005-05-03 | — | — | US | disclosed |
| WO-2005038028-A1 | POXVIRUS VECTOR ENCODING RETROVIRUS (EG HIV) AND CYTOKINE | VIRAX DEVELOPMENT PTY LTD (AU) | 2005-04-28 | — | — | WO | disclosed |
| US-20050090442-A1 | Method of modulating cell survival and reagents useful for same | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-04-28 | — | — | US | disclosed |
| US-6884617-B1 | Isolated nucleic acid encoding murine musculin | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-04-26 | — | — | US | disclosed |
| WO-2005032578-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2005-04-14 | — | — | WO | disclosed |
| US-20050074830-A1 | Screening method for an agent having an affect on a sphingosine kinase signaling pathway | JOHNSON & JOHNSON RESEARCH PTY. | 2005-04-07 | — | — | US | disclosed |
| US-20050075481-A1 | T cell epitopes of the cyn d 1 allergen from bermuda grass pollen | MONASH UNIVERSITY (AU) | 2005-04-07 | — | — | US | disclosed |
| US-20050064593-A1 | Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, THE (AU) | 2005-03-24 | — | — | US | disclosed |
| WO-2005025601-A1 | FOLLISTATIN ISOFORMS AND USES THEREOF | MONASH UNIVERSITY (AU) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026358-A1 | POLYMORPHISMS IN SELENOPROTEIN S | AGT BIOSCIENCES LIMITED (AU) | 2005-03-24 | — | — | WO | disclosed |
| US-20050064542-A1 | Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals | AUTOGEN RESEARCH PTY LTD. (AU) | 2005-03-24 | — | — | US | disclosed |
| US-6870031-B2 | Haemopoietin receptor and genetic sequences encoding same | AMRAD OPERATIONS PTY. LTD. (AU) | 2005-03-22 | — | — | US | disclosed |
| US-20050059108-A1 | Novel gene and uses therefor | ZIMMET PAUL ZEV (AU) | 2005-03-17 | — | — | US | disclosed |
| US-20050058660-A1 | Novel surface antigen | THE UNIVERSITY OF QUEENSLAND | 2005-03-17 | — | — | US | disclosed |
| CN-1596264-A | Differentially expressed genes related to obesity and type 2 diabetes | AUTOGEN RES PTY LTD (AU) | 2005-03-16 | — | — | CN | disclosed |
| US-6867283-B2 | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-03-15 | — | — | US | disclosed |
| WO-2005020677-A1 | METHOD OF SELECTING ANIMAL MODELS FROM ANIMALS WHICH HAVE BEEN SUBJECT TO MUTAGENESIS, AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054827-A1 | Conotoxin amino acid sequences for use as tool in controlling pain; immunotherapy; mimetics | XENOME LIMITED (AU) | 2005-03-10 | — | — | US | disclosed |
| US-20050053918-A1 | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | 2005-03-10 | — | — | US | disclosed |
| US-20050053967-A1 | Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma | MEDIMOLECULAR PTY LTD. (AU) | 2005-03-10 | — | — | US | disclosed |
| EP-1115277-A4 | NOVEL METHOD OF REGULATING SEED DEVELOPMENT IN PLANTS AND GENETIC SEQUENCES THEREFOR | COMMW SCIENT IND RES ORG (AU) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511474-A1 | A METHOD OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20050048528-A1 | Method of diagnosis and treatment and agents useful for same | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, THE (AU) | 2005-03-03 | — | — | US | disclosed |
| EP-1121434-A4 | A METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME | INST MEDICAL W & E HALL (AU) | 2005-03-02 | — | — | EP | disclosed |
| US-20050042213-A1 | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof | INSIGHT BIOPHARMACEUTICALS LTD. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014634-A1 | A GENE AND USES THEREFOR | AGT BIOSCIENCES LIMITED (AU) | 2005-02-17 | — | — | WO | disclosed |
| US-20050032708-A1 | Modulation of physiological processes and agents useful for same | MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA, THE (AU) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011724-A1 | A METHOD OF PRODUCING AN ANTICOAGULATION EFFECT | CRYPTOME PHARMACEUTICALS LTD (AU) | 2005-02-10 | — | — | WO | disclosed |
| EP-1451216-A4 | IMMUNOINTERACTIVE MOLECULES AND USES THEREOF | COOPERATIVE RES CT FOR ASTHMA (AU) | 2005-02-09 | — | — | EP | disclosed |
| US-20050026149-A1 | Nucleic acid constructs capable of high effeciency delivery of polynucleotides into dna containing organelles and methods of utilizing same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-02-03 | — | — | US | disclosed |
| US-6849601-B1 | Peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-02-01 | — | — | US | disclosed |
| US-20050019826-A1 | Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof | UNIVERSITE PARIS 13 NORD (FR) | 2005-01-27 | — | — | US | disclosed |
| US-20050020809-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-27 | — | — | US | disclosed |
| EP-1499343-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2005-01-26 | — | — | EP | disclosed |
| EP-1499337-A1 | IMMUNOTHERAPEUTIC AND IMMUNOPROPHYLACTIC REAGENTS | MONASH UNIVERSITY (AU) | 2005-01-26 | — | — | EP | disclosed |
| WO-2005003328-A1 | A METHOD AND AGENTS FOR IMPROVING PLANT PRODUCTIVITY INVOLVING ENDOPHYTIC ACTINOMYCETES AND METABOLITES THEREOF | FLINDERS TECHNOLOGIES PTY. LTD. (AU) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009732-A1 | Method of treatment and agents useful for same | MEDVET SCIENCE PTY LTD. (AU) | 2005-01-13 | — | — | US | disclosed |
| US-20050008643-A1 | Diagnostic methods and agents | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, THE (AU) | 2005-01-13 | — | — | US | disclosed |
| WO-2005003351-A1 | DIFFERENTIAL EXPRESSION OF NUCLEIC ACID MOLECULES | CHEMGENEX PHARMACEUTICALS LIMITED (AU) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004015-A1 | NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | HILTON DOUGLAS JAMES (AU) | 2005-01-06 | — | — | US | disclosed |
| WO-2004111079-A1 | VIRAL POLYMERASE AND MODULATION THEREOF | MELBOURNE HEALTH (AU) | 2004-12-23 | — | — | WO | disclosed |
| EP-1071707-A4 | NOVEL OMEGA CONOTOXIN PEPTIDES | UNIV QUEENSLAND (AU) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004108955-A1 | METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCITE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF A SUPPRESSOR OF CYTOKINE SIGNALING (SOCS) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-12-16 | — | — | WO | disclosed |
| EP-1436320-A4 | T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN | UNIV MONASH (AU) | 2004-12-15 | — | — | EP | disclosed |
| EP-1299548-A4 | NOVEL THERAPEUTIC MOLECULAR VARIANTS AND USES THEREOF | MEDVET SCIENCE PTY LTD (AU) | 2004-12-01 | — | — | EP | disclosed |
| EP-1015578-A4 | THERAPEUTIC MOLECULES | WALKER AND ELIZA HALL INST OF (AU) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004100978-A1 | A METHOD OF MODULATING CELLULAR TRANSMIGRATION AND AGENTS FOR USE THEREIN | MEDVET SCIENCE PTY. LTD. (AU) | 2004-11-25 | — | — | WO | disclosed |
| EP-1030915-A4 | A NOVEL GENE AND USES THEREFOR | INT DIABETES INST (AU) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004099238-A1 | NOVEL mu-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099412-A1 | NUCLEIC ACID MOLECULES DIFFERENTIALLY EXPRESSED IN ANIMALS EXHIBITING BEHAVIOURAL DISORDERS | AGT BIOSCIENCES LIMITED (AU) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004094630-A1 | INSECT CHYMOTRYPSIN AND INHIBITORS THEREOF | HEXIMA LTD (AU) | 2004-11-04 | — | — | WO | disclosed |
| EP-1033999-A4 | COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR | AMRAD OPERATIONS PTY LTD (AU) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004092387-A1 | VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN AND PROTEIN OF INTEREST | HEPGENICS PTY LTD (AU) | 2004-10-28 | — | — | WO | disclosed |
| EP-1121128-A4 | A METHOD OF MODULATING ION CHANNEL FUNCTIONAL ACTIVITY | UNIV AUSTRALIAN (AU) | 2004-10-27 | — | — | EP | disclosed |
| EP-0886528-B1 | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE | UNIV AUSTRALIAN (AU) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004086048-A1 | DIAGNOSIS OF ADVANCED CANCER | PROSTATE DIAGNOSTICS PTY. LTD. (AU) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084890-A1 | THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS AND USES THEREFOR | CRC FOR ASTHMA LIMITED (AU) | 2004-10-07 | — | — | WO | disclosed |
| EP-1242111-A4 | AN ANIMAL MODEL FOR STUDYING HORMONE SIGNALLING AND METHOD OF MODULATING THE SIGNALLING | INST MEDICAL W & E HALL (AU) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004083455-A1 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS | THE MURDOCH CHILDRENS RESEARCH INSTITUTE (AU) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083453-A1 | A METHOD OF MODULATING SMOOTH MUSCLE CELL FUNCTIONING BY MODULATING SPHINGOSINE KINASE MEDIATED SIGNALLING | MEDVET SCIENCE PTY. LTD. (AU) | 2004-09-30 | — | — | WO | disclosed |
| EP-1385874-A4 | ALPHA CONOTOXIN PEPTIDES WITH ANALGESIC PROPERTIES | LIVETT BRUCE (AU) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004080478-A1 | THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS AND USES THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-09-23 | — | — | WO | disclosed |
| EP-1458406-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland (AU) | 2004-09-22 | — | — | EP | disclosed |
| CN-1531554-A | Humanized antibodies derived from DD-3B 6/22 specific for the D-dimer fragment of fibrin | ��������ҽѧ����˾ | 2004-09-22 | — | — | CN | disclosed |
| US-6794361-B1 | CONOTOXIN POLYPEPTIDE INHIBITS NEURONAL AMINE TRANSPORTERS; INCONTINENCE, CARDIOVASCULAR DISORDERS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-09-21 | — | — | US | disclosed |
| US-20040181046-A1 | Polypeptide and DNA immunization against Coccidioides spp. infections | MEDICAL COLLEGE OF OHIO (US) | 2004-09-16 | — | — | US | disclosed |
| EP-1011654-A4 | A METHOD OF MODULATING CELLULAR ACTIVITY | JOHNSON & JOHNSON PHARM RES (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6790450-B1 | PROPHYLAXIS OR TREATMENT OF INSULIN- DEPENDENT DIABETES MELLITUS; PROLONGING SURVIVAL OF ISLET TISSUE TRANSPLANTED INTO A MAMMAL | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-09-14 | — | — | US | disclosed |
| US-6790637-B1 | FOR DIAGNOSIS, THERAPY, AND DRUG SCREENING OF MAMMALIAN CELLS | CERYLID PTY., LTD. (AU) | 2004-09-14 | — | — | US | disclosed |
| WO-2004075884-A1 | THERAPEUTIC COMPOSITIONS | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076621-A2 | COMPOSITIONS OF NUCLEIC ACIDS FOR TREATING AND DETECTING INFLUENZA VIRUS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004073739-A1 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY. LTD. (AU) | 2004-09-02 | — | — | WO | disclosed |
| EP-1133309-A4 | A METHOD OF TREATMENT | INST MEDICAL W & E HALL (AU) | 2004-09-01 | — | — | EP | disclosed |
| EP-1451216-A1 | IMMUNOINTERACTIVE MOLECULES AND USES THEREOF | Cooperative Research Centre for Asthma (AU) | 2004-09-01 | — | — | EP | disclosed |
| EP-1446414-A1 | DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES | Autogen Research Pty. Ltd. (AU) | 2004-08-18 | — | — | EP | disclosed |
| EP-1224223-A4 | IMMUNOINTERACTIVE MOLECULES AND THEIR USES IN TREATING SUBJECTS SUFFERING FROM HEV B 5 ALLERGIES | UNIV MONASH (AU) | 2004-08-11 | — | — | EP | disclosed |
| CN-1520310-A | Use of angiotensin I derivatives as agents for the treatment and prevention of infarction-related cardiac injuries and disorders | 新加坡国立大学 | 2004-08-11 | — | — | CN | disclosed |
| WO-2004063218-A1 | OBESITY-RELATED GENES | AUTOGEN RESEARCH PTY LTD (AU) | 2004-07-29 | — | — | WO | disclosed |
| EP-1438427-A1 | NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM AND/OR ADENOMA | Medimolecular Pty. Ltd. (AU) | 2004-07-21 | — | — | EP | disclosed |
| EP-1438407-A1 | OBESITY RELATED GENES EXPRESSED AT LEAST IN THE HYPOTALAMUS, LIVER OR PANCREAS | Autogen Research Pty. Ltd. (AU) | 2004-07-21 | — | — | EP | disclosed |
| EP-1438063-A1 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME | The Mental Health Research Institute of Victoria (AU) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
| EP-1436624-A1 | A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436320-A1 | T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN | MONASH UNIVERSITY (AU) | 2004-07-14 | — | — | EP | disclosed |
| EP-1434878-A2 | NUCLEIC ACID CONSTRUCTS CAPABLE OF HIGH EFFICIENCY DELIVERY OF POLYNUCLEOTIDES INTO DNA CONTAINING ORGANELLES AND METHODS OF UTILIZING SAME | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004055047-A1 | A NOVEL PHOSPHOPROTEIN | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004053487-A1 | METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN βC | MONASH UNIVERSITY (AU) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004053138-A1 | DEC-205 (LY 75) / DCL-1 INTERGENIC SPLICE VARIANTS ASSOCIATED WITH HODKIN’S DISEASE, AND USES THEREOF | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004053139-A1 | A METHOD OF ANTIBODY PRODUCTION | APOLLO LIFE SCIENCES LIMITED (AU) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052404-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004050688-A1 | NOVEL χ-CONOTOXIN PEPTIDES (-II) | XENOME LTD (AU) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050690-A1 | NOVEL χ-CONOTOXIN PEPTIDES (-I) | XENOME LTD (AU) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050704-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2004-06-17 | — | — | WO | disclosed |
| EP-1428893-A2 | Methods of and compositions for modulating hair growth via p-cadherin modulators | Sprecher, Eli (IL) | 2004-06-16 | — | — | EP | disclosed |
| EP-1113808-A4 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | UNIV MELBOURNE (AU) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004043483-A1 | A METHOD FOR TREATING SPINAL CORD INJURY | MONASH UNIVERSITY (AU) | 2004-05-27 | — | — | WO | disclosed |
| EP-1259255-A4 | PAI-2 CONJUGATES FOR THE TREATMENT AND IMAGING OF CANCER | UNIV WOLLONGONG (AU) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004037857-A1 | BFK PROTEIN AS THERAPEUTIC MOLECULES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-05-06 | — | — | WO | disclosed |
| CN-1494592-A | Nucleic acid expressed in hypothalamus or muscle tissue in obese animals | ���и��о��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
| US-6730480-B1 | OFGIVEN SEQUENCE; FOR MODULATING CELLULAR ACTIVITY VIA THE MODULATION OF SIGNAL TRANSDUCTION; USEFUL IN TREATMENT AND DIAGNOSIS OF ASTHMA, ARTHRITIS, MENENGITIS, MULTIPLE SCLEROSIS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC | 2004-05-04 | — | — | US | disclosed |
| WO-2004035786-A1 | A METHOD OF MODULATING EPITHELIAL CELL ACTIVITY BY MODULATING THE FUNCTIONAL LEVELS OF SPHINGOSINE KINASE | MEDVET SCIENCE PTY. LTD. (AU) | 2004-04-29 | — | — | WO | disclosed |
| EP-1412388-A1 | HUMANIZED ANTIBODIES DERIVED FROM DD-3B6/22, SPECIFIC FOR THE D-DIMER FRAGMENT OF FIBRIN | AGEN BIOMEDICAL LIMITED (AU) | 2004-04-28 | — | — | EP | disclosed |
| EP-1412754-A1 | DIAGNOSTIC METHODS AND AGENTS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-04-28 | — | — | EP | disclosed |
| EP-1408995-A1 | MODULATING SERUM AMYLOID A INTERACTION WITH TANIS AND AGENTS USEFUL FOR SAME | Autogen Research Pty. Ltd. (AU) | 2004-04-21 | — | — | EP | disclosed |
| EP-1406648-A1 | THE USE OF ANGIOTENSIN I DERIVATIVE AS AN AGENT FOR THE TREATMENT AND PREVENTION OF INFARCTION-RELATED CARDIAC INJURIES AND DISORDERS | National University of Singapore (SG) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004028553-A1 | A METHOD OF MODULATING CELLULAR DEVELOPMENT | MONASH UNIVERSITY (AU) | 2004-04-08 | — | — | WO | disclosed |
| EP-1404364-A1 | SPHINGOSINE KINASE INTERACTS WITH TRAF2 AND MODULATES TUMOR NECROSIS FACTOR-INDUCED CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2004-04-07 | — | — | EP | disclosed |
| EP-1402021-A1 | A GENE AND USES THEREFOR | Autogen Research Pty. Ltd. (AU) | 2004-03-31 | — | — | EP | disclosed |
| EP-1402032-A1 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004022582-A1 | PEPTIDOMIMETIC DRUGS | MONASH UNIVERSITY (AU) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022084-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY AND MOLECULES FOR USE THEREIN | MONASH UNIVERSITY (AU) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022090-A1 | A METHOD OF MODULATING ENDOTHELIAL CELL ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004017727-A1 | A METHOD OF TREATMENT AND PROPHYLAXIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004016647-A2 | FRAGMENTS OF PROINSULIN C-PEPTIDE | CREATIVE PEPTIDES SWEDEN AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016284-A1 | A METHOD OF IMMUNOMODULATION | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2004-02-26 | — | — | WO | disclosed |
| EP-1390408-A1 | A MOLECULAR MARKER | Murdoch Childrens Research Institute (AU) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004014422-A1 | A METHOD OF IMMUNOMODULATION | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2002088184-A9 | A MOLECULAR MARKER | MURDOCH CHILDRENS RES INST (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004015108-A1 | MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS | MELBOURNE HEALTH (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004015417-A1 | A METHOD AND AGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-02-19 | — | — | WO | disclosed |
| EP-1385874-A1 | ALPHA CONOTOXIN PEPTIDES WITH ANALGESIC PROPERTIES | Livett, Bruce (AU) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004007417-A1 | ENZYME INHIBITORS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-01-22 | — | — | WO | disclosed |
| US-20040001843-A1 | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-01 | — | — | US | disclosed |
| WO-2004000996-A2 | NUCLEOTIDE SEQUENCES THAT CODE FOR TORSIN GENES, TORSIN PROTEINS, AND METHODS OF USING THE SAME TO TREAT PROTEIN-AGGREGATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2003-12-31 | — | — | WO | disclosed |
| US-6669934-B1 | Administering interleukins, cytokines, leukemia inhibitory factors, ciliary neurotrophic growth factors, oncostatins and derivatives to mammals to control pregnancy | AMRAD OPERATIONS, PTY. LTD. (AU) | 2003-12-30 | — | — | US | disclosed |
| US-20030235823-A1 | Comprises nucleotide sequences coding dystonia protein (TORSIN) for diagnosing and treating nervous system disorders associated with polypeptide aggregation | THE UNIVERSITY OF ALABAMA | 2003-12-25 | — | — | US | disclosed |
| US-20030224013-A1 | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
| EP-1366164-A1 | NUCLEIC ACID EXPRESSED IN THE HYPOTHALAMUS OR MUSCLE TISSUE IN OBESE ANIMALS | Autogen Research Pty. Ltd. (AU) | 2003-12-03 | — | — | EP | disclosed |
| US-20030219455-A1 | Glucanosyl transferase-1 protein useful for immunization against Coccidioides spp. | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-11-27 | — | — | US | disclosed |
| WO-2003094903-A1 | A METHOD OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-11-20 | — | — | WO | disclosed |
| US-6649362-B2 | Administering an agent to modulate sphingosine kinase signalling pathway to treat coronary heart disease | MEDVET SCIENCE PTY. LTD. (AU) | 2003-11-18 | — | — | US | disclosed |
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003086273-A2 | HISTONE CONJUGATES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-10-23 | — | — | WO | disclosed |
| EP-1351992-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | Ramot at Tel Aviv University Ltd. (IL) | 2003-10-15 | — | — | EP | disclosed |
| WO-2003082924-A1 | IMMUNOTHERAPEUTIC AND IMMUNOPROPHYLACTIC REAGENTS | MONASH UNIVERSITY (AU) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082322-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2003-10-09 | — | — | WO | disclosed |
| US-20030171289-A1 | Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2003-09-11 | — | — | US | disclosed |
| US-6613745-B1 | Peptides and/or mimetics administered as analgesics | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2003-09-02 | — | — | US | disclosed |
| WO-2003068788-A1 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES | MEDIMOLECULAR PTY. LTD. (AU) | 2003-08-21 | — | — | WO | disclosed |
| US-6607729-B2 | For diagnosis, therapy and prophylaxis of Neisseria meningitidis infection; vaccine | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-08-19 | — | — | US | disclosed |
| WO-2003066869-A1 | LMT TUMOR SUPPRESSOR GENE | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-08-14 | — | — | WO | disclosed |
| US-6590080-B1 | Growth factor precursor comprising a recombinant polypeptide chain, B and T cell surface molecule binding portions, cleavable antigen, peptide comprising heavy/light chain domains; useful as a nucleic acid vaccine | Koentgen, Frank (AU) | 2003-07-08 | — | — | US | disclosed |
| US-6589938-B2 | Cardiovascular disorders | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2003-07-08 | — | — | US | disclosed |
| CN-1427725-A | Casein derived peptides and therapeutic uses thereof | CHAY 13 MEDICAL RES GROUP N V (NL) | 2003-07-02 | — | — | CN | disclosed |
| EP-1315752-A1 | MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-06-04 | — | — | EP | disclosed |
| EP-1192247-A4 | SPHINGOSINE KINASE ENZYME | JOHNSON & JOHNSON RES PTY LTD (AU) | 2003-05-28 | — | — | EP | disclosed |
| EP-1227835-A4 | PROTEASE INHIBITORS AS MODULATORS OF PERIODONTAL WOUND HEALING | BIOTECH AUSTRALIA PTY LTD (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003037921-A1 | IMMUNOINTERACTIVE MOLECULES AND USES THEREOF | COOPERATIVE RESEARCH CENTRE FOR ASTHMA (AU) | 2003-05-08 | — | — | WO | disclosed |
| US-6559126-B2 | Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2003-05-06 | — | — | US | disclosed |
| WO-2003035101-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003033513-A1 | DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES | AUTOGEN RESEARCH PTY LTD (AU) | 2003-04-24 | — | — | WO | disclosed |
| EP-1117681-B1 | Rho-cocotoxin peptides having selective alpha-1 adrenoceptor activity | UNIV QUEENSLAND (AU) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003031468-A1 | THERAPEUTIC AND DIAGNOSTIC MOLECULES THAT ARE CAPABLE OF INTERACTING WITH SOCS PROTEINS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-04-17 | — | — | WO | disclosed |
| EP-1299548-A1 | NOVEL THERAPEUTIC MOLECULAR VARIANTS AND USES THEREOF | MEDVET SCIENCE PTY. LTD. (AU) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003026684-A1 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003025214-A1 | NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM AND/OR ADENOMA | MEDIMOLECULAR PTY. LTD. (AU) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003025195-A2 | NUCLEIC ACID CONSTRUCTS FOR THE DELIVERY OF POLYNUCLEOTIDES INTO DNA-CONTAINING ORGANELLES,AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024998-A1 | T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN | MONASH UNIVERSITY (AU) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003023404-A1 | A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-03-20 | — | — | WO | disclosed |
| EP-1290182-A1 | SPHINGOSINE KINASE AND USES THEREOF | Medvet Science Pty. Ltd. (AU) | 2003-03-12 | — | — | EP | disclosed |
| WO-2003018823-A1 | OBESITY RELATED GENES EXPRESSED AT LEAST IN THE HYPOTALAMUS, LIVER OR PANCREAS | AUTOGEN RESEARCH PTY LTD (AU) | 2003-03-06 | — | — | WO | disclosed |
| EP-1135141-A4 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | ANALYTICA LTD (AU) | 2003-03-05 | — | — | EP | disclosed |
| WO-2003016542-A1 | OBESITY RELATED GENES EXPRESSED AT LEAST IN THE HYPOTHALAMUS | AUTOGEN RESEARCH PTY LTD (AU) | 2003-02-27 | — | — | WO | disclosed |
| US-6521741-B1 | Inducing B cell mitogenesis; medical diagnosis | FRANK KOENTGEN PTY LTD. (AU) | 2003-02-18 | — | — | US | disclosed |
| WO-2003008580-A1 | GALECTIN-14 THERAPEUTIC MOLECULE AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003002158-A1 | THE USE OF ANGIOTENSIN I DERIVATIVE AS AN AGENT FOR THE TREATMENT AND PREVENTION OF INFARCTION-RELATED CARDIAC INJURIES AND DISORDERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003003016-A1 | DIAGNOSTIC METHODS AND AGENTS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-01-09 | — | — | WO | disclosed |
| EP-1179074-A4 | NOVEL GENES ENCODING WHEAT STARCH SYNTHASES AND USES THEREFOR | COMMW SCIENT IND RES ORG (AU) | 2003-01-08 | — | — | EP | disclosed |
| WO-2003000273-A1 | MODULATING SERUM AMYLOID A INTERACTION WITH TANIS AND AGENTS USEFUL FOR SAME | AUTOGEN RESEARCH PTY. LTD. (AU) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000722-A1 | MULTI-COPPER OXIDASE PROTEIN ENZYMES FOR IRON(II) ACQUISITION IN PROKARYOTIC CELLS | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000736-A1 | HUMANIZED ANTIBODIES DERIVED FROM DD-3B6/22, SPECIFIC FOR THE D-DIMER FRAGMENT OF FIBRIN | AGEN BIOMEDICAL LIMITED (AU) | 2003-01-03 | — | — | WO | disclosed |
| EP-1268544-A2 | PEPTIDES BLOCKING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-MEDIATED ANGIOGENESIS, POLYNUCLEOTIDES ENCODING SAID PEPTIDES AND METHODS OF USE THEREOF | INSTITUT PASTEUR (FR) | 2003-01-02 | — | — | EP | disclosed |
| EP-1127152-A4 | A METHOD OF RECOMBINATION AND AGENTS USEFUL FOR SAME | MURDOCH INST (AU) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002100416-A1 | SOCS-5 MOLECULES, SCREENING THEREFORE AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2002-12-19 | — | — | WO | disclosed |
| US-6495740-B1 | NUCLEIC ACID ENCODING CELLULOSE SYNTHASE; TRANSGENIC PLANTS | THE AUSTRAILIAN NATIONAL UNIVERSITY (AU) | 2002-12-17 | — | — | US | disclosed |
| US-6495345-B1 | POLYPEPTIDE FROM NEISSERIA MENINGITIDIS; NUCLEOTIDE SEQUENCES ENCODING SUCH POLYPEPTIDES; DIAGNOSTICS, THERAPY, PROPHYLACTIC VACCINES AND IN DESIGN AND/OR SCREENING OF MEDICAMENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-12-17 | — | — | US | disclosed |
| WO-2002098458-A1 | SPHINGOSINE KINASE INTERACTS WITH TRAF2 AND MODULATES TUMOR NECROSIS FACTOR-INDUCED CELLULAR ACTIVITY | MEDVET SCIENCE PTY LTD (AU) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098346-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002097094-A1 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002095020-A1 | A GENE AND USES THEREFOR | AUTOGEN RESEARCH PTY LTD (AU) | 2002-11-28 | — | — | WO | disclosed |
| EP-1259255-A1 | PAI-2 CONJUGATES FOR THE TREATMENT AND IMAGING OF CANCER | UNIVERSITY OF WOLLONGONG (AU) | 2002-11-27 | — | — | EP | disclosed |
| US-6485970-B1 | Immunointeractive antibody | CONE ROBERT E (US) | 2002-11-26 | — | — | US | disclosed |
| US-6479274-B1 | DNA molecules encoding human HELA2 or testisin serine proteinases | AMRAD OPERATIONS PTY., LTD. (AU) | 2002-11-12 | — | — | US | disclosed |
| WO-2002088184-A1 | A MOLECULAR MARKER | MURDOCH CHILDRENS RESEARCH INSTITUTE (AU) | 2002-11-07 | — | — | WO | disclosed |
| EP-1032656-A4 | ISOLATED NUCLEIC ACID MOLECULE ENCODING MAMMALIAN ENDOGLUCURONIDASE AND USES THEREFOR | UNIV AUSTRALIAN (AU) | 2002-10-29 | — | — | EP | disclosed |
| WO-2002079236-A1 | ALPHA CONOTOXIN PEPTIDES WITH ANALGESIC PROPERTIES | LIVETT BRUCE (AU) | 2002-10-10 | — | — | WO | disclosed |
| EP-0956039-A4 | A METHOD OF TREATMENT AND PROPHYLAXIS | INST MEDICAL W & E HALL (AU) | 2002-10-02 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| EP-0975765-A4 | PLANT FATTY ACID EPOXYGENASE GENES AND USES THEREFOR | COMMW SCIENT IND RES ORG (AU) | 2002-09-25 | — | — | EP | disclosed |
| EP-1242111-A1 | AN ANIMAL MODEL FOR STUDYING HORMONE SIGNALLING AND METHOD OF MODULATING THE SIGNALLING | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2002-09-25 | — | — | EP | disclosed |
| EP-1196438-A4 | A LIGAND OF THE PROTEIN \"BEACON\ | AUTOGEN RES PTY LTD (AU) | 2002-09-04 | — | — | EP | disclosed |
| US-6436670-B1 | ISOLATED NUCLEIC ACID MOLECULE COMPRISING NUCLEOTIDE SEQUENCE ENCODING OR COMPLEMENTARY TO SEQUENCE ENCODING PROTEIN WHEREIN SAID NUCLEIC ACID IS EXPRESSED IN LARGER AMOUNTS IN HYPOTHALAMUS TISSUE OF OBESE ANIMALS COMPARED TO LEAN ANIMALS | INTERNATIONAL DIABETES INSTITUTE (AU) | 2002-08-20 | — | — | US | disclosed |
| WO-2002062994-A1 | NUCLEIC ACID EXPRESSED IN THE HYPOTHALAMUS OR MUSCLE TISSUE IN OBESE ANIMALS | AUTOGEN RESEARCH PTY LTD (AU) | 2002-08-15 | — | — | WO | disclosed |
| EP-1230263-A1 | A NOVEL MOLECULE | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-08-14 | — | — | EP | disclosed |
| EP-0868430-A4 | THERAPEUTIC COMPOSITIONS | CERYLID PTY LTD (AU) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227835-A1 | PROTEASE INHIBITORS AS MODULATORS OF PERIODONTAL WOUND HEALING | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-08-07 | — | — | EP | disclosed |
| EP-1224223-A1 | IMMUNOINTERACTIVE MOLECULES AND THEIR USES IN TREATING SUBJECTS SUFFERING FROM HEV B 5 ALLERGIES | MONASH UNIVERSITY (AU) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002055543-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | UNIV RAMOT (IL) | 2002-07-18 | — | — | WO | disclosed |
| EP-1129106-A4 | CYCLISED CONOTOXIN PEPTIDES | UNIV QUEENSLAND (AU) | 2002-07-03 | — | — | EP | disclosed |
| US-6414128-B1 | LEPTIN LIGAND BINDING; MEDICAL DIAGNOSIS, THERAPY, AGONISTS, AND ANTAGONISTS; GENETIC ENGINEERING | AMRAD OPERATIONS PTY. LTD. (AU) | 2002-07-02 | — | — | US | disclosed |
| US-20020068697-A1 | Peptides blocking vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2002-06-06 | — | — | US | disclosed |
| EP-0956353-A4 | MANIPULATION OF CELLULOSE AND/OR BETA-1,4-GLUCAN | UNIV AUSTRALIAN (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002042326-A1 | A METHOD OF EXPRESSION AND AGENTS IDENTIFIED THEREBY | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002018438-A9 | MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF | UNIV AUSTRALIAN (AU) | 2002-05-30 | — | — | WO | disclosed |
| EP-1196562-A1 | NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE | Autogen Research Pty. Ltd. (AU) | 2002-04-17 | — | — | EP | disclosed |
| EP-1196438-A1 | A LIGAND OF THE PROTEIN \"BEACON\ | Autogen Research Pty. Ltd. (AU) | 2002-04-17 | — | — | EP | disclosed |
| EP-1192247-A1 | SPHINGOSINE KINASE ENZYME | Johnson & Johnson Research Pty Limited (AU) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002020598-A1 | MUCIN | MCGUCKIN MICHAEL ANDREW (AU) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002018438-A1 | MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-03-07 | — | — | WO | disclosed |
| EP-0842272-A4 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY LTD (AU) | 2002-03-06 | — | — | EP | disclosed |
| EP-1179074-A1 | NOVEL GENES ENCODING WHEAT STARCH SYNTHASES AND USES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-02-13 | — | — | EP | disclosed |
| WO-2002007769-A1 | A METHOD OF STABILISATION AND COMPOSITIONS FOR USE THEREIN | CSL LIMITED (AU) | 2002-01-31 | — | — | WO | disclosed |
| EP-0932674-A4 | A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES | CERYLID PTY LTD (AU) | 2002-01-30 | — | — | EP | disclosed |
| EP-1174523-A2 | Method for detecting an HBV-derived nucleic acid target sequence | Government of Republic of Singapore (SG) | 2002-01-23 | — | — | EP | disclosed |
| EP-1169452-A1 | VIRAL VARIANTS | Melbourne Health (AU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2002000887-A1 | NOVEL THERAPEUTIC MOLECULAR VARIANTS AND USES THEREOF | MEDVET SCIENCE PTY LTD (AU) | 2002-01-03 | — | — | WO | disclosed |
| EP-1117681-A4 | NOVEL PEPTIDES | UNIV QUEENSLAND (AU) | 2002-01-02 | — | — | EP | disclosed |
| EP-0935612-A4 | PRECURSORS OF CATALYTIC ANTIBODIES | AMRAD OPERATIONS PTY LTD (AU) | 2001-12-12 | — | — | EP | disclosed |
| EP-1117682-A4 | NOVEL PEPTIDES | UNIV QUEENSLAND (AU) | 2001-12-12 | — | — | EP | disclosed |
| EP-1015494-A4 | CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME | KOENTGEN FRANK (AU) | 2001-12-12 | — | — | EP | disclosed |
| US-6329518-B1 | NUCLEIC ACID FROM CREPIS PLANT CODING FOR ENZYME THAT CATALYZES EPOXYGENATION OF CARBON DOUBLE BOND AT DELTA-12 POSITION OF FATTY ACID; EFFICIENT PRODUCTION OF COATINGS, GLUES, PLASTICS, SURFACTANTS AND LUBRICANTS | BASF PLANT SCIENCE GMBH (DE) | 2001-12-11 | — | — | US | disclosed |
| EP-0879244-A4 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | UNIV MELBOURNE (AU) | 2001-12-05 | — | — | EP | disclosed |
| US-6326179-B1 | ENZYMATIC IMMUNOGLOBULIN; FOR USE AS THERAPEUTIC AND DIAGNOSTIC TOOLS IN TREATMENT OF ARTHRITIS, VIRAL DISEASE AND ALZHEIMER'S DISEASE | Koentgen, Frank (AU) | 2001-12-04 | — | — | US | disclosed |
| US-6323317-B1 | PREFERENTIAL POLYPEPTIDES FOR USE IN MODULATION OF SIGNAL TRANSDUCTION | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2001-11-27 | — | — | US | disclosed |
| WO-2001085953-A1 | SPHINGOSINE KINASE AND USES THEREOF | MEDVET SCIENCE PTY. LTD. (AU) | 2001-11-15 | — | — | WO | disclosed |
| EP-0907730-A4 | HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY LTD (AU) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001081540-A2 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001078759-A1 | THE USE OF DES-ASPARTATE-ANGIOTENSIN I AS AN AGENT FOR THE TREATMENT AND PREVENTION OF GLOMERULOSCLEROSIS AND RENAL FAILURE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001075099-A1 | NUCLEIC ACID MOLECULE ENCODING A UTERINE ESTROGEN AGONIST-INDUCIBLE PROTEIN | NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD (SG) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072829-A2 | PEPTIDES BLOCKING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-MEDIATED ANGIOGENESIS, POLYNUCLEOTIDES ENCODING SAID PEPTIDES AND METHODS OF USE THEREOF | INSTITUT PASTEUR (FR) | 2001-10-04 | — | — | WO | disclosed |
| EP-1135141-A1 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | Analytica Ltd. (AU) | 2001-09-26 | — | — | EP | disclosed |
| EP-1135476-A1 | BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR | Melbourne Health (AU) | 2001-09-26 | — | — | EP | disclosed |
| EP-0948522-A4 | THERAPEUTIC AND DIAGNOSTIC AGENTS CAPABLE OF MODULATING CELLULAR RESPONSIVENESS TO CYTOKINES | INST MEDICAL W & E HALL (AU) | 2001-09-19 | — | — | EP | disclosed |
| EP-1133309-A1 | A METHOD OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001066128-A1 | METHODS OF REGULATING CYTOKINE SIGNALLING | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2001-09-13 | — | — | WO | disclosed |
| EP-1129106-A1 | CYCLISED CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001062281-A1 | PAI-2 CONJUGATES FOR THE TREATMENT AND IMAGING OF CANCER | UNIVERSITY OF WOLLONGONG (AU) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062958-A1 | ASSESSMENT OF THE FUNCTIONAL SIGNIFICANCE OF A NUCLEOTIDE SEQUENCE BY SUBJECTING THE READING FRAME DATA TO DATA PROCESSING | NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD. (SG) | 2001-08-30 | — | — | WO | disclosed |
| EP-1127152-A1 | A METHOD OF RECOMBINATION AND AGENTS USEFUL FOR SAME | The Murdoch Institute (AU) | 2001-08-29 | — | — | EP | disclosed |
| EP-1121128-A1 | A METHOD OF MODULATING ION CHANNEL FUNCTIONAL ACTIVITY | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2001-08-08 | — | — | EP | disclosed |
| EP-1121434-A1 | A METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2001-08-08 | — | — | EP | disclosed |
| EP-1117681-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117682-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-07-25 | — | — | EP | disclosed |
| EP-1115277-A1 | NOVEL METHOD OF REGULATING SEED DEVELOPMENT IN PLANTS AND GENETIC SEQUENCES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-07-18 | — | — | EP | disclosed |
| EP-1113808-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE UNIVERSITY OF MELBOURNE (AU) | 2001-07-11 | — | — | EP | disclosed |
| US-6255096-B1 | AN ISOLATED NUCLEIC ACID ENCODING AN AMINO ACID; DIAGNOSIS AND THERAPY FOR PROGRESSIVE MENTAL RETARDATION IN CONJUCTION WITH SKELETAL DEFORMITIES | WOMEN'S AND CHILDREN'S HOSPITAL (AU) | 2001-07-03 | — | — | US | disclosed |
| US-6242238-B1 | NUCLEOTIDE SEQUENCE WHICH CODES FOR HEPARINASE; DRUG SCREENING FOR ANTIMETASTASIS/ANTINFLAMMATORY AGENTS, ANGIOGENESIS INHIBITORS, WOUND HEALING AGENTS; TREATMENT FOR ANGIOPLASTY-INDUCED RESTENOSIS AND ATHEROSCLEROSIS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2001-06-05 | — | — | US | disclosed |
| EP-0871472-A4 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | AMRAD OPERATIONS PTY LTD (AU) | 2001-05-30 | — | — | EP | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2001035732-A1 | AN ANIMAL MODEL FOR STUDYING HORMONE SIGNALLING AND METHOD OF MODULATING THE SIGNALLING | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000016609-A9 | NOVEL METHOD OF REGULATING SEED DEVELOPMENT IN PLANTS AND GENETIC SEQUENCES THEREFOR | COMMW SCIENT IND RES ORG (AU) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001032203-A1 | PROTEASE INHIBITORS AS MODULATORS OF PERIODONTAL WOUND HEALING | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2001-05-10 | — | — | WO | disclosed |
| WO-2001027157-A1 | A BIOLOGICALLY ACTIVE COMPLEX OF NR6 AND CARDIOTROPHIN-LIKE-CYTOKINE | AMRAD OPERATIONS PTY. LTD. (AU) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027147-A1 | A NOVEL MOLECULE | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001023429-A1 | IMMUNOINTERACTIVE MOLECULES AND THEIR USES IN TREATING SUBJECTS SUFFERING FROM HEV B 5 ALLERGIES | MONASH UNIVERSITY (AU) | 2001-04-05 | — | — | WO | disclosed |
| US-6197312-B1 | Surface antigen | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-03-06 | — | — | US | disclosed |
| EP-1071707-A1 | NOVEL OMEGA CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-01-31 | — | — | EP | disclosed |
| WO-2001002560-A1 | NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE | AUTOGEN RESEARCH PTY. LTD. (AU) | 2001-01-11 | — | — | WO | disclosed |
| US-6171589-B1 | ARE USEFUL IN PROTECTING INDIVIDUALS AGAINST INFECTIONS BY SPECIES OF THE GENUS MYCOPLAMA. | THE UNIVERSITY OF MELBOURNE (AU) | 2001-01-09 | — | — | US | disclosed |
| EP-1064374-A1 | NOVEL MOLECULES EXPRESSED DURING MUSCLE DEVELOPMENT AND GENETIC SEQUENCES ENCODING THE SAME | The Victor Chang Cardiac Research Institute (AU) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000070028-A1 | SPHINGOSINE KINASE ENZYME | JOHNSON & JOHNSON RESEARCH PTY. LIMITED (AU) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000067777-A1 | A METHOD OF PROPHYLAXIS AND TREATMENT AND AGENTS USEFUL THEREFOR | BIOFAN PTY LTD (AU) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000066745-A1 | NOVEL GENES ENCODING WHEAT STARCH SYNTHASES AND USES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-11-09 | — | — | WO | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| WO-2000064931-A1 | A LIGAND OF THE PROTEIN 'BEACON' | AUTOGEN RESEARCH PTY LTD. (AU) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000061758-A1 | VIRAL VARIANTS | MELBOURNE HEALTH (AU) | 2000-10-19 | — | — | WO | disclosed |
| EP-1033999-A1 | COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR | Amrad Operations Pty.,Ltd. (AU) | 2000-09-13 | — | — | EP | disclosed |
| EP-1032656-A1 | ISOLATED NUCLEIC ACID MOLECULE ENCODING MAMMALIAN ENDOGLUCURONIDASE AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2000-09-06 | — | — | EP | disclosed |
| EP-1030915-A1 | A NOVEL GENE AND USES THEREFOR | International Diabetes Institute (AU) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000044780-A1 | POLYPEPTIDE CAPABLE OF BINDING TO MANNOSE AND USES THEREFOR | AUSTRALIAN RED CROSS BLOOD SERVICE (AU) | 2000-08-03 | — | — | WO | disclosed |
| EP-1015578-A1 | THERAPEUTIC MOLECULES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2000-07-05 | — | — | EP | disclosed |
| EP-1015494-A1 | CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME | Amrad Operations Pty.,Ltd. (AU) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000037636-A1 | SOCS-BOX CONTAINING PEPTIDES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2000-06-29 | — | — | WO | disclosed |
| EP-1011654-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2000-06-28 | — | — | EP | disclosed |
| EP-1007681-A1 | METHOD OF INCREASING THE IRON CONTENT OF PLANT CELLS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-06-14 | — | — | EP | disclosed |
| US-6075129-A | Protein molecules and uses therefor | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2000-06-13 | — | — | US | disclosed |
| WO-2000028997-A1 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | ANALYTICA LTD (AU) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000028009-A1 | BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR | MELBOURNE HEALTH (AU) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000026396-A1 | A METHOD OF RECOMBINATION AND AGENTS USEFUL FOR SAME | THE MURDOCH INSTITUTE (AU) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000024417-A1 | A METHOD OF REGULATION | MONASH UNIVERSITY (AU) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024413-A1 | A METHOD OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000021538-A1 | A METHOD OF MODULATING ION CHANNEL FUNCTIONAL ACTIVITY | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000020443-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020578-A1 | A METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020444-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000016609-A1 | NOVEL METHOD OF REGULATING SEED DEVELOPMENT IN PLANTS AND GENETIC SEQUENCES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-30 | — | — | WO | disclosed |
| US-6043069-A | ADMINISTERING TO ANIMAL A GROWTH FACTOR HAVING AN ABILITY TO INDUCE B CELL MITOGENESIS LINKED TO A TARGET ANTIGEN TO WHICH CATALYTIC ANTIBODIES ARE SOUGHT; B CELL MITOGENESIS IS THEN DEPENDENT ON CLEAVAGE OF ANTIGEN PORTION BY ANTIBODIES | AMRAD OPERATIONS PTY. LTD. (AU) | 2000-03-28 | — | — | US | disclosed |
| WO-2000015654-A1 | CYCLISED CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015243-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE UNIVERSITY OF MELBOURNE (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000012695-A1 | NOVEL THERAPEUTIC MOLECULES AND USES THEREFOR | MONASH UNIVERSITY (AU) | 2000-03-09 | — | — | WO | disclosed |
| US-6030940-A | FOR TREATING HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR MEDIATED DISORDERS | CHIRON CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| WO-2000006720-A1 | A NOVEL REGULATORY MOLECULE AND GENETIC SEQUENCES ENCODING SAME | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2000-02-10 | — | — | WO | disclosed |
| EP-0975765-A1 | PLANT FATTY ACID EPOXYGENASE GENES AND USES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-02-02 | — | — | EP | disclosed |
| WO-2000003006-A1 | SUCROSE BIOSYNTHESIS GENES AND USES THEREFOR | COMMONWEALTH SCIENTIFIC INDUSTRIAL AND RESEARCH ORGANISATION (AU) | 2000-01-20 | — | — | WO | disclosed |
| WO-2000002589-A1 | MODULATION OF HAEMOPOIETIC CELL ACTIVITY AND AGENTS USEFUL FOR SAME | MONASH UNIVERSITY (AU) | 2000-01-20 | — | — | WO | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
| EP-0956039-A1 | A METHOD OF TREATMENT AND PROPHYLAXIS | Amrad Operations Pty.,Ltd. (AU) | 1999-11-17 | — | — | EP | disclosed |
| EP-0956353-A1 | MANIPULATION OF CELLULOSE AND/OR $g(b)-1,4-GLUCAN | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999054350-A1 | NOVEL OMEGA CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 1999-10-28 | — | — | WO | disclosed |
| EP-0948522-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS CAPABLE OF MODULATING CELLULAR RESPONSIVENESS TO CYTOKINES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999050410-A1 | NOVEL MOLECULES EXPRESSED DURING MUSCLE DEVELOPMENT AND GENETIC SEQUENCES ENCODING THE SAME | THE VICTOR CHANG CARDIAC RESEARCH INSTITUTE (AU) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999049048-A1 | IDENTIFICATION GENES AND GENE PRODUCTS INVOLVED IN CYTOADHERANCE OF PLASMODIUM INFECTED ERYTHROCYTES | MENZIES SCHOOL OF HEALTH RESEARCH (AU) | 1999-09-30 | — | — | WO | disclosed |
| EP-0935612-A1 | PRECURSORS OF CATALYTIC ANTIBODIES | Amrad Operations Pty.,Ltd. (AU) | 1999-08-18 | — | — | EP | disclosed |
| EP-0932674-A1 | A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES | Amrad Operations Pty.,Ltd. (AU) | 1999-08-04 | — | — | EP | disclosed |
| EP-0931149-A2 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | Amrad Operations Pty.,Ltd. (AU) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999029726-A1 | PHOSPHOLIPASE INHIBITOR | HSC (PLA) PTY. LTD. (AU) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999027950-A1 | COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR | AMRAD OPERATIONS PTY. LTD. (AU) | 1999-06-10 | — | — | WO | disclosed |
| WO-1999015563-A9 | CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME | AMRAD OPERATIONS PTY LTD (AU) | 1999-06-03 | — | — | WO | disclosed |
| EP-0886528-A4 | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE | UNIV AUSTRALIAN (AU) | 1999-06-02 | — | — | EP | disclosed |
| WO-1999024055-A1 | THERAPEUTIC MOLECULES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999023217-A1 | A NOVEL GENE AND USES THEREFOR | INTERNATIONAL DIABETES INSTITUTE (AU) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999021975-A1 | ISOLATED NUCLEIC ACID MOLECULE ENCODING MAMMALIAN ENDOGLUCURONIDASE AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1999-05-06 | — | — | WO | disclosed |
| EP-0907730-A1 | HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | Amrad Operations Pty.,Ltd. (AU) | 1999-04-14 | — | — | EP | disclosed |
| WO-1999015563-A1 | CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999014321-A1 | NOVEL THERAPEUTIC MOLECULES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998053061-A9 | THREE NOVEL GENES ENCODING A ZINC FINGER PROTEIN, A GUANINE, NUCLEOTIDE EXCHANGE FACTOR AND A HEAT SHOCK PROTEIN OR HEAT SHOCK BINDING PROTEIN | AMRAD OPERATIONS PTY LTD (AU) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998048011-A9 | NOVEL CHIMERIC MOLECULES | INST MEDICAL W & E HALL (AU) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999014243-A1 | IMMUNOINTERACTIVE MOLECULES AND USES THEREFOR | CONE ROBERT EDWARD (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999012533-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999002687-A1 | METHOD OF INCREASING THE IRON CONTENT OF PLANT CELLS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-01-21 | — | — | WO | disclosed |
| EP-0886528-A1 | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998053061-A1 | THREE NOVEL GENES ENCODING A ZINC FINGER PROTEIN, A GUANINE, NUCLEOTIDE EXCHANGE FACTOR AND A HEAT SHOCK PROTEIN OR HEAT SHOCK BINDING PROTEIN | AMRAD OPERATIONS PTY LTD (AU) | 1998-11-26 | — | — | WO | disclosed |
| EP-0879244-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998048011-A1 | NOVEL CHIMERIC MOLECULES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998046762-A1 | PLANT FATTY ACID EPOXYGENASE GENES AND USES THEREFOR | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-22 | — | — | WO | disclosed |
| EP-0871472-A1 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | Amrad Operations Pty.,Ltd. (AU) | 1998-10-21 | — | — | EP | disclosed |
| EP-0868430-A1 | THERAPEUTIC COMPOSITIONS | Amrad Operations Pty.,Ltd. (AU) | 1998-10-07 | — | — | EP | disclosed |
| WO-1998036054-A1 | NOVEL MOLECULES | AMRAD OPERATIONS PTY. LTD. (AU) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998034951-A1 | A NEW CYTOKINE FAMILY AND USES THEREOF | AMRAD OPERATIONS PTY. LTD. (AU) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998011225-A9 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | — | 1998-07-02 | — | — | WO | disclosed |
| WO-1998027996-A1 | A METHOD OF TREATMENT AND PROPHYLAXIS | AMRAD OPERATIONS PTY LTD (AU) | 1998-07-02 | — | — | WO | disclosed |
| EP-0842272-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | Amrad Operations Pty.,Ltd. (AU) | 1998-05-20 | — | — | EP | disclosed |
| EP-0842281-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998020023-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS CAPABLE OF MODULATING CELLULAR RESPONSIVENESS TO CYTOKINES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998011225-A2 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998010638-A1 | THERAPEUTIC MOLECULES | AMRAD OPERATIONS PTY. LTD. (AU) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998009510-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998007836-A1 | MANIPULATION OF PROANTHOCYANIDIN BIOSYNTHESIS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998000549-A1 | MANIPULATION OF CELLULOSE AND/OR β-1,4-GLUCAN | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1998-01-08 | — | — | WO | disclosed |
| US-5679782-A | INHIBIT RECEPTOR BINDING ACTIVITY OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR | CHIRON CORPORATION | 1997-10-21 | — | — | US | disclosed |
| EP-0672049-A4 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS. | CHIRON MIMOTOPES PTY LTD (AU) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997035971-A1 | A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035887-A1 | PRECURSORS OF CATALYTIC ANTIBODIES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997033614-A1 | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1997-09-18 | — | — | WO | disclosed |
| US-5656726-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | CHIRON CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997025344-A1 | CLIP ANALOGUES AND AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997023629-A1 | A NOVEL RECEPTOR-TYPE TYROSINE KINASE AND USE THEREOF | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023501-A1 | THERAPEUTIC COMPOSITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997021727-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997016202-A1 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
| EP-0745092-A1 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |